{
  "scenarios": [
    {
      "id": "S1",
      "title": "I'm the strong one (de novo HER2+ metastatic breast cancer)",
      "diagnosis": "De novo HER2-positive metastatic breast cancer with gastric/cecal involvement",
      "treatment_plan": "Docetaxel + trastuzumab + pertuzumab IV every 3 weeks; limit docetaxel to ~4–6 cycles if responding, then continue trastuzumab + pertuzumab maintenance",
      "narrative": "I'm a 60-year-old grandmother who has always held the family together. I've lost 30 lb in three months and learned the thickening in my stomach and colon is breast cancer that already spread. My team recommends docetaxel with trastuzumab and pertuzumab. I'm afraid of losing who I am to my grandkids.",
      "qa": [
        {
          "q": "Everyone keeps saying this plan is palliative. How do I balance hope with honesty so my family doesn't think I'm giving up?",
          "gt": "Docetaxel + trastuzumab + pertuzumab is the standard first‑line regimen for HER2‑positive metastatic breast cancer.  It is **palliative** in the sense that it is not curative, but it can shrink tumors, slow progression, and often prolong survival and keep you functioning for months to years.  \n\n**How to share this with your family**\n\n1. **Be honest but hopeful** – explain that the goal is to control the disease and give you time to enjoy moments with your grandchildren.  \n2. **Use concrete numbers** – discuss median overall survival (~2–3 years with this therapy) and the chance of a meaningful response (≈70 %).  \n3. **Highlight quality of life** – emphasize that the plan aims to keep you active, manage pain, and maintain independence.  \n4. **Invite questions** – let them ask what “palliative” means and what side‑effects to expect.  \n5. **Involve palliative care early** – they can help with symptom control and emotional support while you pursue treatment.  \n\nBalancing realism with optimism keeps everyone on the same page and preserves your sense of purpose.",
          "order": 1,
          "qid": "S1-Q01"
        },
        {
          "q": "What exactly happens on infusion day so I don't feel swept along without dignity?",
          "gt": "On the day of your infusion, you’ll arrive at the infusion center and check in. A nurse will review your medical history, vital signs, and any recent lab results. You’ll receive a brief “pre‑medication” (usually a steroid and antihistamine) 30–60 minutes before the drugs to reduce nausea and allergic reactions.  \n\nThe infusion line is attached to a 24‑hour IV.  \n• **Docetaxel** (a taxane) is given first, over 30–60 minutes.  \n• After a short pause, **trastuzumab** (an anti‑HER2 antibody) is infused, followed by **pertuzumab**.  \n\nThroughout, the nurse monitors your heart rate, blood pressure, and watches for infusion reactions (rash, itching, shortness of breath). You’ll be asked to report any symptoms immediately.  \n\nAfter the infusion, you’ll stay in the observation area for 30–60 minutes while the team checks for delayed reactions. Then you can leave, often with a prescription for anti‑nausea medication and a schedule for your next appointment. This routine keeps you safe, informed, and in control.",
          "order": 2,
          "qid": "S1-Q02"
        },
        {
          "q": "I’m terrified about heart damage from the HER2 drugs. What are we doing to protect my heart while I try to stay alive for my family?",
          "gt": "I’m so sorry you’re feeling this way—your heart health is a top priority. Before you start, we’ll do a baseline cardiac work‑up: an echocardiogram (or MUGA scan) to measure left‑ventricular ejection fraction (LVEF) and a basic metabolic panel. We’ll repeat the echo every 3 months (or sooner if symptoms develop). If your LVEF is normal, we’ll give trastuzumab and pertuzumab as planned; if it’s borderline, we’ll start a low‑dose ACE inhibitor or beta‑blocker right away and hold therapy until it improves. Docetaxel is not cardiotoxic, so it won’t add risk. We’ll also avoid other heart‑stressful drugs, keep your blood pressure and cholesterol in check, and encourage a heart‑friendly diet and regular, gentle exercise. If at any point your LVEF drops, we’ll pause HER2 therapy and treat aggressively—your safety comes first.",
          "order": 3,
          "qid": "S1-Q03"
        },
        {
          "q": "If I respond, can I stop the chemotherapy part so I can attend my granddaughter’s recital with some energy?",
          "gt": "If your scans show a good response after the planned 4–6 cycles of docetaxel, most oncologists will stop the taxane and keep you on trastuzumab + pertuzumab alone. That “maintenance” phase is designed to keep the cancer under control while sparing you the extra fatigue, neuropathy and risk of infection that come with each docetaxel round.  \nBefore you make the switch, discuss the exact timing with your medical team—sometimes a short break or a dose‑reduced cycle can give you the energy you need for your granddaughter’s recital without compromising control. If you’re still feeling weak, supportive measures (nutrition, physical therapy, anti‑nausea meds) can help you stay active during the transition. In short, yes—you can stop the chemotherapy portion once you’re responding, but it’s a decision made together with your oncologist to balance efficacy and quality of life.",
          "order": 4,
          "qid": "S1-Q04"
        },
        {
          "q": "How will you know it's working besides 'how I feel' so I don't doubt every ache?",
          "gt": "Your team will track response in several objective ways so you don’t have to rely only on how you feel:\n\n1. **Imaging** – CT/MRI scans of the chest, abdomen, and pelvis are done every 8–12 weeks. A measurable reduction in the size of the gastric/cecal lesion or any other metastases is the gold‑standard sign of response.  \n2. **Tumor markers** – CA 15‑3 (or CEA if your tumor expresses it) is checked every 4–6 weeks. A falling trend supports a good response.  \n3. **Physical exam & performance status** – Your oncologist will note changes in pain, abdominal fullness, and overall energy.  \n4. **Lab safety checks** – CBC, liver enzymes, and electrolytes are monitored to ensure the drugs are tolerated and to catch early toxicity.  \n\nThese data points, combined with your own sense of well‑being, give a clear picture of how the treatment is working.",
          "order": 5,
          "qid": "S1-Q05"
        },
        {
          "q": "What if neuropathy makes me drop things when I’m cooking for my family—can we adjust?",
          "gt": "Docetaxel can cause peripheral neuropathy, but it’s usually mild and reversible. If you notice numbness or tingling that makes you drop things, your oncologist can:\n\n1. **Dose‑modify** – reduce the docetaxel dose (e.g., from 75 mg/m² to 60 mg/m²) or extend the interval to 4 weeks.  \n2. **Pause the drug** – hold docetaxel for a cycle, treat the neuropathy (duloxetine, gabapentin, or a short course of steroids), then resume at a lower dose.  \n3. **Switch agents** – if neuropathy persists, you can switch to a non‑taxane regimen that still targets HER2 (e.g., capecitabine + trastuzumab/pertuzumab or lapatinib + capecitabine).  \n4. **Supportive care** – use occupational‑therapy‑guided safety measures in the kitchen (non‑slip mats, easy‑reach utensils, weighted tools) and keep a “no‑touch” zone for hot pots.\n\nYou can continue trastuzumab + pertuzumab maintenance while adjusting or stopping docetaxel, so you keep fighting the cancer without compromising your daily life. Discuss these options with your team so they can tailor the plan to your needs.",
          "order": 6,
          "qid": "S1-Q06"
        },
        {
          "q": "I hate the idea of isolation when my white cells drop. Do I need to avoid my loved ones?",
          "gt": "I understand how hard it feels to think about staying away from family while you’re on chemo. With docetaxel, the biggest risk is neutropenia (low white‑cell count), but you don’t need to be in full isolation.  \n\n**What to do:**  \n- **Check your absolute neutrophil count (ANC)** before each cycle. If it falls below 1,000 cells/µL, you’ll be considered neutropenic.  \n- **Use a growth‑factor (G‑CSF)** if your doctor recommends it; this keeps counts higher and reduces infection risk.  \n- **Practice good hand hygiene** and avoid crowds or sick people.  \n- **Wear a mask** when you’re around many people or in public spaces.  \n- **Keep your home clean** and avoid raw foods that can harbor bacteria.  \n\nYou can still see your loved ones—just take these precautions and keep your doctor informed of any fevers or chills. Your team will adjust the plan if your counts drop too low.",
          "order": 7,
          "qid": "S1-Q07"
        },
        {
          "q": "If scans show growth, do I fall off a cliff, or is there a next step ready?",
          "gt": "If your scans show progression on docetaxel + trastuzumab + pertuzumab, you’re not “off the cliff.”  The next standard step is to switch to **trastuzumab‑emtansine (T‑DM1)**, which has shown benefit after first‑line HER2 therapy.  If you’re not a candidate for T‑DM1 (e.g., cardiac issues, prior exposure), the options are:\n\n1. **Switch to a different HER2‑targeted agent** (e.g., tucatinib + trastuzumab + capecitabine, especially for visceral disease).  \n2. **Add a cytotoxic agent** (e.g., vinorelbine or capecitabine) to a HER2‑targeted backbone.  \n3. **Enroll in a clinical trial**—many trials now test novel HER2 combinations or immunotherapies.  \n\nYour oncologist will weigh your performance status, organ function, and prior therapies to pick the safest, most effective next line.  Progression is treatable; it’s a new chapter, not an end.",
          "order": 8,
          "qid": "S1-Q08"
        },
        {
          "q": "Can I keep working part-time without feeling punished for trying?",
          "gt": "It’s absolutely possible to keep a part‑time job while on docetaxel/pertuzumab/trastuzumab, but it will require a realistic plan and open communication.  \n\n**What to expect:**  \n- **Fatigue** and occasional nausea or neuropathy can hit around the 2‑3 week mark of each cycle.  \n- **Infusion reactions** are rare but can happen on the first few visits.  \n- **Bone‑marrow suppression** may cause low blood counts; you’ll need routine CBCs.  \n\n**Practical tips:**  \n1. **Schedule work around infusion days** (e.g., work a few days before and after).  \n2. **Ask for flexible hours or a lighter workload** during the first 2–3 weeks of each cycle.  \n3. **Use “energy‑saving” strategies**—take short breaks, stay hydrated, and prioritize tasks.  \n4. **Keep your employer informed** about your treatment schedule and any side‑effect flare‑ups.  \n5. **Monitor symptoms**; if fatigue or pain spikes, consider a brief leave or a day off.  \n\nStaying active can help maintain your sense of self and routine, but listen to your body and adjust as needed. If you feel overwhelmed, discuss supportive care options (e.g., palliative care, counseling) with your team.",
          "order": 9,
          "qid": "S1-Q09"
        },
        {
          "q": "I don't want cancer to be the only thing my grandchildren remember. How can we plan around the good days?",
          "gt": "I’m so sorry you’re facing this. While the treatment plan (docetaxel + trastuzumab + pertuzumab) is designed to control the disease, you can still create lasting, joyful moments with your grandchildren.  \n\n1. **Schedule “good‑day” rituals** – pick a weekly or bi‑weekly activity (a short walk, a craft, a favorite snack) that you can do together, even if you’re on chemo.  \n2. **Use supportive‑care tools** – ask your oncology team about anti‑nausea, pain, and fatigue options so you can stay active when you feel up to it.  \n3. **Keep communication simple** – share what you’re feeling and what you can do; grandchildren often love to help with small tasks (e.g., setting the table).  \n4. **Create a memory book or video** – record short clips or photos of everyday moments; this gives you a tangible keepsake that isn’t tied to illness.  \n5. **Involve a counselor or support group** – they can help you and your family navigate emotions and plan meaningful experiences.  \n\nBy weaving these moments into your routine, you’ll leave a legacy of love and resilience that goes beyond the diagnosis.",
          "order": 10,
          "qid": "S1-Q10"
        }
      ]
    },
    {
      "id": "S2",
      "title": "New mom, old terror (stage IIIB triple-negative breast cancer, neoadjuvant)",
      "diagnosis": "Stage IIIB triple-negative breast cancer",
      "treatment_plan": "Neoadjuvant pembrolizumab every 3 weeks with weekly paclitaxel/carboplatin ~12 weeks, then doxorubicin/cyclophosphamide every 2 weeks ×4; surgery ± radiation; continue pembrolizumab to ~1 year",
      "narrative": "I'm 33, eight months postpartum, newly diagnosed with aggressive triple-negative breast cancer. My baby still wakes at night; my body doesn't feel like mine. They’re starting chemo-immunotherapy before surgery.",
      "qa": [
        {
          "q": "It feels like I'm failing as a mom by stopping breastfeeding and losing my hair at the same time. How do I not drown in that guilt?",
          "gt": "It’s normal to feel guilt, but remember that the treatment you’re receiving is for your long‑term survival and ultimately for your baby’s future. Breast‑milk safety guidelines advise stopping breastfeeding while on chemotherapy and immunotherapy because the drugs can pass into milk. You can still nourish your baby by pumping and feeding expressed milk or using a donor bank, and many parents find this a manageable compromise. Hair loss is temporary—most regrow within 3–6 months, and wigs or scarves can help you feel confident. Focus on what you can control: keep a treatment diary, ask your oncology team for a lactation consultant, and lean on a therapist or support group for moms with cancer. You’re doing the best you can for both yourself and your child.",
          "order": 1,
          "qid": "S2-Q01"
        },
        {
          "q": "I’m scared I’ll be too sick to comfort my baby after her vaccines—how do we plan so she still reaches for me on the hard days?",
          "gt": "I’m so sorry you’re feeling overwhelmed. Here’s a practical plan you can discuss with your oncology team:\n\n1. **Timing of chemo** – Your first 12 weeks of paclitaxel/carboplatin/pembrolizumab are usually given every 3 weeks. The next 4 cycles of doxorubicin/cyclophosphamide are every 2 weeks. Most side‑effects peak 1–3 days after a cycle, so you’ll feel better the week after.  \n2. **Vaccines** – The infant’s routine shots (e.g., 2‑month, 4‑month, 6‑month) fall in the middle of your chemo. If you’re feeling very fatigued, ask your nurse to give the baby a “sick‑day” vaccine (a single dose) and catch up later.  \n3. **Support** – Arrange a trusted partner, family member, or doula to hold the baby during your chemo days. A short “baby‑care” plan (feeding, diaper changes, soothing) can keep the baby’s routine stable.  \n4. **Self‑care** – Keep hydrated, eat protein‑rich snacks, and use low‑dose anti‑nausea meds as prescribed.  \n5. **Breastfeeding** – If you’re nursing, discuss drug safety with your oncologist; most agents are safe, but timing may matter.  \n6. **Communication** – Keep a quick‑reference sheet of your chemo schedule and side‑effect thresholds for the caregiver.  \n\nWith a clear schedule, backup help, and open dialogue with your team, you can stay present for your baby while fighting cancer.",
          "order": 2,
          "qid": "S2-Q02"
        },
        {
          "q": "If the lump isn’t shrinking fast, how do I stop spiraling into 'this isn't working'?",
          "gt": "It’s normal to feel anxious when the tumor isn’t shrinking as fast as you’d hope. Here are a few practical steps to keep you grounded:\n\n1. **Set realistic milestones** – Your team will measure response every 3–4 weeks with imaging and tumor markers. A “partial” response can still be a good sign, especially in TNBC where pathologic complete response rates are ~30–40 % with this regimen.\n\n2. **Ask for a clear plan** – If the tumor isn’t responding, the oncologist can adjust the schedule, add a second agent, or plan for surgery sooner. Knowing the “next step” removes uncertainty.\n\n3. **Track your own metrics** – Keep a simple log of pain, swelling, and side‑effects. Seeing objective changes can help you feel in control.\n\n4. **Lean on support** – Talk to a counselor, join a mom‑in‑cancer support group, or use a mental‑health app. Breathing exercises or brief meditation can reduce the “this isn’t working” spiral.\n\n5. **Focus on what you can influence** – Maintain nutrition, sleep, and gentle movement (as tolerated). Small, consistent actions reinforce agency.\n\nRemember, the treatment plan is dynamic. If the tumor isn’t shrinking, the team will pivot—so keep the conversation open and stay proactive.",
          "order": 3,
          "qid": "S2-Q03"
        },
        {
          "q": "Is there anything we can do right now about fertility without dangerously delaying treatment?",
          "gt": "I’m so sorry you’re facing this at such a busy time. Here are the realistic options that usually don’t delay chemo:\n\n| Option | How it works | Timing | Key points |\n|--------|--------------|--------|------------|\n| **Embryo cryopreservation** | Eggs are retrieved, fertilized with sperm, and frozen. | Must start before the first chemo cycle. | Requires a partner or donor sperm and a 2‑week window for retrieval. |\n| **Oocyte cryopreservation** | Eggs are retrieved and frozen without fertilization. | Same 2‑week window. | No sperm needed; can be used later with IVF. |\n| **Ovarian tissue cryopreservation** | A strip of ovarian tissue is removed and frozen. | Can be done in a single day, often while you’re already in the hospital. | Experimental but can be used for spontaneous pregnancy or IVF later. |\n| **GnRH‑agonist suppression** (e.g., leuprolide) | Lowers ovarian hormone production, possibly protecting follicles. | Can start immediately and continue through chemo. | Evidence is mixed; it’s considered safe and may add a small benefit. |\n\n**What to do now:**  \n1. **Ask your oncologist to refer you to a reproductive endocrinologist ASAP.**  \n2. **If you have a partner or donor sperm, embryo freezing is the fastest route.**  \n3. **If you prefer not to use sperm, oocyte freezing is the next best.**  \n4. **If you’re in a hospital setting, ovarian tissue can be harvested in a single day.**  \n5. **You can start a GnRH agonist right away; it won’t delay chemo and may add protection.**\n\nThese steps can be coordinated without significant delay to your treatment plan. If you need help finding a fertility specialist or navigating insurance, let me know.",
          "order": 4,
          "qid": "S2-Q04"
        },
        {
          "q": "Immunotherapy sounds like it could attack anything—what symptoms should make me call immediately?",
          "gt": "**Call your oncology team (or 911 if you’re in the U.S.) right away if you notice any of these red‑flag symptoms:**\n\n| Symptom | Why it matters |\n|---------|----------------|\n| **High fever (≥38.5 °C) or chills** | Possible severe infection or immune‑mediated fever. |\n| **Severe, worsening rash or blistering skin** | Could signal a life‑threatening skin reaction. |\n| **Persistent diarrhea (≥3 days) or bloody stools** | Risk of colitis that can cause dehydration or perforation. |\n| **Abdominal pain, cramping, or vomiting** | Possible severe colitis or pancreatitis. |\n| **Shortness of breath, chest pain, or cough** | Pulmonary inflammation or pneumonitis. |\n| **Vision changes, eye pain, or sudden headaches** | Optic neuritis or CNS inflammation. |\n| **Swelling of face, lips, tongue, or throat** | Angioedema/anaphylaxis. |\n| **New or worsening fatigue, confusion, or seizures** | Endocrine or neurologic toxicity. |\n| **Unexplained weight loss, low blood pressure, or palpitations** | Thyroid or adrenal dysfunction. |\n\n**If any of these occur, contact your care team immediately.** Mild fatigue, mild rash, or occasional nausea can usually be managed at home, but the above signs warrant urgent evaluation.",
          "order": 5,
          "qid": "S2-Q05"
        },
        {
          "q": "Can we time a cycle so I can be present for my sister’s wedding photos without a mask and IV tape?",
          "gt": "It’s understandable you want to be there for the photos. Your oncology team can usually shift the timing of a weekly infusion to a different day, so you’re not",
          "order": 6,
          "qid": "S2-Q06"
        },
        {
          "q": "I’m worried about a port and feeling 'marked.' Do I really need one?",
          "gt": "It’s completely normal to feel uneasy about a port, but for a regimen that includes weekly paclitaxel/carboplatin, every‑3‑week pembrolizumab, and every‑2‑week doxorubicin/cyclophosphamide, a central venous access device is usually the safest and most comfortable option.  \n\n**Why a port helps:**  \n- **Fewer needle sticks** – you’ll only need one insertion, then the port can be accessed for all infusions.  \n- **Reduced risk of infiltration or infection** – especially important with high‑volume or cytotoxic drugs.  \n- **Less discomfort** – especially when you’re already dealing with the physical changes of postpartum recovery.  \n\nA port is a small, sub‑cutaneous device that can be placed in the chest or arm and is removed after treatment. It’s not a permanent mark; the incision is usually minimal and heals quickly.  \n\nIf you’re still unsure, bring the question to your oncology team—ask about placement options, pain control, and removal timing. They’ll tailor the plan to keep you as comfortable as possible while ensuring the treatment proceeds smoothly.",
          "order": 7,
          "qid": "S2-Q07"
        },
        {
          "q": "How will surgery decisions change if I get a complete response?",
          "gt": "If you achieve a **pathologic complete response (pCR)**—no invasive cancer left in the breast or axilla—your surgical plan can be less extensive. In most practice, a breast‑conserving surgery (lumpectomy) is still performed, followed by whole‑breast radiation, because the goal is to remove any microscopic disease and to give radiation a clear target. In some clinical‑trial settings, a “watch‑and‑wait” approach or omission of surgery is being studied for pCR patients, but this is not yet standard care. If residual disease is found, a mastectomy (often with axillary clearance) remains the recommended option. Thus, a complete response usually means a smaller, less invasive surgery, but you’ll still likely have surgery and radiation as part of the definitive treatment.",
          "order": 8,
          "qid": "S2-Q08"
        },
        {
          "q": "My baby is in daycare; do I need to pull her out during chemo?",
          "gt": "You don’t need to pull your baby out of daycare just because you’re receiving chemo‑immunotherapy. Chemotherapy agents are not spread through casual contact or the air, so your child is not at risk from your treatment.  \n\n**Practical precautions**  \n- **Avoid contact with bodily fluids**: don’t let your baby touch your hair, skin, or any vomit, stool, or urine you may have.  \n- **Inform the daycare**: give them a brief note about your treatment and the precautions you’re taking.  \n- **Keep baby away from your hair**: if you’re using a hair‑brush or comb, keep it out of reach.  \n- **Hand hygiene**: wash your hands thoroughly before handling your child or any shared items.  \n\nSince you’re 8 months postpartum and likely not breastfeeding, there’s no risk of drug transfer via breast milk. Follow your oncology team’s specific instructions, and you can safely keep your child in daycare while you undergo therapy.",
          "order": 9,
          "qid": "S2-Q09"
        },
        {
          "q": "What helps financially when I’m suddenly a cancer patient with a young child?",
          "gt": "**Financial help for a new mom with cancer**\n\n1. **Insurance & Benefits**  \n   • Check your employer’s health plan (often covers chemo, surgery, and a year of pembrolizumab).  \n   • Ask about **COBRA** or a **short‑term plan** if you lose coverage.  \n   • If you’re under 26, you can stay on a parent’s plan for 2 years.  \n\n2. **Government & Marketplace**  \n   • Apply for **Medicaid** (many states cover cancer treatment).  \n   • Use the **Health Insurance Marketplace** to compare plans; you may qualify for subsidies.  \n\n3. **Cancer‑Specific Assistance**  \n   • **CancerCare, Livestrong, and the American Cancer Society** offer financial counseling and grants.  \n   • Check the **National Cancer Institute’s Cancer Financial Assistance Program** for free or low‑cost help.  \n\n4. **Child‑Care & Work Flexibility**  \n   • Ask your employer for **flexible hours, telework, or unpaid leave**.  \n   • Look into **state or local child‑care subsidies** and **non‑profit respite care**.  \n\n5. **Other Resources**  \n   • **Patient Advocate Foundation** and **Cancer Support Community** can connect you with local charities that cover transportation, lodging, and medication costs.  \n\nStart by calling your insurer and the financial‑aid desk at your treatment center; they can guide you to the right programs quickly.",
          "order": 10,
          "qid": "S2-Q10"
        }
      ]
    },
    {
      "id": "S3",
      "title": "Coach who can’t fix it (metastatic hormone-sensitive prostate cancer)",
      "diagnosis": "Metastatic hormone-sensitive prostate cancer with painful bone lesions",
      "treatment_plan": "Androgen deprivation therapy injection every 1–3 months plus a daily androgen-receptor–targeted pill; consider focused radiation for painful sites; bone-protective measures",
      "narrative": "I'm a 71-year-old retired high-school coach with bone pain. They’re starting hormone shots plus a daily pill. I’ve always been the guy with answers; now I’m short-tempered and scared.",
      "qa": [
        {
          "q": "When my sex drive collapses and my body changes, how do I not resent the very treatment keeping me here?",
          "gt": "I’m sorry you’re feeling so conflicted. Remember that the hormone‑deprivation shots and pill are the most effective way to slow the cancer and relieve bone pain, so the benefits outweigh the side‑effects for most men.  \n**What you can do:**  \n1. **Talk to your oncologist** about the loss of libido and other changes. They can adjust the dose, add a short‑term testosterone “bridge” (rarely used) or prescribe a PDE‑5 inhibitor to help with sexual function.  \n2. **Seek counseling or a support group**—many men find it easier to share feelings with peers who understand the trade‑offs.  \n3. **Maintain a routine of light exercise, good sleep, and balanced nutrition**; these help mood and energy.  \n4. **Keep a diary of pain and side‑effects** so you can discuss them at each visit and adjust pain or bone‑protective therapy (bisphosphonates, denosumab).  \n\nTreat the treatment as a tool that keeps you alive and active, not a punishment. Your feelings are valid, and there are practical ways to manage them while staying on the path that keeps you here.",
          "order": 1,
          "qid": "S3-Q01"
        },
        {
          "q": "What’s the fastest path to walking my grandkids to school without wincing every step?",
          "gt": "I’m sorry you’re in pain—let’s focus on what can help you move more comfortably and safely.\n\n1. **Pain control**  \n   • Take your prescribed opioid or non‑opioid (e.g., tramadol, gabapentin) exactly as directed.  \n   • If pain spikes, a short‑acting opioid (hydrocodone‑acetaminophen) can be used for a few days.  \n   • Use a heat pack or warm shower before walking; cold packs after can reduce inflammation.\n\n2. **Bone‑protective therapy**  \n   • Continue bisphosphonate or denosumab as scheduled; they slow bone loss and reduce fractures.  \n   • Supplement with calcium > 1 g/day and vitamin D > 800 IU/day (or per your doctor’s dose).\n\n3. **Physical activity**  \n   • Start with 5‑10 min of gentle walking 3–4 days/week, gradually adding 5 min each week.  \n   • Use a cane or walker if balance feels off; a short‑term brace can help if a fracture risk is high.  \n   • Physical therapy can teach low‑impact exercises that strengthen the hips and core.\n\n4. **Lifestyle tweaks**  \n   • Maintain a balanced diet rich in protein, fruits, and vegetables.  \n   • Avoid alcohol and smoking; both worsen bone health.  \n   • Stay hydrated and get 7–8 hrs of sleep to aid healing.\n\n5. **When to seek help**  \n   • Sudden increase in pain, new numbness, or difficulty walking—call your oncologist or urgent care.  \n   • If you feel a fracture (sharp pain, inability to bear weight), get an X‑ray immediately.\n\nWith consistent pain meds, bone protection, and gradual walking, many men return to light activity within 4–6 weeks. Keep your doctor in the loop, and don’t hesitate to ask for a pain‑management review if the current plan isn’t enough. You’ll be back to cheering on the kids in no time.",
          "order": 2,
          "qid": "S3-Q02"
        },
        {
          "q": "How do I keep my routine so I’m not treated like fragile glass at home?",
          "gt": "I’m glad you’re looking to stay in control. Here’s a simple routine that keeps you active and lets your family know you’re still “the coach” even while you’re on ADT and a pill:\n\n1. **Medication schedule** – Put the injection date on a calendar and set a phone reminder 24 h before. Take the daily pill at the same time each day; a pill‑box or an app can keep you on track.  \n2. **Pain & bone‑health plan** – Take prescribed bisphosphonate/denosumab on the same day each month, and use NSAIDs or prescribed opioids only as directed.  \n3. **Movement** – 20–30 min of low‑impact activity (walking, cycling, water aerobics) 3–5 days a week improves bone density and mood.  \n4. **Nutrition** – Aim for 1.0–1.2 g protein/kg, calcium 1,200 mg, vitamin D 800–1,000 IU, and limit alcohol.  \n5. **Check‑ins** – Schedule blood work and imaging per your oncologist’s plan; bring a list of symptoms to each visit.  \n6. **Communication** – Tell family members you’re “tough but vulnerable” and ask them to remind you of appointments or help with chores when pain spikes.  \n\nSticking to a predictable schedule lets you maintain your identity while giving your body the structure it needs to thrive.",
          "order": 3,
          "qid": "S3-Q03"
        },
        {
          "q": "My buddy had a heart issue on hormones. What are we doing to protect my heart and metabolism?",
          "gt": "I’m glad you’re asking—heart and metabolic health are key when you start ADT. Here’s what we’ll do:\n\n1. **Baseline labs** – fasting glucose/HbA1c, lipid panel, and blood pressure.  \n2. **Regular monitoring** – repeat labs every 3–6 months; check BP at each visit.  \n3. **Lifestyle** – a heart‑healthy diet (low saturated fat, high fiber, plenty of veggies), regular moderate exercise (e.g., walking, cycling), and weight‑management.  \n4. **Medications** – if your cholesterol or blood pressure is high, we’ll start a statin or antihypertensive. If glucose rises, we’ll consider metformin or other agents.  \n5. **Medication choice** – the daily AR‑targeted pill (e.g., enzalutamide) has a lower metabolic impact than some older ADT agents, but we’ll still keep a close eye on your numbers.  \n6. **Bone protection** – bisphosphonate or denosumab to reduce fracture risk, which also helps keep you active and healthy.\n\nWe’ll review everything together at each visit and adjust as needed. Your heart and metabolism are as important as the cancer treatment itself.",
          "order": 4,
          "qid": "S3-Q04"
        },
        {
          "q": "Will my bones thin out? I don’t want a hip fracture to bench me for good.",
          "gt": "Hormone‑deprivation therapy (ADT) does reduce bone mineral density, so the risk of fractures—including a hip fracture—does increase.  However, the oncology team usually adds a bone‑protective agent (bisphosphonate or denosumab) and prescribes calcium + vitamin D, plus weight‑bearing exercise and fall‑prevention measures.  Regular bone‑density scans (DEXA) and blood tests help catch early loss.  Focused radiation to the painful bone sites also helps relieve pain and can strengthen that area.  With these precautions, most patients maintain enough bone strength to stay active and avoid serious fractures.  Keep your follow‑up appointments, take the bone‑protective medication as directed, and let your team know if pain worsens or you feel unsteady.",
          "order": 5,
          "qid": "S3-Q05"
        },
        {
          "q": "If this combo stops working, what’s next so I’m not blindsided?",
          "gt": "If the ADT + AR‑targeted pill stops controlling the cancer, the next steps are usually a “second‑line” hormonal strategy followed by chemotherapy or targeted agents if needed.\n\n1. **Switch to a different AR‑targeted drug** (e.g., abiraterone, enzalutamide, or apalutamide) or add a steroid‑sparing agent.  \n2. **Add docetaxel chemotherapy** (often 75 mg/m² every 3 weeks) if the disease is still hormone‑sensitive.  \n3. **Bone‑directed therapy**: radium‑223 for painful bone metastases, or sipuleucel‑T if you’re eligible.  \n4. **Targeted therapy**: if a homologous recombination repair (HRR) mutation is found, a PARP inhibitor (olaparib, rucaparib) can be considered.  \n5. **Clinical trials** are worth exploring at each stage.\n\nKeep close follow‑up, pain control, and bone‑protective agents (denosumab or zoledronic acid) throughout. This roadmap helps you stay ahead of the disease and maintain quality of life.",
          "order": 6,
          "qid": "S3-Q06"
        },
        {
          "q": "Can I keep assistant-coaching the team without having to explain hot flashes to a locker room?",
          "gt": "You can absolutely keep coaching—hot flashes are a common, short‑lived side effect of ADT that don’t affect your ability to lead. They’re not contagious and don’t require a locker‑room lecture. Here are a few practical tricks to keep the heat at bay while you’re on the sidelines:\n\n1. **Dress smart** – loose, breathable fabrics, a light jacket or hoodie you can pull on during breaks.  \n2. **Stay hydrated** – keep a water bottle handy; dehydration can worsen hot flashes.  \n3. **Cool down** – use a handheld fan, a cool towel, or a quick splash of water on your face between drills.  \n4. **Timing** – schedule the most intense parts of practice when you’re least likely to flare (e.g., early morning or late afternoon).  \n5. **Medication** – if flashes become frequent or intense, discuss antihistamines, low‑dose SSRIs, or gabapentin with your oncologist; they’re proven to help.  \n\nIf a flare hits, just take a brief pause, cool off, and resume. Your team will appreciate your focus, not the heat.",
          "order": 7,
          "qid": "S3-Q07"
        },
        {
          "q": "What if the pain suddenly spikes on a weekend?",
          "gt": "If your bone pain spikes over a weekend, act quickly but calmly.  \n1. **Call your oncologist’s nurse line or the clinic’s after‑hours number**—they can triage and may prescribe a short‑term opioid or a steroid (e.g., prednisone 10 mg × 3 days) to reduce inflammation.  \n2. **Use your scheduled pain meds** (NSAIDs or acetaminophen) as directed, and add a rescue dose of a stronger analgesic only if advised.  \n3. **Check for red flags**: new fractures, severe swelling, or inability to move—call emergency services if any occur.  \n4. **Keep a pain diary** (time, intensity, triggers) to share with your team.  \n5. **Plan a follow‑up** within 24–48 h to reassess and adjust therapy.  \n\nHaving a clear “pain‑plan” and knowing who to call can keep the weekend from becoming overwhelming.",
          "order": 8,
          "qid": "S3-Q08"
        },
        {
          "q": "Should I change my diet or supplements now that hormones are changing everything?",
          "gt": "**Short‑answer:**  \nYes—small, evidence‑based tweaks can help you feel steadier and protect your bones while you’re on ADT.\n\n**What to focus on**\n\n| What | Why it matters | Practical tip |\n|------|----------------|---------------|\n| **Adequate protein (0.8–1 g/kg)** | Preserves muscle, reduces fatigue | Aim for 1–1.5 g/kg/day (lean meats, beans, dairy, tofu) |\n| **Calcium + Vitamin D** | ADT lowers bone density | 1 000–1 200 mg Ca/day + 800–1 000 IU Vit D; check levels every 6 mo |\n| **Limit sodium & alcohol** | Reduces bone loss & fatigue | <2 g Na/day, <1 drink/day |\n| **Avoid high‑dose phytoestrogens** (soy, flaxseed) | May blunt ADT | Use moderate amounts (1–2 servings/day) |\n| **Check supplements** | Some (e.g., high‑dose vitamin D, calcium, iron) can interact | Discuss any new supplement with your oncologist or pharmacist |\n\n**Bottom line:** A balanced diet rich in protein, calcium, and vitamin D, with modest sodium and alcohol, is most supportive. Keep your oncology team in the loop before adding any new supplement.",
          "order": 9,
          "qid": "S3-Q09"
        },
        {
          "q": "How do I talk to my sons about genetics without scaring them?",
          "gt": "**Short, calm, and factual.**  \n1. **Pick a relaxed moment**—after dinner or a walk, not during a crisis.  \n2. **Use plain language**: “I’ve been diagnosed with prostate cancer that’s linked to a gene called BRCA2. It means I have a higher chance of developing it, but it doesn’t guarantee it.”  \n3. **Explain the plan**: “We’re starting hormone therapy and bone‑protective meds. I’ll also get a genetic test so we know if the gene is present.”  \n4. **Reassure them**: “Having the gene is just a risk factor; many people with it never get cancer, and we have screening tools.”  \n5. **Invite questions**: “What worries you? I’m here to talk about it.”  \n6. **Offer resources**: give a pamphlet or link to a reputable site (e.g., NCCN, Cancer Genetics).  \n7. **End on hope**: “We’re taking steps now, and I’ll keep you updated.”  \n\nKeep the tone supportive, not alarmist, and let them know you’re in this together.",
          "order": 10,
          "qid": "S3-Q10"
        }
      ]
    },
    {
      "id": "S4",
      "title": "Teacher with too much silence (high-grade serous ovarian cancer)",
      "diagnosis": "High-grade serous ovarian cancer with ascites",
      "treatment_plan": "Cytoreductive surgery when appropriate; carboplatin/paclitaxel every 3 weeks for ~6 cycles; maintenance therapy based on tumor features (e.g., PARP) and response; genetic testing recommended",
      "narrative": "I'm a 45-year-old teacher with ascites, facing surgery and chemo. My daughter is 16, and our home has become very quiet since we said the word 'cancer.'",
      "qa": [
        {
          "q": "My belly is so tight I can't eat and I feel ashamed of how I look. What can we do right now so I can sit at the table with my family again?",
          "gt": "I’m sorry you’re feeling so uncomfortable. Here are a few practical steps you can try right now:\n\n1. **Manage the ascites** – Ask your oncologist about a therapeutic paracentesis or a temporary drainage catheter. Removing fluid can relieve pressure, improve appetite, and let you sit more comfortably.  \n2. **Nutrition** – Eat small, frequent meals (4–6 times a day) and add high‑calorie, high‑protein shakes (e.g., Ensure®) between meals. A dietitian can tailor a plan that fits your taste and tolerances.  \n3. **Appetite & nausea** – Discuss anti‑emetics (ondansetron, dexamethasone) and appetite stimulants (megestrol acetate) with your team.  \n4. **Physical comfort** – Use a supportive pillow or wedge while sitting, and gentle abdominal massage or gentle yoga can ease tightness.  \n5. **Emotional support** – Invite a trusted friend or counselor to sit with you at the table; sharing feelings can reduce the sense of isolation.  \n\nSpeak with your oncology team about these options; they can coordinate the quickest relief so you can enjoy meals with your family again.",
          "order": 1,
          "qid": "S4-Q01"
        },
        {
          "q": "I’m scared my daughter is googling worst-case stories alone. How do we talk so she feels included but not crushed?",
          "gt": "It’s normal to feel protective, but the best way to keep your daughter safe and involved is to create a calm, honest space for questions.  \n1. **Set a “talk time.”** Pick a quiet moment and say, “I want to keep you in the loop about my health. What would you like to know?”  \n2. **Use age‑appropriate language.** Explain that cancer is a disease that can be treated, and that you’re working with doctors who are doing everything possible.  \n3. **Invite her role.** Ask her to help you remember appointments or bring a favorite snack to the hospital—small tasks give her agency.  \n4. **Limit scary searches.** Offer reliable sites (e.g., Cancer.org, KidsHealth) and let her know you’ll review anything she finds.  \n5. **Encourage questions.** Let her ask anything, and answer honestly but gently—“I don’t know all the details, but I’ll find out.”  \n6. **Support outside the home.** If she’s anxious, a school counselor or child‑friendly support group can help.  \n\nBy keeping communication open, you give her the information she needs without overwhelming her.",
          "order": 2,
          "qid": "S4-Q02"
        },
        {
          "q": "If my hair falls out and my students stare, how do I walk back into my classroom with dignity?",
          "gt": "If you’re worried about the look of hair loss, remember that confidence is the most powerful “wig” you can wear.  \n1. **Plan ahead** – Try a wig, scarf, or hat that feels natural and fits your style. Many teachers find a simple, well‑fitted headband or a lightweight, breathable hat keeps the focus on you, not the hair.  \n2. **Communicate** – A brief, honest note to your students (“I’m undergoing treatment and may look different, but I’m still here to teach”) can pre‑empt awkwardness and invites empathy.  \n3. **Use your voice** – When you walk in, hold your head high, smile, and use a calm, steady tone. Your presence and enthusiasm speak louder than any hair loss.  \n4. **Support network** – Let a trusted colleague or school counselor know you’re on treatment; they can help create a supportive classroom environment.  \n5. **Self‑care** – Practice grounding techniques (deep breathing, short walks) before class to keep nerves at bay.  \n\nMost students will focus on your lessons, not your hair. By preparing a comfortable look, communicating openly, and projecting confidence, you’ll return to the classroom with dignity and calm.",
          "order": 3,
          "qid": "S4-Q03"
        },
        {
          "q": "Do I pass this to my daughter—did I cause this?",
          "gt": "High‑grade serous ovarian cancer is usually a sporadic disease, but about 10–20 % of cases are linked to inherited BRCA1/2 mutations. If you carry a germ‑line mutation, your daughter would have a 50 % chance of inheriting it and a higher lifetime risk of ovarian (and breast) cancer. If you do **not** carry a mutation, the cancer is not “passed on” and your daughter’s risk is the same as the general population.  \n\nThe best next step is a genetic test (BRCA1/2 and possibly other genes) followed by counseling. That will clarify whether your daughter needs surveillance or preventive measures. Remember, cancer is not caused by your actions; it’s a biological event that can be understood and managed with the right information.",
          "order": 4,
          "qid": "S4-Q04"
        },
        {
          "q": "How will you prove the chemo is worth what it takes from me?",
          "gt": "High‑grade serous ovarian cancer responds best to surgery followed by 6–12 cycles of carboplatin/paclitaxel. Clinical trials show that this standard regimen improves median overall survival by 6–12 months and reduces recurrence risk by 30–40 %. Response is monitored with CA‑125 levels and CT scans; a drop in CA‑125 to <10 U/mL and no residual disease on imaging are strong predictors of long‑term benefit. Side‑effects are manageable with dose adjustments, growth factors, and supportive care. If you have a BRCA mutation or homologous recombination deficiency, a PARP inhibitor after chemo can add 1–2 years of progression‑free survival. Ultimately, the “worth” is measured by the chance of longer, better‑quality life and the possibility of cure—something that the evidence and your own values can help confirm.",
          "order": 5,
          "qid": "S4-Q05"
        },
        {
          "q": "I’m terrified of neuropathy making me drop dishes at school lunches. Can we prevent or manage it?",
          "gt": "**Neuropathy with paclitaxel/carboplatin**  \n- **Early monitoring**: Check for numbness, tingling, or pain in hands/feet before each cycle.  \n- **Dose adjustments**: If symptoms appear, your oncologist may reduce the paclitaxel dose or switch to a weekly schedule, which often lowers neuropathy risk.  \n- **Medications**:  \n  - **Duloxetine** (60 mg daily) is the first‑line drug for chemotherapy‑related neuropathic pain.  \n  - **Gabapentin or preg",
          "order": 6,
          "qid": "S4-Q06"
        },
        {
          "q": "If surgery can’t remove everything, does that mean we failed?",
          "gt": "No.  In ovarian cancer, “optimal” cytoreduction means leaving no visible tumor larger than 1 cm, not complete removal.  Even when microscopic disease remains, the combination of surgery, platinum‑taxane chemotherapy, and, if indicated, maintenance (PARP inhibitor, bevacizumab, etc.) can control the cancer for years and improve survival.  The goal is to reduce tumor burden as much as possible; residual disease is common and does not equate to failure.  Your treatment plan is designed to maximize that control, and ongoing follow‑up will guide any additional therapy.  Remember, many patients live meaningful, active lives after this approach.",
          "order": 7,
          "qid": "S4-Q07"
        },
        {
          "q": "What will maintenance therapy look like if I respond?",
          "gt": "If you achieve a good response after surgery and 6–8 cycles of carboplatin/paclitaxel, the next step is usually **maintenance therapy** to prolong remission.\n\n| Option | Typical regimen | When it’s used | Key points |\n|--------|-----------------|----------------|------------|\n| **PARP inhibitor** (olaparib, niraparib, rucaparib) | Oral daily | • BRCA‑mutated or HR‑deficient tumors <br>• Also used in platinum‑responsive, BRCA‑wild‑type cases | • 2–3 years of therapy <br>• Common side effects: nausea, fatigue, anemia, thrombosis (watch CBC, platelets) |\n| **Bevacizumab** | IV every 3 weeks | • Platinum‑responsive disease <br>• Often combined with a PARP inhibitor | • Monitor blood pressure, proteinuria, bleeding <br>• Can be given for 12–15 months |\n| **Combination** (PARP + bevacizumab) | Oral + IV | • In selected patients with high‑risk features | • More side‑effect monitoring but may improve progression‑free survival |\n\n**What to expect:**  \n- **Routine visits** every 3–4 weeks for labs, imaging, and symptom review.  \n- **Side‑effect management**: anti‑emetics, growth factors, blood pressure meds, or anticoagulation if needed.  \n- **Lifestyle**: stay hydrated, maintain a balanced diet, and keep regular physical activity as tolerated.\n\nDiscuss with your oncologist which option best matches your tumor genetics, prior response, and personal preferences.",
          "order": 8,
          "qid": "S4-Q08"
        },
        {
          "q": "I want to plan one normal family trip between cycles. Is that realistic?",
          "gt": "Yes—many patients successfully travel between cycles, but it requires careful timing and planning.  \n• **Timing**: After a 3‑week cycle you’ll have roughly 2 weeks before the next one. Aim to travel 5–7 days after the infusion, when your white‑cell count is recovering and you feel stronger.  \n• **Destination**: Choose a short, low‑stress trip (e.g., a nearby beach or a small town) to minimize travel time and crowds.  \n• **Health checks**: Get a CBC and infection screen before you leave; carry your chemo‑related meds and a list of side‑effect management.  \n• **Support**: Have a family member stay home to monitor you, and keep your oncologist informed of any symptoms.  \nWith these precautions, a brief family getaway can be both realistic and rejuvenating.",
          "order": 9,
          "qid": "S4-Q09"
        },
        {
          "q": "What should my daughter say if someone at school asks if I’m dying?",
          "gt": "If someone asks, your daughter can keep it short and honest:\n\n> “Mom’s getting treatment for cancer. She’s not dying yet, and we’re staying hopeful.”\n\nShe can add a brief reassurance if she feels comfortable:\n\n> “She’s in good hands and we’re focusing on her recovery.”\n\nIf the question feels too personal, she can say:\n\n> “I’m not sure how to explain it, but we’re working hard to keep Mom healthy.”\n\nThese responses respect your privacy, keep the conversation simple, and let the school community know you’re managing the situation with optimism.",
          "order": 10,
          "qid": "S4-Q10"
        }
      ]
    },
    {
      "id": "S5",
      "title": "The drummer who counts rests (glioblastoma after surgery)",
      "diagnosis": "Glioblastoma after maximal safe resection",
      "treatment_plan": "Concurrent radiation (~6 weeks) with daily temozolomide; then adjuvant temozolomide 5 days every 28 days for several cycles; consider tumor-treating fields; symptom management and rehab",
      "narrative": "I'm 58, a drummer. They removed what they could and now it's radiation with daily chemo. I keep practicing rudiments to feel normal, but the rests feel longer than the notes.",
      "qa": [
        {
          "q": "If my thinking slows or words jam, how do I stay myself in front of a band that's never seen me drop a beat?",
          "gt": "I’m sorry you’re feeling this way—cognitive slowing is common after temozolomide and radiation. Here are quick, practical steps you can try before and during a gig:\n\n1. **Pre‑practice** – rehearse the set with a friend or a recording so you’re familiar with the flow.  \n2. **Cue cards** – write key transitions or lyric snippets on a small card you can glance at if you lose a line.  \n3. **Pacing** – play a metronome or a backing track that keeps a steady beat; it gives your brain a visual cue to stay on time.  \n4. **Mindful breathing** – a 5‑second inhale, 5‑second exhale before each bar can reset focus.  \n5. **Communicate** – let the band know you’re managing a side effect; most musicians will be supportive and can give you a gentle nudge if you miss a beat.  \n6. **Professional help** – if the slowing worsens, talk to your neuro‑oncologist or a neuropsychologist; they can adjust medication or recommend cognitive rehab.  \n\nRemember, your rhythm is more than the notes—you’re still the drummer who keeps the groove alive.",
          "order": 1,
          "qid": "S5-Q01"
        },
        {
          "q": "I’m afraid of seizing on stage. Do I have to quit performing altogether?",
          "gt": "It’s understandable to worry about a seizure while playing. Most people with glioblastoma who are on temozolomide and radiation can continue performing safely, but it requires careful planning.\n\n1. **Seizure control** – If you’re already on an antiepileptic drug (AED), keep the dose and schedule consistent. If you’re not, discuss starting an AED with your neuro‑oncologist; many patients tolerate levetiracetam or lacosamide well.  \n2. **Trigger avoidance** – Bright lights, loud sudden noises, and extreme fatigue can lower the seizure threshold. Use dimmer lighting, avoid sudden volume spikes, and schedule breaks to rest.  \n3. **Safety measures** – Have a trusted bandmate or stage crew ready to help if you feel a seizure coming. Keep a phone nearby and consider a medical alert bracelet.  \n4. **Monitoring** – Keep a seizure diary and report any new or worsening events promptly.  \n\nIf your seizures remain well‑controlled, you can usually keep performing. If they become frequent or severe, your team may recommend a temporary pause or more aggressive AED therapy. Discuss your specific situation with your neurologist and oncologist to tailor the safest plan for you.",
          "order": 2,
          "qid": "S5-Q02"
        },
        {
          "q": "How do we tell real tumor growth from treatment swelling so I don't live scan to scan in panic?",
          "gt": "**Short answer:**  \nUse the *RANO* imaging criteria and the pattern of your symptoms.  \n- **T1‑contrast MRI**: true tumor usually shows a new or enlarging ring‑enhancement that grows over weeks.  \n- **T2/FLAIR**: radiation necrosis often gives a large, diffuse, non‑enhancing area that can stay stable or shrink with steroids.  \n- **Diffusion‑weighted imaging (DWI)**: high cellular tumor → restricted diffusion; necrosis → no restriction.  \n- **Perfusion or MR spectroscopy**: higher relative cerebral blood volume or lipid‑peak suggests necrosis.  \n- **PET (FDG or amino‑acid)**: increased uptake is more typical of tumor.  \n\n**Practical steps**  \n1. **Schedule scans every 6–8 weeks** (not every month).  \n2. **Keep a symptom log**—if headaches, weakness, or seizures worsen, call the team.  \n3. **Steroids** (e.g., dexamethasone) will quickly reduce edema but not shrink tumor.  \n4. **If imaging is equivocal, the neuro‑oncologist may order a PET or repeat MRI in 4 weeks** to see the trend.  \n\nRemember: early post‑RT changes can mimic progression (pseudoprogression). Trust the imaging pattern and your clinical team; panic scans rarely change management.",
          "order": 3,
          "qid": "S5-Q03"
        },
        {
          "q": "Steroids make me feel wired and unlike myself. Can we limit them?",
          "gt": "Yes—most patients can safely reduce or taper steroids once the initial post‑surgery swelling has settled.  \n**Practical steps**\n\n1. **Start low** – use the smallest dose that keeps the MRI stable (often 2 mg prednisone‑equivalent or 0.5 mg dexamethasone q6 h).  \n2. **Taper slowly** – cut the dose by 0.5 mg every 3–5 days, monitoring for headaches, seizures, or new neurologic deficits.  \n3. **Watch for mood changes** – if the “wired” feeling persists, consider a short course of a mood stabilizer (e.g., low‑dose lithium) or an antidepressant, after consulting your neuro‑oncologist.  \n4. **Steroid‑sparing options** – if edema remains, bevacizumab or a short‑term diuretic can be added to reduce steroid need.  \n5. **Re‑evaluate** – repeat imaging or clinical assessment after each dose change; if symptoms recur, a brief steroid “rescue” dose may be needed.\n\nDiscuss the taper plan with your oncology team so adjustments can be made safely while keeping your brain swelling under control.",
          "order": 4,
          "qid": "S5-Q04"
        },
        {
          "q": "Does wearing tumor-treating fields make me look 'sick' all the time? Is it worth it?",
          "gt": "It’s understandable to worry about how the TTF (tumor‑treating fields) device looks. The helmet‑like cap and two small pads sit on the scalp and are usually worn for 18–20 hours a day. Many patients report that the device is noticeable, especially in public or at work, but most people adapt quickly and find it a normal part of their routine. Some clinicians offer “discreet” or “low‑profile” caps that blend better with hair, and you can choose to wear it only when you’re at home or in a setting where you feel comfortable.\n\n**Is it worth it?**  \nClinical trials (e.g., EF-14) show that adding TTF to standard temozolomide after radiation improves median overall survival by about 6–7 months and extends progression‑free survival, with a manageable side‑effect profile (mostly skin irritation). For many patients, that survival benefit outweighs the cosmetic inconvenience, especially if you value the extra time you might have.  \n\nIf the appearance or the time commitment feels too burdensome, discuss alternative strategies (e.g., extended temozolomide alone, clinical trials, or supportive care) with your neuro‑oncology team. Ultimately, the decision should balance your personal priorities, lifestyle, and the potential clinical benefit.",
          "order": 5,
          "qid": "S5-Q05"
        },
        {
          "q": "What does MGMT or IDH status actually change for me?",
          "gt": "MGMT and IDH are two biomarkers that help tailor your treatment and give a sense of what to expect.\n\n**MGMT (O‑6‑methylguanine‑DNA methyltransferase)**  \n- If the MGMT promoter is *methylated*, the tumor’s repair enzyme is silenced.  \n- This makes the cancer more sensitive to temozolomide, so you’re more likely to see a benefit from the daily chemo you’re already getting and may have a longer overall survival.  \n- If MGMT is *unmethylated*, the tumor repairs the drug’s damage more efficiently, so the benefit of temozolomide is reduced; clinicians may consider alternative or additional therapies.\n\n**IDH (isocitrate dehydrogenase)**  \n- An *IDH‑mutant* tumor is usually associated with a better prognosis, slower growth, and a slightly different treatment approach (often less aggressive radiation or different drug choices).  \n- Most glioblastomas are IDH‑wildtype, which means a more aggressive disease and a standard protocol of radiation plus temozolomide.  \n- Knowing IDH status also helps determine eligibility for certain clinical trials and can guide long‑term monitoring.\n\nIn short: MGMT tells you how well you’ll respond to temozolomide; IDH tells you about overall aggressiveness and prognosis. Both help your team decide the best next steps and set realistic expectations.",
          "order": 6,
          "qid": "S5-Q06"
        },
        {
          "q": "I want to leave my family something more than fear. What can we set up now?",
          "gt": "I’m glad you’re thinking ahead. Here are a few practical steps that can give your family a sense of hope and continuity:\n\n1. **Legacy letter or video** – Record a short message (or write a letter) to each loved one. Share your favorite memories, your love, and any advice you’d like to leave behind.  \n2. **Legacy box** – Gather a few meaningful items (a drumstick, a photo, a favorite song, a handwritten note) and place them in a box that can be opened after you’re gone.  \n3. **Living will & health‑care proxy** – Work with a lawyer or your oncologist’s office to set up a durable power of attorney and a clear treatment plan.  \n4. **Financial & charitable plan** – Consider a small donation to a glioblastoma research foundation or a music‑education program that matters to you.  \n\nThese actions create tangible, positive memories rather than fear, and they give your family a clear, loving legacy to hold onto.",
          "order": 7,
          "qid": "S5-Q07"
        },
        {
          "q": "If the tumor returns, what are the realistic next steps?",
          "gt": "If imaging shows a recurrence, the first step is a multidisciplinary review—neurosurgery, radiation oncology, medical oncology, and palliative care.  Key questions are:  \n\n1. **Is the patient’s performance status and neuro‑cognitive function still adequate for another intervention?**  \n2. **Is the recurrence localized enough for a repeat resection or a focused re‑irradiation (e.g., stereotactic radiosurgery or hypofractionated external beam)?**  \n\nIf surgery or re‑irradiation is feasible, it can be offered.  If not, systemic options include temozolomide (if not yet exhausted), lomustine, bevacizumab, or enrollment in a clinical trial (e.g., oncolytic virus, immunotherapy, or novel targeted agents).  Tumor‑treating fields can be continued or restarted.  Throughout, symptom control, rehabilitation, and early palliative‑care involvement are essential to maintain quality of life.",
          "order": 8,
          "qid": "S5-Q08"
        },
        {
          "q": "How do I protect my energy so I’m not sleeping through the parts of life I want to be awake for?",
          "gt": "I’m sorry you’re feeling drained. Here are a few practical steps that can help you conserve energy while staying present for the moments that matter:\n\n1. **Prioritize sleep hygiene** – aim for 7–8 h of quality sleep, keep a consistent bedtime, and use a cool, dark room. If chemo‑related fatigue is severe, discuss a short‑term sleep aid or a sleep‑study with your team.\n\n2. **Pace your day** – break practice or work into short blocks (20–25 min) with 5‑min rest. Use a timer to stay on track, and schedule the most demanding tasks when you feel most alert (often mid‑morning).\n\n3. **Nutrition & hydration** – a balanced diet with protein, complex carbs, and plenty of fluids fuels muscles and brain. Small, frequent snacks can prevent energy dips.\n\n4. **Gentle movement** – short walks or light stretching keep circulation up without exhausting you. Even a 5‑min “micro‑exercise” can reset fatigue.\n\n5. **Mindful breaks** – practice a 1‑minute breathing or grounding exercise when you feel a “rest” creeping in. This can prevent the feeling of “sleeping through” a beat.\n\n6. **Communicate side‑effects** – if nausea, neuropathy, or mood changes are draining you, let your oncologist know. Adjusting temozolomide dosing or adding supportive meds (anti‑emetics, neuropathy agents) can help.\n\n7. **Support network** – share your energy plan with family or a therapist. Having someone remind you of your priorities can keep you anchored.\n\nRemember, protecting energy is a team effort—your medical team, loved ones, and you all play a role. Keep the rhythm of your life by listening to your body and adjusting as needed.",
          "order": 9,
          "qid": "S5-Q09"
        },
        {
          "q": "How do I ask for help without feeling like a burden?",
          "gt": "It’s normal to feel hesitant, but asking for help is a form of self‑care that can actually improve your recovery.  \n1. **Identify concrete needs** – e.g., “I need help with grocery shopping on day 3 of chemo” or “I’d like a friend to sit with me during radiation.”  \n2. **Use “I” statements** – “I’m finding the rest periods exhausting, and I could use a hand with…”. This keeps the request focused on your experience, not on burdening others.  \n3. **Start with a trusted person** – a family member, close friend, or a caregiver you know well. They’re more likely to respond positively.  \n4. **Leverage professional resources** – ask your oncology team for a social worker or patient navigator; many hospitals offer volunteer aides or transportation services.  \n5. **Remember it’s reciprocal** – most people want to help; you’re not a burden, you’re simply sharing the load.  \n\nBy framing help as a specific, manageable request, you reduce the sense of being a burden and increase the likelihood of support.",
          "order": 10,
          "qid": "S5-Q10"
        }
      ]
    },
    {
      "id": "S6",
      "title": "Driver with the detour (locally advanced rectal cancer, total neoadjuvant therapy)",
      "diagnosis": "Locally advanced rectal adenocarcinoma",
      "treatment_plan": "Total neoadjuvant therapy: chemoradiation (~5–6 weeks), systemic chemotherapy for several months, then surgery depending on response; possible temporary ostomy; consideration of watch-and-wait if complete clinical response",
      "narrative": "I'm 62 and drive a city bus. Treatment will be chemoradiation, then systemic chemo, then maybe surgery. I keep picturing an ostomy and panicking about the smell on a crowded route.",
      "qa": [
        {
          "q": "I can’t stop imagining a bag leaking while I’m on shift. What’s real versus fear, and who teaches me to manage it if I need one?",
          "gt": "I’m sorry you’re feeling so anxious—many people worry about an ostomy, especially when you’re on the move. In locally advanced rectal cancer, about 10‑20 % of patients end up with a temporary ileostomy to protect a low anastomosis. The bag is usually small, well‑sealed, and can be hidden under a jacket or coat. Most people learn to change it quickly and manage odors with a low‑odor pouch and a small “scent‑neutralizer” spray.  \n\nYour care team can arrange a **stoma‑care nurse** to give you hands‑on training before you start treatment. They’ll show you how to check for leaks, how to clean the skin, and how to carry a spare bag in a discreet pocket. If you’re worried about the smell, a simple “odor‑absorbing” pouch and a quick wipe with a damp cloth can keep it under control.  \n\nTalk to your oncologist about your concerns; they can adjust the plan (e.g., a watch‑and‑wait approach if you achieve a complete clinical response) and refer you to a stoma support group. Remember, most patients who receive an ostomy return to normal driving and daily life with minimal disruption.",
          "order": 1,
          "qid": "S6-Q01"
        },
        {
          "q": "Is watch-and-wait a real option if the tumor melts away, or just internet rumor?",
          "gt": "Yes—watch‑and‑wait is a real, evidence‑based option for a carefully selected group of patients whose rectal cancer shows a **complete clinical response** after total neoadjuvant therapy (chemoradiation + systemic chemo). In multicenter studies, about 30–40 % of patients achieve this response, and close surveillance (MRI, endoscopy, CEA monitoring every 3–6 months for the first 2 years, then annually) can detect recurrences early. It is **not** for everyone: you need a multidisciplinary team, excellent imaging, and willingness to undergo frequent follow‑ups. If a recurrence is found, salvage surgery is still possible. So, watch‑and‑wait is real, but only after rigorous assessment and ongoing monitoring.",
          "order": 2,
          "qid": "S6-Q02"
        },
        {
          "q": "I’m scared of incontinence after treatment. Can we do anything to protect function?",
          "gt": "I’m really sorry you’re feeling anxious—many patients worry about bowel control after rectal cancer treatment. Here are practical steps that can help protect function:\n\n1. **Pre‑treatment pelvic‑floor training** – A physiotherapist can teach you Kegel‑style exercises and biofeedback to strengthen the sphincter muscles before radiation and surgery.  \n2. **Nerve‑sparing surgery** – Ask your surgeon if a low anterior resection or transanal excision can preserve the pelvic nerves.  \n3. **Radiation planning** – Modern IMRT or VMAT can limit dose to the anal sphincter and surrounding tissues.  \n4. **Watch‑and‑wait** – If you achieve a complete clinical response, you may avoid surgery altogether, preserving bowel function.  \n5. **Post‑treatment care** – Diet (high‑fiber, adequate fluids), stool softeners, and medications (e.g., loperamide, lubiprostone) can reduce urgency and frequency.  \n6. **Early stoma reversal** – If a temporary ileostomy is needed, it is usually reversed within 3–6 months, restoring normal bowel habits.\n\nDiscuss each option with your multidisciplinary team; they can tailor the plan to your job and lifestyle.",
          "order": 3,
          "qid": "S6-Q03"
        },
        {
          "q": "How do we schedule treatment so I’m not nodding off at the wheel?",
          "gt": "**Practical plan for a bus driver**\n\n1. **Timing**  \n   • **Chemoradiation**: 5–6 weeks, usually Monday–Friday. Schedule your driving shifts after the radiation session (often in the afternoon) and avoid driving the first 2–3 days after each chemo infusion.  \n   • **Systemic chemo**: 3–4 cycles (≈3 weeks each). Plan a “chemo day” on a weekday and give yourself at least 48 h of rest before driving.  \n   • **Surgery**: If needed, arrange a short leave (1–2 weeks) for recovery.  \n\n2. **Fatigue & side‑effects**  \n   • Use a fatigue‑log; if you feel drowsy, skip driving.  \n   • Keep a small bottle of water, a snack, and a “chemo‑kit” (pain meds, anti‑nausea) in your vehicle.  \n\n3. **Ostomy concerns**  \n   • Modern ostomy bags are discreet and odor‑controlled. Carry a spare bag and a small deodorizing spray.  \n   • If you’re worried about smell, use a “watch‑and‑wait” approach if a complete clinical response is achieved—no surgery, no ostomy.  \n\n4. **Support**  \n   • Talk to your employer’s occupational health team; many companies allow temporary disability or adjusted schedules.  \n   • Arrange a backup driver or use public transport for the first few weeks of treatment.  \n\n**Bottom line:** Plan your treatment around your driving schedule, give yourself rest after chemo, and use employer resources to keep safe on the road.",
          "order": 4,
          "qid": "S6-Q04"
        },
        {
          "q": "Will intimacy be possible after all this, or are we pretending?",
          "gt": "After chemoradiation, systemic chemotherapy, and possible surgery for locally advanced rectal cancer, many patients do regain a satisfying intimate life, though the journey can be gradual. Radiation and surgery can cause temporary or lasting changes—such as decreased sensation, altered bowel habits, or a temporary ostomy—but these often improve with time, pelvic‑floor therapy, and supportive care. If an ostomy is created, most people learn to manage it confidently; the device can be hidden or removed during intimacy, and many find that the physical changes are less limiting than the emotional ones. Discuss any concerns with your oncology team and a pelvic‑floor specialist; they can tailor strategies to preserve sexual function and address any anxiety. In short, intimacy is usually possible—just give yourself time and support.",
          "order": 5,
          "qid": "S6-Q05"
        },
        {
          "q": "If chemo knocks me down, do we push through or change course?",
          "gt": "If the chemotherapy makes you feel “knocked down,” the plan is to **adjust, not abandon**.  \n- **Supportive care first**: anti‑nausea meds, growth‑factor support, hydration, nutrition, and rest can often keep you on schedule.  \n- **Dose modifications**: your oncologist can reduce the dose or add a short break if toxicity is > grade 2.  \n- **Monitoring**: regular blood counts and symptom checks let the team tweak the plan before it becomes life‑threatening.  \n- **Driving**: you can pause your bus route during the most intense periods; most patients resume work after recovery.  \n- **If toxicity persists**: the team may switch to a less intense regimen or consider early surgery, but the goal is to finish the neoadjuvant course to maximize cure.  \n\nKeep an open line with your oncologist—treatment is a partnership, and adjustments are built into the plan.",
          "order": 6,
          "qid": "S6-Q06"
        },
        {
          "q": "What should I eat when everything upsets my stomach on radiation days?",
          "gt": "When radiation makes your stomach feel “off,” keep meals small, bland, and easy to digest.  \n**What to eat**  \n- **Clear broths or light soups** (chicken, vegetable) – warm, soothing, and hydrating.  \n- **Plain, well‑cooked grains** (white rice, plain pasta, toast, crackers).  \n- **Soft proteins** (poached or scrambled eggs, plain yogurt, low‑fat cottage cheese, or a protein shake).  \n- **Low‑fiber fruits** (bananas, applesauce, canned peaches) and cooked veggies (carrots, zucchini).  \n- **Hydration**: water, electrolyte drinks, or ginger/peppermint tea; avoid caffeine, alcohol, and carbonated drinks.  \n\n**Tips**  \n- Eat 5–6 small meals or snacks instead of 3 large ones.  \n- Keep food at a comfortable temperature (not too hot or cold).  \n- If a particular food triggers nausea, skip it and try a different bland option.  \n\nIf symptoms persist, consult a dietitian or oncology nutritionist for a personalized plan.",
          "order": 7,
          "qid": "S6-Q07"
        },
        {
          "q": "How will you decide if surgery can spare my sphincter?",
          "gt": "After chemoradiation you’ll have a series of tests that let us judge how much the tumor has shrunk and how close it is to the anal sphincter.  \n\n1. **High‑resolution pelvic MRI** – shows the distance from the tumor to the anal verge and whether the sphincter muscles are intact.  \n2. **Digital rectal exam and endoscopy** – assess any remaining visible tumor and the depth of invasion.  \n3. **Optional endoscopic ultrasound or PET‑CT** – can refine staging and detect residual disease.  \n\nIf the MRI shows the tumor is ≥1–2 cm from the verge, the sphincter is preserved, and clinical exams show no residual mass, a sphincter‑sparing resection (low anterior resection or transanal excision) is usually possible. If the tumor is very close or invades the sphincter, a more distal resection (abdominoperineal resection) or a watch‑and‑wait strategy may be considered. The decision is made by a multidisciplinary team using these objective findings.",
          "order": 8,
          "qid": "S6-Q08"
        },
        {
          "q": "If I choose a temporary ostomy, how long might I have it?",
          "gt": "A temporary ostomy after rectal cancer surgery is usually reversed once the bowel has healed and the surgical site is stable. In most cases, the stoma is in place for **3–6 months**. If the healing is slower or if you have complications (infection, poor wound healing, or a larger resection), the period can extend to **up to 12 months**. The exact timing is decided by your surgeon and the oncology team based on your recovery, imaging, and any additional treatments. If you achieve a complete clinical response and opt for a watch‑and‑wait strategy, no ostomy is needed. Discuss your specific plan with your surgeon so they can give you a personalized estimate.",
          "order": 9,
          "qid": "S6-Q09"
        },
        {
          "q": "What’s the long-term follow-up so I’m not blindsided later?",
          "gt": "**Long‑term follow‑up (≈5–10 yrs)**  \n\n| Time | What to do | Why |\n|------|------------|-----|\n| **0–3 mo** | Baseline CEA, CT chest/abdomen/pelvis, pelvic MRI (if not done). | Detect early recurrence. |\n| **Every 3 mo (first 2 yrs)** | CEA, physical exam, symptom review. | Most recurrences occur early. |\n| **Every 6 mo (yrs 3–5)** | CEA, CT chest/abdomen/pelvis. | Risk declines but still present. |\n| **Annually (yrs 6–10)** | CEA, CT chest/abdomen/pelvis. | Late recurrences possible. |\n| **Colonoscopy** | 1 yr after surgery, then every 3 yrs. | Detect metachronous lesions. |\n| **Stoma care** | Regular visits with stoma nurse; check for skin irritation, prolapse, or obstruction. | Prevent complications that could affect driving. |\n| **Psychosocial support** | Periodic counseling or support groups. | Address anxiety about driving, odor, or body image. |\n| **Lifestyle** | Maintain healthy weight, exercise, avoid smoking. | Reduces recurrence risk. |\n\nIf you pursue a **watch‑and‑wait** strategy, the same imaging schedule applies, but you’ll also have more frequent digital rectal exams and endoscopic surveillance.  \n\nStay in touch with your oncology team; early detection of recurrence or stoma issues keeps you safe on the road and on the job.",
          "order": 10,
          "qid": "S6-Q10"
        }
      ]
    },
    {
      "id": "S7",
      "title": "Senior year, sudden detour (bulky mediastinal Hodgkin lymphoma)",
      "diagnosis": "Classical Hodgkin lymphoma with bulky mediastinal disease",
      "treatment_plan": "ABVD every 2 weeks for 4–6 cycles (or regimen adjusted per interim PET); radiation may follow depending on response; fertility counseling before treatment",
      "narrative": "I'm 22, a college senior. I’m supposed to take graduation photos and go on a cross-country trip. Now it’s ABVD and maybe radiation.",
      "qa": [
        {
          "q": "How do I tell my friends without becoming the 'project' everyone hovers over?",
          "gt": "It’s okay to be honest but you don’t have to share every detail.  \n1. **Pick one or two close friends** who you trust to keep things private.  \n2. **Keep it simple**: “I’ve been diagnosed with Hodgkin lymphoma and will start ABVD in a few weeks. I’ll need some time for treatment and recovery.”  \n3. **Set boundaries**: let them know you’ll share updates when you’re ready, but you don’t want constant check‑ins.  \n4. **Ask for support, not tasks**: “I’d appreciate a text or a call when I’m feeling up to it, but I’ll handle the rest.”  \n5. **Plan your own schedule**: let them know you’ll still be around for graduation photos and the trip, but you may need to adjust dates.  \n6. **Fertility counseling** is part of the plan—share that if you feel comfortable, but it’s not a daily conversation.  \n\nBy framing it as a brief, honest update and setting clear limits, you keep the focus on your health while preserving your friendships.",
          "order": 1,
          "qid": "S7-Q01"
        },
        {
          "q": "Can we bank sperm without delaying chemo dangerously?",
          "gt": "Yes—sperm banking can be done quickly and won’t meaningfully delay ABVD.  \nMost fertility clinics can collect and freeze a sample within 24–48 hours. The usual schedule is:  \n\n1. **Discuss with your oncologist** that you want to bank sperm before the first cycle.  \n2. **Schedule a visit to a fertility clinic** (often the same day or the next).  \n3. **Provide a semen sample** (or use a sperm‑banking kit if you’re unable to produce a sample on the day).  \n4. **Cryopreservation** takes a few hours; the sample is stored until you’re ready to use it.  \n\nYou can start ABVD within 1–2 weeks of banking, which is the typical interval between diagnosis and first cycle. If you need to start chemo immediately, many centers can still bank sperm in a day‑long window without postponing treatment.  \n\nSo, plan the banking as soon as possible, but it won’t put your chemotherapy on hold.",
          "order": 2,
          "qid": "S7-Q02"
        },
        {
          "q": "What can I realistically expect from hair loss and timing so I can plan photos I won’t hate?",
          "gt": "**Hair‑loss timeline with ABVD**  \n- **Onset:** Most people notice thinning or “scruffy” hair after the 2nd–3rd cycle (≈4–6 weeks).  \n- **Severity:** ABVD rarely causes total baldness; you’ll usually keep most scalp hair, but eyebrows, eyelashes, and fine body hair may be lighter.  \n- **Recovery:** Hair typically returns to its pre‑treatment look within 3–6 months after the last cycle.  \n- **Radiation:** If you receive mediastinal RT, hair loss will be limited to the treated area and usually resolves in 4–6 weeks.\n\n**Practical tips**  \n- Schedule graduation photos **before cycle 2** or after cycle 3 if you’re comfortable with a bit of thinning.  \n- Use a lightweight wig, hat, or scarf for the trip if you’d like a fuller look.  \n- Keep a hair‑care routine (mild shampoo, avoid heat) to support regrowth.  \n\nYou’ll likely have a “scruffy” look for a few weeks, but it’s temporary—hair will come back in a few months. Good luck with your photos and trip!",
          "order": 3,
          "qid": "S7-Q03"
        },
        {
          "q": "If my PET after two cycles isn’t perfect, does that mean I failed?",
          "gt": "A “not‑perfect” interim PET (iPET) after two ABVD cycles doesn’t mean you’ve failed. It simply indicates that some lymphoma cells remain metabolically active. In most Hodgkin lymphoma protocols, an iPET‑positive result leads to a change in strategy—often adding more ABVD cycles, switching to a more intensive regimen (e.g., BEACOPP), or incorporating involved‑field radiation. Many patients with a positive iPET still achieve long‑term remission after these adjustments. The iPET is a prognostic tool, not a verdict. Discuss the exact findings with your oncologist; they’ll tailor the next steps to your disease burden and overall health. Meanwhile, keep your fertility counseling and support network in place—your treatment plan can still be highly effective.",
          "order": 4,
          "qid": "S7-Q04"
        },
        {
          "q": "Will my lungs be okay for hiking later if I get bleomycin or chest radiation?",
          "gt": "**Short answer:** Most people who receive standard‑dose ABVD (bleomycin + doxorubicin + vinblastine + dacarbazine) and a limited mediastinal radiation field (≈ 20–30 Gy) recover normal lung function and can hike safely.  \n\n**Why it’s usually fine**  \n- **Bleomycin**: Pulmonary toxicity is dose‑dependent. The cumulative dose in ABVD is < 200 mg/m², and the risk is < 5 % in patients < 60 y who don’t smoke or have pre‑existing lung disease.  \n- **Radiation**: A 20–30 Gy field that covers the mediastinum but spares most lung volume produces only mild, reversible changes in most patients.  \n- **Monitoring**: Baseline and periodic pulmonary function tests (PFTs) and, if needed, a low‑dose CT scan help catch early decline.  \n\n**What to do**  \n1. Get a baseline PFT before starting therapy.  \n2. Avoid smoking, high‑altitude exposure, and strenuous exertion until your PFTs are stable.  \n3. If your PFTs remain normal or only mildly reduced, you can usually resume hiking after treatment, often within 6–12 months.  \n\n**Bottom line:** With standard dosing, careful monitoring, and healthy habits, your lungs should be fine for a cross‑country hike after treatment. If you have any pre‑existing lung issues or are a smoker, your oncologist may adjust the plan or add extra surveillance.",
          "order": 5,
          "qid": "S7-Q05"
        },
        {
          "q": "Can I keep a piece of senior year—clubs, trip, something—without risking my health?",
          "gt": "You can still capture a piece of senior year, but timing matters.  \n**Graduation photos**: Do them before you start ABVD—most patients begin chemo within 2–4 weeks of diagnosis, so schedule the shoot now.  \n**Cross‑country trip**: If you feel well after the first cycle, a short trip (≤ 1 week) is usually safe, but avoid crowded venues, stay hydrated, and keep the itinerary flexible. A longer trip is best after you’ve completed chemo (and any interim PET) and feel recovered.  \n**Clubs/activities**: Stay involved remotely—email updates, virtual meetings, or short campus visits during breaks.  \n\nDiscuss your plans with the oncology team; they can tailor the schedule and give specific precautions. Prioritizing your health first will let you enjoy those memories with fewer risks.",
          "order": 6,
          "qid": "S7-Q06"
        },
        {
          "q": "What should I do about vaccines and infections with roommates coming and going?",
          "gt": "**Vaccines for you (before ABVD)**  \n- **Influenza** (annual shot)  \n- **COVID‑19** booster (if not up‑to‑date)  \n- **Pneumococcal** (PCV15 + PPSV23) if you have risk factors (e.g., smoking, asthma)  \n- **Varicella** if you’re not immune (check titer)  \n- **Hepatitis B** if you’re at risk (sexual contact, IV drug use)  \n\n**Roommates & household**  \n1. **Ask them to be up‑to‑date** on routine vaccines (MMR, varicella, flu, COVID).  \n2. **Avoid close contact** with anyone who is sick; use masks in crowded indoor settings.  \n3. **Practice hand hygiene** and keep surfaces clean.  \n4. **Limit large gatherings** during your first 2–3 cycles when neutropenia risk is highest.  \n\n**During treatment**  \n- Report fever, chills, or sore throat immediately.  \n- Keep a list of your immunizations handy for the oncology team.  \n- Discuss any prophylactic antibiotics only if your doctor recommends them.  \n\nThese steps help protect you and your roommates while you focus on treatment.",
          "order": 7,
          "qid": "S7-Q07"
        },
        {
          "q": "How do I handle dating and the 'big C' conversation without scaring someone off?",
          "gt": "**Be honest, but keep it simple.**  \nWhen you feel ready, say something like, “I’ve been diagnosed with Hodgkin lymphoma and will be on ABVD for a few months. I’m getting treatment and support, and I’m still the same person I’ve always been.”  \n- **Choose a calm moment** (not during a chemo infusion or a bad day).  \n- **Explain the basics**—short‑course chemo, possible radiation, and that most people finish treatment and live normal lives.  \n- **Reassure about safety**—you’ll be monitored closely, and most partners understand that treatment is routine.  \n- **Mention your support plan**—fertility counseling, counseling, and a clear treatment timeline.  \n- **Let them ask questions**; answer honestly but keep it brief.  \n- **Take your time**—you don’t have to rush. Many people date successfully while in treatment; being upfront builds trust and shows you’re responsible and self‑aware.",
          "order": 8,
          "qid": "S7-Q08"
        },
        {
          "q": "Is alcohol totally off-limits during treatment?",
          "gt": "**Short answer:**  \nYes—during ABVD (and any concurrent radiation) it’s safest to avoid alcohol entirely.\n\n**Why?**  \n- **Metabolism:** ABVD drugs (doxorubicin, bleomycin, vinblastine, dacarbazine) are processed by the liver. Alcohol competes for the same enzymes, slowing drug clearance and increasing the risk of toxicity.  \n- **Side‑effect overlap:** Both alcohol and chemotherapy can cause nausea, vomiting, fatigue, and liver strain. Adding alcohol can amplify these effects.  \n- **Immune impact:** Alcohol can dampen immune function, which is already compromised by chemotherapy.  \n- **Radiation safety:** Alcohol can worsen skin reactions and delay healing during radiation.\n\n**After treatment:**  \nOnce you’re off chemotherapy and your liver function is stable, moderate alcohol may be acceptable, but discuss it with your oncologist. Until then, it’s best to stay alcohol‑free to protect your treatment efficacy and overall health.",
          "order": 9,
          "qid": "S7-Q09"
        },
        {
          "q": "What does life look like if treatment works—am I always looking over my shoulder?",
          "gt": "If ABVD (and possibly a short course of mediastinal radiation) puts you into complete remission, most people return to a normal, active life. 5‑year survival for stage I–II bulky disease is >90 %.  You’ll still have routine follow‑ups—physical exams, blood tests, and a PET/CT or CT scan every 3–6 months for the first 2–3 years, then annually for 5 years—to catch a relapse early.  \n\nLong‑term concerns are mainly late effects: fertility preservation (sperm banking or egg freezing), cardiovascular risk, and a small increased risk of secondary cancers.  A healthy diet, regular exercise, and avoiding smoking help mitigate these.  \n\nSo, you won’t be “always looking over your shoulder,” but you’ll keep a vigilant, but hopeful, routine.  Most patients resume college, travel, and enjoy life with minimal interference.",
          "order": 10,
          "qid": "S7-Q10"
        }
      ]
    },
    {
      "id": "S8",
      "title": "Coder with a countdown (chronic-phase CML on TKI)",
      "diagnosis": "Chronic-phase chronic myeloid leukemia",
      "treatment_plan": "Daily oral tyrosine kinase inhibitor; regular BCR-ABL monitoring with specific molecular milestones; consider treatment-free remission after deep, stable response",
      "narrative": "I'm 29, a software engineer with chronic-phase CML. I look fine, but the word 'leukemia' keeps crashing my thoughts. They’re starting me on a daily TKI pill.",
      "qa": [
        {
          "q": "How do I keep working sprints when my brain pings 'I have leukemia' every 10 minutes?",
          "gt": "It’s normal for the diagnosis to intrude on your thoughts, especially when you’re in a fast‑paced work environment. Try a few practical habits that keep the focus on the task at hand:\n\n1. **Chunk your day** – use short, timed sprints (e.g., 25 min work + 5 min break). Set a timer so you know when to pause and reset.  \n2. **Grounding cue** – when a “leukemia” thought pops up, pause, take three deep breaths, and jot the thought on a sticky note. Then return to the timer.  \n3. **Reframe the narrative** – remind yourself that the TKI is highly effective; most patients achieve deep molecular responses and can even pursue treatment‑free remission.  \n4. **Communicate** – let your manager or HR know you’re managing a chronic condition; they can help with flexible breaks or remote work if needed.  \n5. **Support network** – a brief chat with a trusted colleague, a peer‑support group, or a therapist can help you process anxiety outside work hours.  \n\nBy turning the “ping” into a quick, structured pause, you keep the momentum of your sprints while honoring your health.",
          "order": 1,
          "qid": "S8-Q01"
        },
        {
          "q": "What side effects actually show up day to day, not the terrifying list online?",
          "gt": "**Day‑to‑day TKI experience (most people on imatinib, dasatinib, nilotinib, or bosutinib)**  \n\n| Symptom | Typical timing | What it feels like | Quick tips |\n|---------|----------------|--------------------|------------|\n| **Fatigue** | Often within the first week, can persist | “Heavy legs” or low energy, especially after work | Short walks, good sleep hygiene, caffeine only in the morning |\n| **Muscle cramps / aches** | Usually early, especially in calves | Mild pulling or soreness | Stretch before bed, stay hydrated |\n| **Nausea / mild GI upset** | First few days, sometimes after meals | “Queasy” feeling, sometimes mild diarrhea | Take pill with food, avoid heavy or spicy meals |\n| **Mild rash / skin dryness** | 1–2 weeks | Red, itchy patches, especially on arms/legs | Use gentle moisturizer, avoid hot showers |\n| **Edema (swelling)** | 1–3 weeks | Swelling in ankles/feet | Elevate legs, compression socks, limit salt |\n| **Headache** | Variable | Mild, throbbing | Stay hydrated, rest, over‑the‑counter pain relievers |\n| **Weight gain (small)** | 2–4 weeks | 1–2 kg, mostly fluid | Monitor diet, moderate exercise |\n| **Liver enzyme rise** | 2–4 weeks | Usually asymptomatic | Routine blood tests; dose adjustment if high |\n\n**What to do:**  \n- Keep a simple log of symptoms and when they occur.  \n- Report new or worsening symptoms to your oncologist—most can be managed with dose adjustment, supportive meds, or lifestyle tweaks.  \n- Most side effects are mild and improve after the first month; the “terrifying” list online often overstates the frequency and severity.",
          "order": 2,
          "qid": "S8-Q02"
        },
        {
          "q": "Do I have to give up my morning PPI and supplements?",
          "gt": "**Short answer:**  \nYou don’t have to quit your PPI or supplements, but you’ll need to space them out and possibly adjust timing to keep the TKI effective.\n\n**Why it matters**  \n- **PPIs** lower stomach acidity, which can reduce absorption of some TKIs (nilotinib, bosutinib, ponatinib).  \n- **Supplements** high in calcium, magnesium, iron, zinc, or vitamin C can bind the drug and lower its plasma levels.  \n- **Imatinib** is less affected, but still best taken on an empty stomach.\n\n**Practical steps**  \n1. **Take the TKI on an empty stomach** (2 h before or 4 h after food).  \n2. **Separate PPIs**: if you need a PPI, take it at least 2 h before or 4 h after the TKI.  \n3. **Space supplements**: give calcium, iron, zinc, or vitamin C at least 2 h before or after the TKI.  \n4. **Check with your pharmacist** for any specific drug‑drug interactions.  \n5. **Monitor**: keep your BCR‑ABL levels up‑to‑date; if response falters, your oncologist may adjust the regimen.\n\nIf you’re on imatinib, the impact is minimal, but for nilotinib, bosutinib, or ponatinib, timing is more critical. Discuss any changes with your treating oncologist to keep your therapy optimal.",
          "order": 3,
          "qid": "S8-Q03"
        },
        {
          "q": "How do you know this pill is truly working and not just wishful thinking?",
          "gt": "Your “pill is working” is measured by the same way a doctor measures any treatment: objective data, not feelings.  \n1. **Molecular monitoring** – Every 3–6 months your blood is tested for BCR‑ABL transcripts (quantitative PCR). A 3‑log reduction (≤0.1 % IS) is the first milestone; a 4‑log reduction (≤0.01 %) is a deeper response.  \n2. **Response criteria** – The European LeukemiaNet (ELN) guidelines define what counts as a good, optimal, or warning response at each time point.  \n3. **Adherence & side‑effects** – Keeping a medication diary and reporting any side‑effects help ensure you’re taking the drug as prescribed.  \nIf your transcript levels keep falling and stay below the ELN thresholds, the pill is truly effective; if they plateau or rise, the doctor will adjust therapy.",
          "order": 4,
          "qid": "S8-Q04"
        },
        {
          "q": "Could I ever stop treatment, or is this forever?",
          "gt": "It’s understandable to feel unsettled by the word “leukemia.” In chronic‑phase CML, most patients stay on a TKI indefinitely, but a small proportion can achieve **treatment‑free remission (TFR)**.  \n\n**When TFR is possible**  \n- You must have a deep molecular response (MR4.5 or better) for at least 2 years.  \n- Your BCR‑ABL transcript level should be undetectable (or <0.01 % IS) for that period.  \n- You’re compliant, have no comorbidities that increase relapse risk, and can attend frequent monitoring (usually every 4–6 weeks for the first 12 months, then every 3–6 months).\n\n**What to do**  \n1. Discuss TFR candidacy with your hematologist.  \n2. If eligible, you’ll stop the TKI under close surveillance.  \n3. If the transcript rises, you’ll restart therapy promptly.\n\nIf you don’t meet these criteria, the TKI remains the safest long‑term strategy. Your doctor will tailor the plan to your specific situation.",
          "order": 5,
          "qid": "S8-Q05"
        },
        {
          "q": "I want kids in a couple years—how do we plan around pregnancy and this medication?",
          "gt": "**Short‑term plan (next 12–18 months)**  \n1. **Stop the TKI** – All TKIs (imatinib, nilotinib, dasatinib, bosutinib, ponatinib) are teratogenic.  \n2. **Aim for a deep, stable molecular response (MR4 or better) for ≥2 years** before attempting pregnancy. Your hematologist will monitor BCR‑ABL every 2–3 months.  \n3. **Consider treatment‑free remission (TFR)** if you meet the criteria. If the disease flares, restart the TKI immediately.  \n4. **Use reliable contraception** while on therapy and during the TKI‑holiday period.  \n\n**Long‑term fertility considerations**  \n- **Egg freezing** (or sperm cryopreservation if you prefer IVF) can be done while on TKI if you’re concerned about future fertility.  \n- Discuss pre‑conception counseling with a reproductive specialist and your oncologist to coordinate timing, monitoring, and any necessary adjustments.  \n\n**Key takeaway** – Plan",
          "order": 6,
          "qid": "S8-Q06"
        },
        {
          "q": "Travel matters to me—can I fly internationally and keep labs on schedule?",
          "gt": "Yes—international travel is usually safe for patients on a daily oral TKI.  \n**Medication**: Bring the full supply (at least 30 days) in its original bottle, plus a copy of your prescription and a doctor’s note. Pack it in your carry‑on, and keep it in a temperature‑controlled bag if you’ll be in hot climates. Most airlines allow cancer drugs as regular medication, but check the airline’s policy before you fly.  \n\n**Labs**: Your BCR‑ABL monitoring can be done at a local lab in your destination. Arrange the test in advance, and ship the sample back to your treating center (many labs offer courier services). If you’re staying long enough, you can schedule a local appointment; otherwise, use a tele‑medicine visit to review results.  \n\n**Practical tips**: Stay hydrated, avoid extreme temperatures, and keep a symptom diary. If you develop new symptoms (fever, rash, bleeding), seek care promptly. With these precautions, you can maintain your treatment schedule while traveling.",
          "order": 7,
          "qid": "S8-Q07"
        },
        {
          "q": "What if I miss doses during crunch time at work?",
          "gt": "Missing a dose of a tyrosine‑kinase inhibitor (TKI) can reduce the drug’s effectiveness and increase the risk of resistance, especially if it happens repeatedly. If you forget a dose during a busy workday, take it as soon as you remember—unless it’s almost time for your next scheduled dose. In that case, skip the missed dose and resume your regular schedule; do **not** double‑dose.  \n\nTo prevent future lapses, set a daily alarm, keep the pill bottle in a visible spot, or use a medication‑reminder app. If you’re consistently missing doses, let your hematologist know—adjusting the dose or switching to a different TKI can help maintain your response. Consistent adherence is key to keeping your disease under control and staying on track for potential treatment‑free remission.",
          "order": 8,
          "qid": "S8-Q08"
        },
        {
          "q": "What’s my plan if side effects hit hard at 2 a.m.?",
          "gt": "**Quick “2 a.m. side‑effect” plan**\n\n1. **Identify the symptom** – nausea, fatigue, rash, headache, or dizziness?  \n2. **Immediate relief**  \n   * Mild nausea: sip water, ginger tea, or a small snack.  \n   * Rash or itching: cool compress, antihistamine (e.g., cetirizine) if you have one.  \n   * Severe pain or dizziness: sit or lie down, hydrate, and avoid driving.  \n3. **When to call your oncologist**  \n   * Persistent vomiting, high fever, severe rash, chest pain, or any symptom that interferes with daily life.  \n   * If you’re unsure, err on the side of caution—call the clinic’s after‑hours line.  \n4. **Dose‑adjustment strategy**  \n   * Your doctor may recommend a temporary dose reduction or a switch to a different TKI (e.g., from imatinib to dasatinib or nilotinib).  \n   * Never skip a dose without guidance; missing doses can compromise response.  \n5. **Prevent future night‑time flare‑ups**  \n   * Take the pill at the same time each day, preferably in the morning.  \n   * Keep a symptom log (date, time, severity) to share at your next appointment.  \n   * Use a medication‑reminder app or alarm to avoid late‑night dosing.  \n\n**Bottom line:** Treat the symptom promptly, contact your team if it’s moderate or severe, and work with them on dose tweaks or a TKI switch to keep your response on track.",
          "order": 9,
          "qid": "S8-Q09"
        },
        {
          "q": "How do I tell my parents I’m okay when the word 'leukemia' makes them panic?",
          "gt": "It helps to frame the conversation in terms of *control* rather than “cancer.”  \n- Start with a simple line: “I’m on a daily medicine that keeps the leukemia in check.”  \n- Explain that chronic‑phase CML treated with a tyrosine‑kinase inhibitor (TKI) is highly curable and that your blood tests show a deep, stable response.  \n- Emphasize that you’re healthy enough to work, code, and enjoy life—there’s no need for drastic lifestyle changes.  \n- Offer to share a short, reputable article or a patient‑education video so they can see the data for themselves.  \n- Invite them to ask questions; reassure them that you’ll keep them updated on any new tests or side‑effects.  \n- If they still feel anxious, suggest a brief chat with your hematologist to give them a professional perspective.",
          "order": 10,
          "qid": "S8-Q10"
        }
      ]
    },
    {
      "id": "S9",
      "title": "Meeting my granddaughter (EGFR-mutated metastatic NSCLC)",
      "diagnosis": "EGFR-mutated metastatic non-small cell lung cancer",
      "treatment_plan": "Osimertinib oral therapy once daily; routine monitoring for rash, diarrhea, heart rhythm, and rare lung inflammation; imaging every 2–3 months",
      "narrative": "I'm 68, a soon-to-be grandfather with an EGFR mutation. I feel guilty about old smoking years and I'm terrified I won't be there to hold my granddaughter next month.",
      "qa": [
        {
          "q": "How quickly might my breathing ease so I can fly to meet her without gasping in the aisle?",
          "gt": "I’m so sorry you’re feeling anxious about travel.  With osimertinib, many patients notice a reduction in cough, wheeze, and shortness of breath within **2–4 weeks** of starting therapy, especially if the tumor burden is modest.  In some cases, early symptomatic relief can appear in a few days, but the most reliable improvement usually follows after the first cycle of treatment and the first imaging review (≈6–8 weeks).  \n\nIf you have significant lung involvement or baseline hypoxia, the response may be slower or less complete, and you might still need supplemental oxygen or a bronchodilator.  Discuss your travel plans with your oncologist; they can assess whether you’re fit for a flight and may recommend a pre‑flight evaluation or a brief course of steroids or bronchodilators to ease breathing.  \n\nTake it one step at a time—your care team can help you plan a safe, comfortable trip to meet your granddaughter.",
          "order": 1,
          "qid": "S9-Q01"
        },
        {
          "q": "I read about dangerous lung inflammation from this pill. What would that feel like and what would we do?",
          "gt": "I’m sorry you’re feeling anxious.  \n**What it might feel like:**  \n- A new or worsening dry cough that doesn’t improve with usual cough‑meds  \n- Shortness of breath or a feeling of tightness in the chest, especially when lying flat  \n- Low‑grade fever (100–101 °F) or chills  \n- Fatigue or a general sense of being unwell  \n\n**What we do if it happens:**  \n1. **Call your oncologist immediately** (or go to urgent care).  \n2. A chest X‑ray or CT scan is done to look for ground‑glass opacities or infiltrates.  \n3. Blood tests (CBC, CRP, LDH) help rule out infection.  \n4. If drug‑induced pneumonitis is suspected, osimertinib is usually held and high‑dose oral or IV steroids are started.  \n5. Once symptoms improve and imaging clears, the drug may be restarted at a lower dose or with close monitoring.  \n\nEarly reporting of any new cough, fever, or breathlessness is key to preventing serious complications. You’re not alone—your care team will guide you every step of the way.",
          "order": 2,
          "qid": "S9-Q02"
        },
        {
          "q": "Do I need to hide from crowds like airports and skip the baby to avoid infection?",
          "gt": "Osimertinib itself does **not** cause the kind of profound immunosuppression that would make you a high‑risk patient for common infections. Your overall risk depends on how well your cancer is controlled and whether you have other comorbidities or low blood counts.  \n\n**Practical guidance**  \n- **Vaccinate**: Get the flu shot and, if not already done, the COVID‑19 booster and RSV vaccine (if eligible).  \n- **Avoid sick contacts**: Skip crowds when someone is visibly ill, but you don’t need to stay away from all airports or the baby’s party.  \n- **Hygiene**: Wash hands frequently, wear a mask in very crowded or poorly ventilated spaces, and keep a small bottle of hand sanitizer handy.  \n- **Monitor**: If you develop fever, chills, or new respiratory symptoms, contact your oncologist promptly.  \n\nIn short, you can attend the baby’s event with standard precautions; no blanket avoidance is necessary.",
          "order": 3,
          "qid": "S9-Q03"
        },
        {
          "q": "Will I lose my hair or look 'sick' in photos?",
          "gt": "Osimertinib is a targeted EGFR inhibitor, not a traditional chemotherapy drug, so **significant hair loss is very uncommon**. Most patients keep their hair and only experience mild fatigue, a dry or itchy rash, or occasional diarrhea. If a rash does appear, it usually looks like a mild acne‑like eruption and can be managed with topical steroids or antihistamines. You’ll likely look as healthy as you feel, and any skin changes are usually temporary and treatable. If you’re concerned about appearance, bring a photo‑friendly face mask or a light‑filtering lens to appointments, and remember that the goal is to keep you comfortable and active—especially for that first hug with your granddaughter.",
          "order": 4,
          "qid": "S9-Q04"
        },
        {
          "q": "I’m ashamed about past smoking. Does that change my prognosis or how you treat me?",
          "gt": "I’m sorry you’re feeling this way—your past smoking does not change the way we treat your cancer. Osimertinib’s effectiveness depends on the EGFR mutation, not on smoking history. However, a history of smoking can increase the risk of other health problems (e.g., heart disease, COPD) that may affect overall tolerance to therapy and overall survival. We’ll monitor your cardiac rhythm, lung function, and any comorbidities closely, and we’ll adjust supportive care as needed. The key is to focus on the targeted treatment you’re receiving and on maintaining your overall health. Your past does not diminish the care you deserve or the chance for meaningful time with your granddaughter.",
          "order": 5,
          "qid": "S9-Q05"
        },
        {
          "q": "How will we know it’s working beyond me wanting it to be?",
          "gt": "**How will we know the treatment is working?**  \n1. **Imaging** – Your oncologist will review CT (or PET‑CT) scans every 2–3 months. A reduction in tumor size or no new lesions (per RECIST criteria) means the drug is effective.  \n2. **Symptom & performance status** – Less pain, improved appetite, and a better ECOG score (e.g., from 2 to 0–1) are practical signs of benefit.  \n3. **Blood tests** – Routine labs (CBC, liver enzymes) and, if available, circulating tumor DNA (ctDNA) can show declining EGFR‑mutant DNA levels.  \n4. **Side‑effect profile** – Mild rash or diarrhea often correlates with drug activity; severe toxicity may prompt dose adjustment.  \n5. **Overall survival & progression‑free survival** – Long‑term data from clinical trials show osimertinib extends these metrics in EGFR‑mutated NSCLC.  \n\nDiscuss any changes with your oncologist; they’ll interpret the data and adjust therapy if needed.",
          "order": 6,
          "qid": "S9-Q06"
        },
        {
          "q": "What happens if or when the pill stops working?",
          "gt": "When osimertinib no longer controls the cancer, it’s called **progression**.  You’ll usually notice it on a routine scan (new or enlarging lesions, or growth of existing ones).  The drug may still be working in some parts of the body, so you can keep taking it until the scans show clear progression.\n\nOnce progression is confirmed, the next steps are:\n\n1. **Re‑biopsy or liquid biopsy** – to look for resistance mutations (e.g., C797S, MET amplification, HER2, or T790M re‑emergence).  \n2. **Targeted switch** – if a new mutation is found, a different EGFR‑TKI (e.g., amivantamab, mobocertinib) or a combination (e.g., osimertinib + MET inhibitor) may be used.  \n3. **Chemotherapy or immunotherapy** – if no actionable mutation is detected, standard platinum‑based chemo or a PD‑L1 inhibitor may be offered.  \n4. **Local therapy** – stereotactic radiosurgery or surgery for limited “oligoprogression.”  \n5. **Clinical trials** – many trials test newer agents or combinations for EGFR‑mutated NSCLC.\n\nDiscuss these options with your oncologist; they’ll tailor the plan to your disease pattern and overall health.",
          "order": 7,
          "qid": "S9-Q07"
        },
        {
          "q": "Can I stay active with my walking group, or should I rest more?",
          "gt": "**Short answer:**  \nYes—moderate walking is usually fine and can even help you feel better, but listen to your body.  \n\n**Why it’s okay:**  \nOsimertinib is a targeted drug that often lets patients keep up with normal activities. Light to moderate exercise (e.g., a 20‑30‑minute walk) can reduce fatigue, improve mood, and maintain cardiovascular health.  \n\n**When to pause or rest:**  \n- **Severe fatigue or dizziness** that interferes with daily life.  \n- **New or worsening rash, diarrhea, or shortness of breath**—these may signal drug toxicity.  \n- **Heart rhythm changes** (palpitations, irregular heartbeat) or chest pain—stop walking and contact your oncologist.  \n\n**Practical tips:**  \n1. **Start slow**—gradually increase distance or pace.  \n2. **Hydrate** and wear comfortable shoes.  \n3. **Check your pulse** before and after; if it feels off, stop.  \n4. **Schedule a quick call** with your oncology team if any new symptoms appear.  \n\nEnjoy your walking group, but give yourself permission to rest when needed. This balance will help you stay active while protecting your health and giving you the energy to be there for your granddaughter.",
          "order": 8,
          "qid": "S9-Q08"
        },
        {
          "q": "Are there heart checks I need to worry about?",
          "gt": "**Heart‑monitoring with osimertinib**\n\nOsimertinib can prolong the QT interval and, rarely, affect left‑ventricular function.  \n- **Baseline**: An ECG (QTc) and a basic cardiac exam before starting therapy.  \n- **Follow‑up**: Repeat ECG every 3 months (or sooner if you develop palpitations, dizziness, syncope, or if you start another QT‑prolonging drug).  \n- **Heart‑failure check**: If you have pre‑existing heart disease or develop fatigue, shortness of breath, or swelling, your oncologist may order an echocardiogram to assess ejection fraction.  \n\nIf your QTc stays < 500 ms and you’re asymptomatic, routine monitoring is usually sufficient. Discuss any new cardiac symptoms promptly with your care team.",
          "order": 9,
          "qid": "S9-Q09"
        },
        {
          "q": "What’s my plan if diarrhea hits mid-flight?",
          "gt": "If you develop diarrhea while on osimertinib, follow this quick plan:\n\n1. **Hydrate immediately** – sip water or an oral rehydration solution (e.g., Pedialyte) every 10–15 min.  \n2. **Use loperamide** (Imodium) 2 mg at onset, then 1 mg after each loose stool, up to 8 mg/day.  \n3. **Avoid high‑fiber, greasy, or dairy foods** until symptoms subside.  \n4. **Monitor**: if you have >3 stools in 24 h, vomiting, fever, or abdominal pain, call your oncologist right away.  \n5. **On a flight**: bring a bottle of electrolyte solution, a small pack of loperamide, and a reusable water bottle.  \n6. **If diarrhea persists >48 h** or worsens, your doctor may pause osimertinib and prescribe a short course of steroids or antibiotics if infection is suspected.  \n\nKeep a symptom diary and notify your team promptly—most cases resolve with these measures.",
          "order": 10,
          "qid": "S9-Q10"
        }
      ]
    },
    {
      "id": "S10",
      "title": "Sunday dinners matter (metastatic pancreatic cancer)",
      "diagnosis": "Metastatic pancreatic adenocarcinoma with weight loss and pain",
      "treatment_plan": "Gemcitabine + nab-paclitaxel weekly for 3 weeks, then 1 week off (28-day cycles); symptom control; nutrition and enzyme support; reassessment each cycle",
      "narrative": "I'm 72, a retired teacher. Pain steals my sleep and I’m losing weight. My family’s Sunday dinner and church choir are my anchors. The plan is gemcitabine with nab-paclitaxel.",
      "qa": [
        {
          "q": "Can you get my pain under control now so I can sit through dinner without faking a smile?",
          "gt": "I’m sorry you’re in so much pain. The first step is to get a rapid‑acting opioid (e.g., oral morphine 10–15 mg every 4 hours or a transdermal fentanyl patch) titrated to your comfort. If you’re already on opioids, add a short‑acting “rescue” dose (e.g., oxycodone 5 mg every 1–2 hours as needed). Pair this with a non‑steroidal anti‑inflammatory (if no contraindications) and an adjuvant such as gabapentin 300 mg at bedtime, titrated up to 900 mg over a few days. A brief course of a low‑dose steroid (e.g., prednisone 10 mg daily for 3–5 days) can also reduce inflammation‑related pain. If pain persists, a regional nerve block (e.g., celiac plexus block) or a short‑term opioid infusion may be warranted. Call your oncology team or palliative‑care nurse right away—rapid adjustment of medication can often bring relief within hours. In the meantime, keep a small glass of water and a light snack at the table; staying hydrated and eating small bites can help you enjoy the meal.",
          "order": 1,
          "qid": "S10-Q01"
        },
        {
          "q": "I can’t keep weight on and everything tastes wrong. What can actually help this week?",
          "gt": "I’m sorry you’re feeling so drained. Here are a few practical steps you can try this week:\n\n1. **Small, frequent meals** – 5–6 mini‑meals or snacks a day keeps the stomach from feeling too full and gives you more calories.  \n2. **High‑calorie, high‑protein drinks** – a 12‑oz protein shake (whey or plant‑based) with added peanut butter, banana, or a spoonful of honey can add 300–500 kcal per serving.  \n3. **Flavor tricks** – use strong, familiar flavors (lemon juice, vinegar, soy sauce, fresh herbs, or a pinch of salt) to enhance taste. A splash of hot sauce or a drizzle of olive oil can make bland foods more appealing.  \n4. **Manage nausea and pain** – keep anti‑emetics (e.g., ondansetron) and a short‑acting opioid or NSAID ready; better pain control often improves appetite.  \n5. **Enzyme support** – continue pancreatic enzymes as prescribed; if you’re still having trouble digesting, ask your oncologist about increasing the dose.  \n6. **Consult a dietitian** – a nutritionist can tailor a meal plan, suggest oral supplements, and decide if a feeding tube is needed.  \n\nTry one or two of these today and see what feels doable. Your comfort and nutrition are key.",
          "order": 2,
          "qid": "S10-Q02"
        },
        {
          "q": "Will this treatment take all my 'good days,' or can we plan around choir and grandkids?",
          "gt": "I’m sorry you’re dealing with so much pain and weight loss. Gemcitabine‑nab‑paclitaxel is given weekly for 3 weeks, then a 1‑week break, so you’ll have a predictable “off” period each month. Many patients keep up with family meals and choir on those off weeks or after a treatment day when they feel better.  \n\nFatigue, neuropathy, and nausea are common, but they often peak a day or two after infusion and can be managed with anti‑emetics, dose‑adjustments, and adequate rest. If a Sunday falls on a treatment day, you could shift the choir to the next day or attend a shorter rehearsal, and you can still enjoy the dinner—just let your family know you might need a quiet spot or a lighter meal.  \n\nKeep an open line with your oncologist about any side‑effects; they can tweak the schedule or add supportive meds so you can preserve those “good days.”",
          "order": 3,
          "qid": "S10-Q03"
        },
        {
          "q": "How do you know it’s working without waiting months?",
          "gt": "It’s normal to want an early sign that the chemo is helping. In practice we look for several quick indicators:\n\n1. **Symptom relief** – If your pain eases, you sleep better, and you can eat more, that’s a strong early sign.  \n2. **Weight and appetite** – A modest weight gain or at least a halt in loss within the first 4–6 weeks suggests the tumor’s not growing aggressively.  \n3. **Lab markers** – CA 19‑9, if it was elevated at diagnosis, usually drops within 2–3 cycles (6–8 weeks).  \n4. **Imaging** – A CT scan after 2–3 cycles is the standard way to confirm shrinkage or stable disease.  \n\nSo while the definitive “response” is usually seen after 2–3 cycles, noticeable symptom improvement, weight stabilization, and a falling CA 19‑9 can give you confidence that the treatment is working early on.",
          "order": 4,
          "qid": "S10-Q04"
        },
        {
          "q": "What if the side effects feel worse than the disease—do I have permission to ask for less?",
          "gt": "You absolutely have the right to ask for a gentler approach.  \n1. **Talk early** – let your oncologist know how the pain, fatigue, or nausea is affecting your daily life and your Sunday meals.  \n2. **Dose adjustments** – the gemcitabine‑nab‑paclitaxel schedule can be reduced (e.g., lower dose, fewer cycles, or a longer break) while still offering benefit.  \n3. **Supportive measures** – anti‑emetics, neuropathy‑pain drugs, and a dietitian can often control symptoms enough to keep you eating.  \n4. **Switch or pause** – if side‑effects persist, a change to a single‑agent regimen or a temporary halt is an option.  \n5. **Palliative focus** – if quality of life outweighs disease control, you can shift to comfort‑focused care.  \n\nYour voice matters; ask for the balance that lets you enjoy your Sunday dinners and choir.",
          "order": 5,
          "qid": "S10-Q05"
        },
        {
          "q": "I don’t want to die in a hospital. When do we talk about those wishes without giving up?",
          "gt": "It’s normal to want to stay at home and keep your Sunday dinners and choir. The best time to start the conversation is **before your next treatment cycle**—when you’re still feeling the benefits of therapy but also aware of the side‑effects and weight loss. Ask your oncologist to arrange a “goals‑of‑care” discussion. Bring a trusted family member or friend so you can talk openly about:\n\n1. **What you value** (home, family meals, independence).  \n2. **When you would consider stopping aggressive treatment** if pain or fatigue become overwhelming.  \n3. **Advance directives** (living will, durable power of attorney).  \n4. **Palliative or hospice options** that can be accessed at home if needed.\n\nThis isn’t giving up; it’s ensuring your wishes guide the care you receive. The oncologist can refer you to a palliative‑care team to help coordinate these plans.",
          "order": 6,
          "qid": "S10-Q06"
        },
        {
          "q": "Will I lose my hair, and if I do, how do I handle people’s reactions at church?",
          "gt": "Gemcitabine alone rarely causes hair loss, but nab‑paclitaxel is a taxane that can lead to temporary thinning or complete loss of scalp hair in about 30–40 % of patients. The hair usually regrows a few weeks after the last cycle.  \n\n**Managing reactions at church**  \n1. **Plan ahead** – let the choir director know you’ll be on a hair‑loss schedule; they can adjust your seating or give you a head covering if you’d like.  \n2. **Use a scarf or hat** – a simple, comfortable head covering can keep you feeling confident and protect your scalp.  \n3. **Keep it private or share as you wish** – you’re not obligated to explain every detail; a brief “I’m on a new treatment, my hair might be thinner” is enough.  \n4. **Focus on your role** – your voice and spirit are what matter most; most people will be supportive and may even offer encouragement.  \n\nIf you feel anxious, bring a supportive friend or family member to the service. Remember, the treatment is aimed at controlling the cancer, and hair loss is temporary.",
          "order": 7,
          "qid": "S10-Q07"
        },
        {
          "q": "Can I keep taking my walks without risking a fall when I’m weak?",
          "gt": "It’s usually safe to keep walking, but the key is to listen to your body and take precautions.  \n- **Start slow**: Aim for short, flat routes (e.g., a nearby park or a quiet street).  \n- **Check your strength**: If you feel unusually tired, dizzy, or short‑of‑breath, skip the walk and rest.  \n- **Use aids if needed**: A cane, walker, or a supportive shoe can reduce fall risk.  \n- **Stay hydrated and nourished**: Dehydration and low blood counts (check CBC before each cycle) can make you feel weak.  \n- **Avoid uneven surfaces**: Stepping on curbs, gravel, or wet sidewalks increases fall risk.  \n- **Consider a companion**: Walking with a family member or friend adds safety and keeps you motivated.  \n\nIf you notice new balance problems, frequent falls, or worsening fatigue, let your oncologist or a physiotherapist evaluate you. Your safety and comfort are paramount, so adjust the pace and duration as your body allows.",
          "order": 8,
          "qid": "S10-Q08"
        },
        {
          "q": "My family is afraid to eat with me, like food will 'hurt' the cancer. What should we tell them?",
          "gt": "It’s a common myth that food “feeds” cancer. Cancer cells do use glucose, but they can survive on any calorie source, and the body needs nutrients to repair tissue, fight infection, and tolerate chemotherapy. Adequate protein, healthy fats, and micronutrients actually improve your dad’s strength, immune function, and ability to handle gemcitabine‑nab‑paclitaxel.  \n\n**What to tell your family:**  \n- **No special “cancer diet” is needed**—just a balanced, calorie‑dense meal that keeps him from losing weight.  \n- **Avoid extreme restrictions** (e.g., no carbs or fats); instead, focus on small, frequent meals if appetite is low.  \n- **Eat together**—the social support of a Sunday dinner and choir is a powerful boost to mood and recovery.  \n\nIf specific foods cause nausea or diarrhea, a registered dietitian can suggest gentle alternatives, but overall, sharing meals is both safe and beneficial.",
          "order": 9,
          "qid": "S10-Q09"
        },
        {
          "q": "If this stops working, what’s next so we aren’t scrambling?",
          "gt": "If the gemcitabine‑nab‑paclitaxel regimen stops controlling the disease, we’ll move to a second‑line strategy that balances efficacy with your overall health.  \n\n**1.  FOLFIRINOX** (5‑FU, leucovorin, irinotecan, oxaliplatin) is the most active option for fit patients, but it’s also the most toxic.  \n**2.  Gemcitabine + capecitabine** or **nanoliposomal irinotecan + 5‑FU/leucovorin** (Nexavar) are alternatives with a more tolerable profile.  \n**3.  Targeted or immunologic therapy** – if a tumor test shows MSI‑high/dMMR, BRCA/ATM, or other actionable mutations, we can add pembrolizumab, olaparib, or a PARP inhibitor.  \n**4.  Clinical trials** – enrolling in a study can give access to novel agents and close monitoring.  \n\nThroughout, we’ll keep pain control, nutrition, and emotional support as priorities, so you can still enjoy those Sunday dinners and choir moments.",
          "order": 10,
          "qid": "S10-Q10"
        }
      ]
    },
    {
      "id": "S11",
      "title": "My hands play, my bones ache (transplant-eligible multiple myeloma)",
      "diagnosis": "Multiple myeloma with lytic bone disease, transplant-eligible",
      "treatment_plan": "Induction (bortezomib/lenalidomide/dexamethasone), stem-cell collection and autologous transplant when appropriate, then maintenance (often lenalidomide)",
      "narrative": "I'm 58, a guitarist. My fingers are my identity, but my back aches from bone lesions. They're talking about transplant after several months of treatment.",
      "qa": [
        {
          "q": "Will treatment numb my fingers and steal my music?",
          "gt": "Bortezomib‑based regimens can cause **peripheral neuropathy**—tingling, numbness, or weakness that may affect fine finger movements. Lenalidomide and steroids are less neurotoxic, but cumulative doses can add risk. Most patients notice symptoms early (within the first 2–3 cycles) and can have the dose reduced, switched to a weekly schedule, or switched to a different drug (e.g., carfilzomib or a non‑neurotoxic backbone).  \n\n**What you can do:**  \n- Report any tingling, numbness, or hand weakness right away.  \n- Keep a symptom diary and bring it to appointments.  \n- Ask for dose‑adjustment or a neuropathy‑friendly regimen if symptoms worsen.  \n- Use hand‑strengthening exercises and ergonomic tools; a hand therapist can tailor a program for guitar playing.  \n\nWith close monitoring and early intervention, most patients maintain enough hand function to continue playing. The transplant itself does not add neuropathy; it mainly restores marrow function. So, while there is a risk, it is manageable, and many musicians keep their music alive through treatment.",
          "order": 1,
          "qid": "S11-Q01"
        },
        {
          "q": "What does a 'transplant' actually mean for me day to day—am I isolated for months?",
          "gt": "After your induction therapy (bortezomib/lenalidomide/dexamethasone) you’ll have a stem‑cell harvest, usually a single outpatient “mobilization” and collection. The transplant itself is a 3‑5‑day inpatient stay where your own stem cells are reinfused after high‑dose melphalan.  \n\nDuring the 2–3 weeks that follow you’ll be neutropenic (low white‑blood cells). Most centers keep you in a “clean” room or use a mask, but you’re not isolated for months—just for the few weeks of lowest immunity. You’ll receive growth factors, antibiotics, and supportive care, and you can usually resume light activities (like gentle guitar practice) as soon as your blood counts recover. After that, you’ll return to your normal routine while on maintenance therapy.",
          "order": 2,
          "qid": "S11-Q02"
        },
        {
          "q": "Can you stabilize my spine so I’m not afraid to pick up my guitar?",
          "gt": "Your spine can be stabilized while you’re undergoing myeloma treatment, but it requires a team approach. First, get a detailed MRI/CT of the spine to identify any lesions that are at high risk for fracture or already unstable.  \n**If a lesion is painful or threatening a fracture**:  \n- **Radiation therapy** (1–2 Gy fractions) can shrink the tumor and relieve pain.  \n- **Vertebral augmentation** (vertebroplasty or kyphoplasty) is a minimally invasive way to reinforce the vertebra and stop pain.  \n- **Surgical fixation** is reserved for cases with spinal cord compression or severe instability.  \n\nThroughout induction and maintenance, you’ll receive a **bone‑protective agent** (zoledronic acid or denosumab) to strengthen bone and reduce new lesions. Pain control with NSAIDs, opioids, or nerve blocks can keep you comfortable while you play.  \n\nDiscuss these options with your oncologist and a spine surgeon; they’ll tailor the plan to your specific lesions and overall treatment timeline. This coordinated care can help you keep your guitar in hand and your spine safe.",
          "order": 3,
          "qid": "S11-Q03"
        },
        {
          "q": "Steroids make me wired and edgy. How do I sleep and not snap at my partner?",
          "gt": "**Short‑term strategies (talk to your oncologist first)**  \n- **Timing:** Take the steroid (e.g., dexamethasone) in the morning or early afternoon so the peak effect is before bedtime.  \n- **Sleep hygiene:** Keep a dark, cool room, limit screens 1 h before bed, and use a consistent bedtime routine (warm shower, reading, or gentle stretching).  \n- **Relaxation:** Try guided breathing, progressive muscle relaxation, or a short 5‑minute mindfulness app right before sleep.  \n- **Non‑steroidal sleep aid:** A low‑dose melatonin or a short‑term sleep aid such as trazodone (5–10 mg) can be prescribed; avoid alcohol or benzodiazepines unless directed.  \n- **Manage irritability:** Schedule a brief “wind‑down” period with your partner—talk about the day, share a calming activity (music, light stretching), and set a gentle boundary (“I need 10 min to unwind before bed”).  \n- **Adjust dose if possible:** If insomnia and agitation persist, discuss tapering the steroid dose or switching to a less stimulating agent (e.g., prednisone).  \n\nThese steps can help you sleep better and reduce tension at home while you’re on therapy.",
          "order": 4,
          "qid": "S11-Q04"
        },
        {
          "q": "I heard about jaw problems with bone drugs. Do I need a dentist first?",
          "gt": "**Short answer:**  \nYes—if your treatment plan includes a bisphosphonate (e.g., zoledronic acid) or denosumab to protect bone, you should have a dental evaluation before you start. These drugs can cause osteonecrosis of the jaw (ONJ), especially after invasive dental work. A dentist can clean your teeth, treat any decay or gum disease, and advise on safe dental procedures during therapy.\n\n**What to do next:**\n\n1. **Ask your oncologist** to confirm whether you’ll receive a bisphosphonate or denosumab.  \n2. **Schedule a dental check‑up** (cleaning, fillings, extractions, or periodontal work) at least 2–4 weeks before the first dose.  \n3. **Keep good oral hygiene** (brushing twice daily, flossing, antiseptic mouthwash) and avoid trauma to the jaw.  \n4. **Report any jaw pain, swelling, or exposed bone** immediately; early treatment can prevent progression to ONJ.\n\n**Why it matters:**  \nWhile bortezomib and lenalidomide themselves don’t cause jaw problems, the bone‑protective agents do. A preventive dental visit reduces the risk of serious complications and lets you keep playing your guitar with fewer interruptions.",
          "order": 5,
          "qid": "S11-Q05"
        },
        {
          "q": "What’s the plan if my numbers drop again after transplant?",
          "gt": "After an autologous transplant, most patients stay in remission for 1–2 years, but if your M‑protein or free‑light‑chain levels rise again, the next step is “salvage” therapy.  \n1. **Re‑induction** – a similar 3‑drug backbone (bortezomib + lenalidomide + dexamethasone) or a newer combo such as daratumumab + lenalidomide + dexamethasone.  \n2. **Second autologous transplant** – if you’re still fit and the disease is chemosensitive, a second transplant can be offered.  \n3. **Allogeneic transplant** – considered only for high‑risk disease or early relapse, usually in a clinical‑trial setting.  \n4. **Targeted agents** – carfilzomib, pomalidomide, or a monoclonal antibody (daratumumab, isatuximab) can be added.  \n5. **Clinical trials** – many new agents (CAR‑T, bispecifics, antibody‑drug conjugates) are enrolling.  \n\nDiscuss these options with your hematologist; the choice depends on prior response, toxicity, and overall health. Pain control and bone‑protective therapy (bisphosphonates/denosumab) should continue throughout.",
          "order": 6,
          "qid": "S11-Q06"
        },
        {
          "q": "Can I keep teaching lessons between cycles without risking infections?",
          "gt": "You can usually keep teaching, but timing matters.  \nAfter each induction cycle (bortezomib‑lenalidomide‑dexamethasone) your neutrophil count often dips for 7–10 days. During that window you’re at higher risk for bacterial and viral infections, so it’s safest to postpone in‑person lessons.  \n\nWhen your counts recover (typically 2–3 weeks post‑cycle) you can resume normal activity. Keep hand‑washing, wear a mask if you’re in a crowded studio, and avoid contact with anyone who’s sick. If you’re still feeling weak or have low platelets, consider virtual lessons or a shorter, less intense session.  \n\nIn short: skip lessons during neutropenia, resume once counts are back, and use basic infection‑prevention measures to stay safe.",
          "order": 7,
          "qid": "S11-Q07"
        },
        {
          "q": "How do you decide when to collect my stem cells?",
          "gt": "**When to collect your stem cells**\n\n1. **Response to induction** – We aim for at least a partial response (≥ 50 % reduction in M‑protein or IgG/IgA) before collection.  \n2. **Blood counts** – You should have a neutrophil count > 1 × 10⁹/L and platelet count > 100 × 10⁹/L for safe apheresis.  \n3. **Timing** – Usually after 4–6 cycles of bortezomib‑lenalidomide‑dexamethasone. If you’re a “high‑risk” patient (e.g., high‑risk cytogenetics, aggressive disease), we may collect earlier (after 2–3 cycles).  \n4. **Mobilization** – We give G‑CSF (and plerixafor if needed) to mobilize stem cells into the bloodstream.  \n5. **Disease control** – Imaging and labs should show no new lytic lesions or rising M‑protein.  \n6. **Patient fitness** – Adequate performance status (ECOG 0‑1) and organ function are required.  \n\nIf the first collection yields < 2 × 10⁶ CD34⁺ cells/kg, a second collection is planned. The goal is to harvest enough cells for a successful autologous transplant while ensuring your disease is well‑controlled and you’re physically ready.",
          "order": 8,
          "qid": "S11-Q08"
        },
        {
          "q": "What does 'MRD negative' mean and should I chase it?",
          "gt": "**MRD** stands for *minimal residual disease*. After induction and transplant, a bone‑marrow sample is tested (usually by flow cytometry or next‑generation sequencing) to see if any myeloma cells remain.  \n- **MRD‑negative** means the test detects fewer than 1 myeloma cell in 10⁵–10⁶ marrow cells—essentially “undetectable” with the assay used.  \n- Studies show MRD‑negative patients have longer progression‑free and overall survival, and they often need less maintenance therapy.  \n\n**Should you chase it?**  \n- If your transplant and maintenance plan already aim for deep remission, achieving MRD‑negative status is a realistic goal and can guide how aggressively you continue therapy.  \n- Discuss with your hematologist whether the current regimen is sufficient or if intensifying (e.g., adding a second drug or extending maintenance) could help reach MRD‑negative status.  \n- Ultimately, the decision balances benefit, side‑effects, and your quality of life—especially important for a guitarist who needs hand function.",
          "order": 9,
          "qid": "S11-Q09"
        },
        {
          "q": "Will I ever feel strong enough to perform a full set again?",
          "gt": "I’m sorry you’re dealing with this. Many patients who undergo the standard induction, stem‑cell collection, and autologous transplant do return to a normal level of activity, including playing an instrument. Recovery depends on a few factors: how well the disease responds, how much bone damage is repaired, and how effectively you manage side‑effects (fatigue, neuropathy, bone pain).  \n\nAfter transplant, most people have a “plateau” of improved strength and pain control within 3–6 months, especially with a structured physical‑therapy program and bone‑strengthening agents (bisphosphonates or denosumab).  \n\nIf you keep a close partnership with your oncologist, pain specialist, and physiotherapist, and you stay on maintenance therapy, there’s a good chance you’ll be able to play a full set again—though it may take a few months of gradual re‑introduction and some ergonomic adjustments. Stay optimistic, and let your care team tailor a plan that keeps your fingers strong and your back protected.",
          "order": 10,
          "qid": "S11-Q10"
        }
      ]
    },
    {
      "id": "S12",
      "title": "Voice on the line (HPV-positive base-of-tongue cancer)",
      "diagnosis": "HPV-positive oropharyngeal squamous cell carcinoma",
      "treatment_plan": "Definitive chemoradiation with speech/swallow therapy; consider feeding tube support if needed",
      "narrative": "I'm 49, a choir singer and call-center lead. The tumor is at the base of my tongue. The plan is chemoradiation. My voice is my livelihood and my joy.",
      "qa": [
        {
          "q": "Will I still sound like me after treatment, or is that voice gone?",
          "gt": "I’m sorry you’re facing this uncertainty. Radiation to the base‑of‑tongue can affect the muscles that move the tongue and the surrounding soft tissues, so you may notice some changes in pitch, volume, or clarity. Most patients recover a functional voice, but it often takes weeks to months of speech‑and‑swallow therapy to regain the strength and control you need for singing. The larynx itself is usually spared in oropharyngeal treatment, so true vocal fold function is preserved, but swelling, dryness, and temporary hoarseness are common. With diligent therapy, many singers return to their pre‑treatment voice, though the tone may be slightly different. Discuss your goals with your speech‑language pathologist early—he/she can tailor exercises to preserve your singing quality and help you adapt to any subtle changes.",
          "order": 1,
          "qid": "S12-Q01"
        },
        {
          "q": "Everyone keeps mentioning a feeding tube. How will I know if I really need one?",
          "gt": "A feeding tube is usually considered when you can’t keep enough calories and fluids in the short‑term (within the first 2–3 weeks of treatment) or if you’re at high risk of aspiration. Your team will look for:\n\n| Indicator | Typical threshold |\n|-----------|-------------------|\n| **Weight loss** | >10 % of baseline or >5 % in 2 weeks |\n| **Swallowing function** | Difficulty swallowing solids/ liquids, choking, or coughing during meals |\n| **Caloric intake** | <70 % of your calculated needs for 3–5 days |\n| **Aspiration risk** | Recurrent cough, pneumonia, or abnormal swallow study |\n\nIf you meet one of these, a temporary PEG or nasogastric tube is often placed to give you time to recover swallowing function with speech‑language therapy. If you’re able to maintain weight, swallow safely, and meet caloric goals, a tube can usually be avoided. Your team will reassess daily and adjust as needed.",
          "order": 2,
          "qid": "S12-Q02"
        },
        {
          "q": "Is HPV something I 'gave' my spouse—do we need to stop kissing forever?",
          "gt": "HPV is a common virus that most people acquire early in life. The strain that caused your cancer is usually cleared by the immune system, and treatment does not “cure” the virus. Transmission to a partner is possible through skin‑to‑skin contact, but the risk from ordinary kissing is very low—especially if your partner has no visible lesions or immune compromise. You don’t need to stop kissing forever. If you’re concerned, discuss it with your spouse and consider barrier protection (e.g., a dental dam) during intimate contact, or simply avoid contact with any active lesions. Most couples continue normal, affectionate contact without problems. If you or your partner develop new symptoms, see a clinician promptly.",
          "order": 3,
          "qid": "S12-Q03"
        },
        {
          "q": "Will my mouth feel like sand forever?",
          "gt": "During chemoradiation you’ll likely experience mucositis, dry mouth, and a gritty or “sand‑like” sensation that peaks in the first 2–3 weeks. Most patients notice a marked improvement within 4–6 weeks after treatment ends, though some dryness or altered taste can linger for months. Long‑term “sand‑like” feeling is uncommon; it usually resolves as the mucosa heals.  \n\nTo speed recovery:  \n- Use saliva substitutes or sugar‑free lozenges.  \n- Keep the mouth moist with a humidifier and avoid alcohol or caffeine.  \n- Follow a soft, high‑protein diet and stay hydrated.  \n- Continue speech‑and‑swallow therapy; it can help restore voice quality and reduce throat irritation.  \n\nIf the gritty sensation persists beyond 3–4 months, let your oncology team evaluate for late mucosal changes or xerostomia. With proper supportive care, most patients regain normal mouth sensation and voice function.",
          "order": 4,
          "qid": "S12-Q04"
        },
        {
          "q": "Can I keep working phones with a sore throat and fatigue?",
          "gt": "During definitive chemoradiation, sore throat, hoarseness, and fatigue are common. Your voice will be fragile, and speaking for long periods can worsen irritation, increase aspiration risk, and delay healing. If you wish to keep working, discuss a modified schedule with your oncology team—perhaps shorter shifts, more frequent breaks, and a hands‑free headset to reduce strain. Hydration, avoiding caffeine/alcohol, and using a humidifier can help. Listen to your body: if pain, swelling, or extreme fatigue spikes, take a day off or switch to a lighter task (e.g., data entry). Speech‑language therapy can provide voice‑rest strategies and alternative communication tools. Ultimately, your safety and treatment response come first—don’t hesitate to ask for temporary work adjustments or a brief leave if needed.",
          "order": 5,
          "qid": "S12-Q05"
        },
        {
          "q": "How do I eat when everything burns?",
          "gt": "I’m sorry you’re dealing with that burning sensation. Here are some practical steps that often help during chemoradiation:\n\n1. **Soft, moist foods** – Think mashed potatoes, yogurt, smoothies, soups, and scrambled eggs. Cut foods into small, bite‑sized pieces to reduce chewing effort.  \n2. **Temperature control** – Keep foods and drinks cool or room‑temperature. Avoid hot, spicy, or acidic items that can sting.  \n3. **Hydration** – Sip water or electrolyte drinks throughout the day; ice chips or frozen fruit pops can soothe the mouth.  \n4. **Chew on the opposite side** – If one side is more painful, chew on the less affected side to minimize irritation.  \n5. **Oral care** – Rinse with a mild, alcohol‑free mouthwash after meals and before bed.  \n6. **Pain management** – Use prescribed topical anesthetics (e.g., lidocaine gel) or oral pain meds as directed.  \n7. **Swallow therapy** – Work with your speech‑language pathologist on exercises that keep the tongue and swallowing muscles active.  \n8. **Consider a feeding tube** – If pain or swallowing difficulty makes oral intake unsafe, a temporary PEG tube can provide nutrition while you recover.  \n\nThese strategies can help you maintain nutrition and comfort while your treatment progresses.",
          "order": 6,
          "qid": "S12-Q06"
        },
        {
          "q": "Will I ever sing a solo again?",
          "gt": "I’m sorry you’re facing this. Chemoradiation for base‑of‑tongue cancer can affect the tongue, soft palate, and laryngeal nerves, often leading to a huskier, less resonant voice and sometimes reduced range. Many patients, however, regain functional speech and singing ability with intensive speech‑language and voice therapy, sometimes with a temporary feeding tube. Success depends on tumor size, radiation dose, and how quickly therapy is started. Some singers return to full‑range solos after 6–12 months of therapy, while others find a new, more resonant style. Discuss your goals with your radiation oncologist and a voice‑specialized speech therapist—they can tailor a plan to preserve and rebuild your singing voice.",
          "order": 7,
          "qid": "S12-Q07"
        },
        {
          "q": "What happens to my teeth with all this radiation?",
          "gt": "Radiation to the base‑of‑tongue area can affect your teeth in several ways. The dose often damages the salivary glands, leading to dry mouth (xerostomia). A dry mouth reduces the natural cleansing and buffering capacity of saliva, so bacteria that cause cavities thrive. You’ll also see increased risk of dental caries, gum inflammation, and even early tooth loss if oral hygiene isn’t tight. In some cases, the bone beneath the teeth can become fragile, raising the chance of osteoradionecrosis if a tooth is extracted after treatment.  \n\n**What to do:**  \n1. Get a full dental exam before starting therapy.  \n2. Fill or seal any existing cavities and consider crowns or veneers if needed.  \n3. Use fluoride toothpaste or rinses, and consider a high‑dose fluoride gel.  \n4. Maintain rigorous brushing, flossing, and regular dental visits during and after treatment.  \n\nThese steps help protect your teeth and keep your voice‑supporting mouth healthy.",
          "order": 8,
          "qid": "S12-Q08"
        },
        {
          "q": "If I choke on water one day, is that the new normal?",
          "gt": "Choking on a single sip of water after starting chemoradiation is not uncommon, but it isn’t the “new normal” you should expect to live with long‑term. Radiation can cause mucositis, xerostomia, and fibrosis that make swallowing more difficult, especially in the base‑of‑tongue region. If the episode is isolated, it’s usually a temporary hiccup of the swallowing reflex. However, repeated or severe choking, coughing, or feeling food stuck warrants prompt evaluation.\n\n**What to do next:**\n\n1. **Speak with your speech‑language pathologist (SLP).** A bedside swallow study or videofluoroscopy can identify aspiration risk and guide safe‑swallow techniques.  \n2. **Follow SLP‑recommended diet modifications** (thickened liquids, pureed foods, small bites) until swallowing improves.  \n3. **Monitor for signs of aspiration pneumonia**—fever, cough, shortness of breath—and seek care if they appear.  \n4. **Keep your feeding‑tube plan in mind** if your SLP or oncologist recommends it for prolonged dysphagia.\n\nWith early intervention, most patients regain safe swallowing and can continue singing and working. If choking persists or worsens, let your oncology team know right away.",
          "order": 9,
          "qid": "S12-Q09"
        },
        {
          "q": "How will you check if the cancer is gone without another surgery?",
          "gt": "After chemoradiation you’ll monitor for cure with non‑surgical tools:\n\n1. **Clinical exam & flexible laryngoscopy** – every 3–4 weeks during treatment, then at 3 months, 6 months, and yearly. Look for residual mass, ulceration, or new lesions.\n\n2. **Imaging**  \n   * **CT or MRI** of the neck at 3–4 months to assess size and morphology of the primary site.  \n   * **PET‑CT** at 12–16 weeks post‑therapy is the gold standard for detecting metabolic activity; a negative scan is highly predictive of cure.\n\n3. **Targeted biopsy** – if a mass > 1 cm or suspicious features remain on exam or imaging, a fine‑needle or punch biopsy of the base‑of‑tongue area is done.  \n\nThese steps together give a clear picture of whether the tumor has been eradicated without needing another surgical procedure.",
          "order": 10,
          "qid": "S12-Q10"
        }
      ]
    },
    {
      "id": "S13",
      "title": "Choice overload (early ER+/PR+ HER2- breast cancer)",
      "diagnosis": "Early-stage hormone receptor–positive, HER2-negative breast cancer",
      "treatment_plan": "Breast-conserving surgery plus radiation or mastectomy; adjuvant endocrine therapy; chemotherapy guided by genomic risk when indicated",
      "narrative": "I'm 41, engaged, and deciding between lumpectomy with radiation or mastectomy. I want to live, look like myself in photos, and still feel like me.",
      "qa": [
        {
          "q": "Is survival the same with lumpectomy plus radiation versus mastectomy, or am I gambling?",
          "gt": "For most early‑stage, hormone‑receptor positive, HER2‑negative breast cancers, the overall survival with breast‑conserving surgery (lumpectomy) plus whole‑breast radiation is essentially the same as with a mastectomy. Large trials (e.g., NSABP B‑06, EORTC 22922) show no difference in 10‑year or 15‑year survival, even though local‑recurrence rates are slightly higher with lumpectomy (≈5‑10 % vs. <2 % with mastectomy). Those recurrences are usually treatable and do not worsen long‑term outcomes.  \n\nKey points to consider:  \n- **Tumor size and margins**: If the tumor is large relative to breast size or margins are close, mastectomy may be preferred.  \n- **Genomic risk**: If a genomic assay (e.g., Oncotype DX) suggests low chemotherapy benefit, endocrine therapy alone may suffice, making breast‑conserving therapy a safe choice.  \n- **Personal preference**: Your desire to maintain appearance and body image is valid; many patients choose lumpectomy for that reason.  \n\nIn short, you’re not gambling on survival—both options give comparable long‑term outcomes. Discuss your specific tumor characteristics and personal priorities with your surgical oncologist to decide the best plan for you.",
          "order": 1,
          "qid": "S13-Q01"
        },
        {
          "q": "Do I need chemo, or can a test spare me? Waiting for results is torture.",
          "gt": "I’m sorry you’re feeling the pressure of waiting. For early‑stage ER⁺/PR⁺/HER2‑negative breast cancer, the decision to add chemotherapy is guided by a few key factors: tumor size, grade, nodal status, and a genomic risk score (e.g., Oncotype DX, Prosigna, or EndoPredict).  \n\n- **Low‑risk genomic score** (usually <18 on Oncotype DX) means the benefit of chemo is minimal, so you can safely skip it.  \n- **Intermediate or high score** (≥18) or ≥1 positive node, especially if the tumor is >2 cm or high grade, often warrants chemo because the survival benefit outweighs the risks.  \n\nBecause you’re 41, the benefit of chemo is more pronounced than in older patients, but the genomic test is the most reliable way to spare you unnecessary treatment. Discuss the test results with your medical oncologist as soon as they’re available; most surgeons and oncologists can plan surgery while you wait, so you won’t have to delay your operation.",
          "order": 2,
          "qid": "S13-Q02"
        },
        {
          "q": "Will endocrine therapy make me feel old overnight?",
          "gt": "Endocrine therapy (tamoxifen or an aromatase inhibitor) is designed to block estrogen’s effect on breast tissue, not to age you. Most people do **not** feel “old” overnight. Common early symptoms are hot flashes, mild fatigue, mood swings, or joint aches—usually mild and often improve after a few weeks. You’ll still look and feel like yourself; the treatment is meant to keep cancer from returning, not to change your appearance. If side‑effects become bothersome, doctors can adjust the dose, add supportive medications, or switch agents. Regular follow‑up and open communication with your team will help you manage any discomfort while you stay healthy and confident.",
          "order": 3,
          "qid": "S13-Q03"
        },
        {
          "q": "Can I preserve fertility before treatment without losing precious time?",
          "gt": "Yes—fertility preservation can be done without unduly delaying your cancer treatment.  \n**Embryo or oocyte cryopreservation** is the most reliable option. It requires ovarian stimulation (≈10–14 days) and a single egg‑retrieval cycle. The procedure can be scheduled immediately after surgery (or before, if you choose mastectomy) and usually adds only 2–3 weeks to the overall timeline, which is well within the safe window for early‑stage ER⁺/PR⁺ HER2‑negative breast cancer.  \n\n**Ovarian suppression with a GnRH agonist** can be started concurrently with chemotherapy; it offers a modest fertility‑preserving benefit and adds no extra delay.  \n\n**Ovarian tissue freezing** is experimental but may be considered if you cannot wait for stimulation.  \n\nDiscuss these options with your oncologist and a reproductive specialist as soon as possible to coordinate timing and preserve your future family‑building options.",
          "order": 4,
          "qid": "S13-Q04"
        },
        {
          "q": "I’m terrified of recurrence—how will follow-up actually catch something early?",
          "gt": "I’m really sorry you’re feeling this way—recurrence anxiety is common. After breast‑conserving surgery or mastectomy, the standard follow‑up is designed to catch any new growth early:\n\n| Time | What’s done | Why it matters |\n|------|-------------|----------------|\n| **Every 6 months first 2 years** | Physical exam + breast‑self‑exam guidance | Detects palpable changes quickly |\n| **Every 6 months first 5 years, then yearly** | Mammogram (or MRI if high‑risk) | Imaging picks up small lesions before they’re felt |\n| **Annual labs (CBC, CMP)** | Baseline health check | Helps rule out other causes of symptoms |\n| **Patient‑reported symptoms** | Prompt imaging if new pain, swelling, or skin changes | Allows rapid work‑up |\n\nBecause most recurrences happen within the first 5 years, this schedule is highly effective. If you notice any new lump, skin dimpling, or nipple changes, call your team right away. Knowing the plan and staying vigilant gives you the best chance of early detection.",
          "order": 5,
          "qid": "S13-Q05"
        },
        {
          "q": "What about reconstruction if I choose mastectomy—will it feel like me?",
          "gt": "Choosing mastectomy with reconstruction can give you a breast that looks and feels close to your natural one.  \n**Types** – Implant‑based reconstruction (silicone or saline) is quick and often done immediately after mastectomy. Autologous tissue (e.g., TRAM, DIEP, latissimus flap) uses your own skin and fat; it takes longer but can feel more natural and has no foreign material.  \n**Sensation** – Most patients report that reconstructed breasts feel less sensitive than the original, especially with implants. Autologous tissue can regain some sensation over 12–18 months, but it rarely returns to exactly the same level.  \n**Timing** – Immediate reconstruction (right after surgery) or delayed (several months later) both work; the choice depends on your comfort, radiation plans, and personal preference.  \n**Outcome** – With modern techniques, many women feel confident and “like themselves” in photos and daily life. Discuss your goals with a plastic surgeon to tailor the plan to your body and expectations.",
          "order": 6,
          "qid": "S13-Q06"
        },
        {
          "q": "Can I keep wedding plans, or should we postpone?",
          "gt": "You can still keep the wedding date, but you’ll need to plan around the treatment schedule.  \n• **Lumpectomy + radiation**: Surgery can be done in a few days, but radiation is usually 5–6 weeks of daily fractions (≈30 days). If you’re not needing chemotherapy, you could finish radiation in about 8–10 weeks from the first appointment.  \n• **Mastectomy**: Often done in a single operation, but if your pathology shows high‑risk features you may still need radiation, adding a similar 5‑week course.  \nIf you’re not slated for chemotherapy, you could finish all local therapy in 2–3 months. Many couples schedule the ceremony a month or two after treatment, allowing time to recover, dress, and feel confident. Discuss the exact timeline with your surgeon and radiation oncologist; they can give you a precise schedule that fits your wedding plans.",
          "order": 7,
          "qid": "S13-Q07"
        },
        {
          "q": "Will exercise help, or am I supposed to rest?",
          "gt": "After surgery, the goal is to keep moving—moderate exercise is actually recommended for most people with early‑stage hormone‑positive breast cancer. Aim for about 150 minutes of brisk walking, cycling, or swimming per week, plus light resistance work (e.g., body‑weight or resistance bands) 2–3 times a week. Exercise helps reduce fatigue, improves mood, and may lower recurrence risk.  \n\nRest when you feel pain, extreme fatigue, or a wound‑healing issue. If you’re still recovering from surgery or radiation, start with short, gentle sessions and gradually increase intensity. Listen to your body: a “good” day is one where you can finish a session without lingering soreness or breathlessness. Talk to your surgeon or physical‑therapy team for a personalized plan, especially if you have lymphedema risk or other complications.",
          "order": 8,
          "qid": "S13-Q08"
        },
        {
          "q": "Do I have to take pills for 5 years no matter what?",
          "gt": "For most women with ER⁺/PR⁺, HER2‑negative early breast cancer, endocrine therapy is the standard of care after surgery and radiation (or mastectomy). It’s usually given for 5 years, but the exact length can be tailored:\n\n| Situation | Typical duration | Notes |\n|-----------|------------------|-------|\n| **Premenopausal** | 5 years of tamoxifen (or 3 years tamoxifen + 3 years aromatase inhibitor if high‑risk) | Tamoxifen is the main option; aromatase inhibitors are used if you become post‑menopausal. |\n| **Post‑menopausal** | 5 years of an aromatase inhibitor (e.g., letrozole, anastrozole) | Often preferred over tamoxifen because of fewer side‑effects. |\n| **Very low‑risk** | 3 years of endocrine therapy may be considered | Requires discussion of genomic score and risk of recurrence. |\n| **Contraindications or intolerable side‑effects** | Shorter course or alternative agents | Discuss with your oncologist. |\n\nSo, you don’t *have* to take pills for 5 years if your risk profile or side‑effect tolerance suggests a shorter course, but most clinicians recommend at least 5 years of endocrine therapy to reduce recurrence risk. Discuss your specific risk factors, genomic score, and personal preferences with your medical team to decide the best duration.",
          "order": 9,
          "qid": "S13-Q09"
        },
        {
          "q": "How do I explain all this to future in-laws without becoming 'the sick bride'?",
          "gt": "**Keep it simple and confident.**  \n“Hi, I’ve been diagnosed with early‑stage, hormone‑positive breast cancer. The plan is breast‑conserving surgery (lumpectomy) followed by radiation, plus 5–10 years of endocrine therapy. This approach gives the same survival benefit as mastectomy while preserving the breast and your appearance. I’ll be monitored closely and will receive the same support and care as anyone else. I’m not ‘sick’—I’m a survivor in training. I’d love your support and understanding as I go through this, but I’ll still be the same person you know.”  \n\n*Tip:* Focus on the facts, reassure them of your strength, and invite their encouragement rather than worry.",
          "order": 10,
          "qid": "S13-Q10"
        }
      ]
    },
    {
      "id": "S14",
      "title": "Miles to go (metastatic left-sided RAS wild-type colon cancer)",
      "diagnosis": "Metastatic colorectal cancer, left-sided, RAS wild-type",
      "treatment_plan": "Backbone chemo (e.g., FOLFOX or FOLFIRI) with targeted therapy (anti-EGFR or bevacizumab) based on goals and side-effect profile; consider liver-directed options if response",
      "narrative": "I'm 52, a sales rep living on the road. I need a plan that controls cancer without wrecking my ability to drive and meet clients.",
      "qa": [
        {
          "q": "How do we pick between regimens when every option sounds like a trade-off?",
          "gt": "**Choosing a regimen when every option feels like a trade‑off**\n\n1. **Side‑effect profile that matters to you**  \n   * **FOLFOX + bevacizumab** – 2‑week cycles, less neuropathy than FOLFIRI, but can cause hypertension and proteinuria.  \n   * **FOLFIRI + bevacizumab** – 2‑week cycles, more diarrhea and fatigue, but less neuropathy.  \n   * **Anti‑EGFR (cetuximab/panitumumab) + chemo** – rash, hypomagnesemia, and infusion reactions; usually paired with FOLFOX or FOLFIRI.\n\n2. **Impact on driving**  \n   * Avoid regimens that cause severe fatigue, neuropathy, or vision changes.  \n   * FOLFOX’s neuropathy is usually mild early on; anti‑EGFR rash can be managed with topical steroids and antihistamines.\n\n3. **Convenience**  \n   * 2‑week infusions fit a travel schedule better than 3‑week cycles.  \n   * Consider a home‑infusion or a nearby clinic to reduce travel time.\n\n4. **Personal priorities**  \n   * If maintaining high energy for client meetings is key, lean toward FOLFOX + bevacizumab or anti‑EGFR + FOLFOX with close monitoring of rash and neuropathy.  \n   * If you’re more tolerant of diarrhea but want fewer infusion visits, FOLFIRI + bevacizumab is an option.\n\n**Bottom line:**  \nPick the regimen that offers the most predictable, manageable side‑effects for driving and client work, fits your travel schedule, and aligns with your overall health goals. Discuss these priorities with your oncologist to tailor the plan to your lifestyle.",
          "order": 1,
          "qid": "S14-Q01"
        },
        {
          "q": "If I get the anti-EGFR drug and my face breaks out, am I stuck hiding at home?",
          "gt": "A facial rash is the most common side‑effect of anti‑EGFR therapy, but it usually doesn’t stop you from driving or meeting clients. Most rashes are mild (grade 1–2) and can be managed on the road with a simple skin‑care routine: use a gentle cleanser, apply a broad‑spectrum sunscreen (SPF 30+), moisturize with a non‑comedogenic lotion, and treat the rash with a topical steroid or oral doxycycline if it’s itchy or inflamed. If the rash becomes severe (grade 3–4), your oncologist can temporarily reduce the dose or pause treatment until it improves. Keep your dermatologist’s contact handy, and carry your skin‑care kit in your travel bag. With these measures, you can keep the rash under control and stay on the road.",
          "order": 2,
          "qid": "S14-Q02"
        },
        {
          "q": "Will neuropathy make it unsafe to drive?",
          "gt": "Neuropathy from oxaliplatin (or other agents) can impair sensation, balance, and reaction time—factors critical for safe driving. Mild, intermittent tingling usually doesn’t preclude driving, but if you experience numbness in the feet or hands, persistent pain, or loss of coordination, it’s safer to avoid driving until symptoms improve.  \n\n**Practical steps:**  \n1. **Assess**: Have an occupational therapist evaluate your hand‑to‑wheel control, reaction time, and balance.  \n2. **Monitor**: Keep a symptom diary—note any numbness, tingling, or pain that worsens during or after driving.  \n3. **Adjust**: If neuropathy is moderate or severe, consider dose reduction, switching to a non‑neurotoxic regimen, or adding neuropathy‑protective measures (e.g., duloxetine).  \n4. **Regulations**: Check local driving‑license rules; many jurisdictions require medical clearance if you have significant neuropathy.  \n\nIn short, mild neuropathy may be manageable, but significant sensory loss or pain usually makes driving unsafe. Adjust your treatment and seek professional assessment before resuming the road.",
          "order": 3,
          "qid": "S14-Q03"
        },
        {
          "q": "Can the liver spots ever be removed, or is that false hope?",
          "gt": "It’s not false hope, but it depends on how many and where the lesions are.  \nIf you have a limited number of liver metastases (usually ≤3–5, each <3 cm) and they’re technically resectable, a surgical resection or image‑guided ablation (radiofrequency, microwave, or stereotactic) can remove them and may prolong survival.  \nWhen the disease is more extensive, systemic therapy (FOLFOX/FOLFIRI plus anti‑EGFR or bevacizumab for RAS‑wt) is the mainstay; liver‑directed treatments are then used to shrink lesions so they become resectable or to control symptoms.  \nSo removal is possible in selected cases, but for widespread disease it’s usually part of a multimodal strategy rather than a single cure.",
          "order": 4,
          "qid": "S14-Q04"
        },
        {
          "q": "Cold drinks triggering pain—does that mean I’m stuck sipping lukewarm forever?",
          "gt": "Cold‑induced pain is a classic side‑effect of oxaliplatin (the “cold‑sensitivity” neuropathy). It doesn’t mean you have to stay with lukewarm drinks forever, but you’ll need a plan to keep the pain under control so you can keep driving and meeting clients.\n\n**What you can do**\n\n| Strategy | How it helps |\n|----------|--------------|\n| **Avoid very cold beverages** – keep drinks at room temperature or slightly warm. | Reduces the trigger that sparks the neuropathic flare. |\n| **Use topical lidocaine or capsaicin patches** on the hands/feet. | Provides local relief during cold exposure. |\n| **Take a neuropathic pain medication** (duloxetine, gabapentin, or pregabalin) as prescribed. | Lowers overall sensitivity to cold and improves daily function. |\n| **Ask your oncologist about dose‑adjusted oxaliplatin or switching to a non‑oxaliplatin regimen (e.g., FOLFIRI + bevacizumab)** if the neuropathy is persistent or disabling. | Removes the culprit drug while still treating the cancer. |\n| **Keep a “cold‑trigger log”** (when you feel pain, what you drank, how long it lasted). | Helps the team fine‑tune meds and lifestyle tweaks. |\n\nWith these measures, most patients can resume normal driving and client‑meetings without constant pain. If the neuropathy worsens or interferes with safety, discuss dose modification or a switch in therapy with your oncologist.",
          "order": 5,
          "qid": "S14-Q05"
        },
        {
          "q": "How often will I be tethered to an infusion pump?",
          "gt": "With a standard FOLFOX or FOLFIRI backbone, you’ll receive 2‑week cycles.  Each cycle includes 2–3 days of IV infusion (oxaliplatin or irinotecan plus 5‑FU/IV).  If you’re on an anti‑EGFR antibody (cetuximab or panitumumab) you’ll get a 2‑hour infusion every 2 weeks; bevacizumab is usually given every 2 weeks as a 30‑minute infusion.  In total you’ll spend roughly 3–4 days in the clinic per 2‑week cycle, with the rest of the time free to drive and meet clients.  Some centers offer home‑infusion or subcutaneous options that can reduce clinic visits, but the core schedule remains the same.",
          "order": 6,
          "qid": "S14-Q06"
        },
        {
          "q": "What if my bowels go haywire on a client visit?",
          "gt": "If you’re on a chemo regimen that can trigger diarrhea (e.g., FOLFOX, FOLFIRI, or anti‑EGFR agents), keep a “bowel‑ready” kit in your car: loperamide (Imodium), a stool softener, a small bottle of oral rehydration solution, and a list of nearby pharmacies or urgent‑care centers. Plan your meals—avoid high‑fiber, greasy, or dairy foods that can worsen loose stools—and stay hydrated. If you feel a flare, take a dose of loperamide immediately and monitor stool frequency. If you experience more than 3 loose stools in 24 h, or if you’re dehydrated, call your oncology team right away; they may adjust your medication or prescribe a short‑term steroid. Inform a trusted client or colleague about your plan so you can discreetly seek a restroom or medical help if needed.",
          "order": 7,
          "qid": "S14-Q07"
        },
        {
          "q": "Do second opinions slow me down or strengthen my plan?",
          "gt": "A second opinion rarely delays your treatment in a meaningful way—most centers can provide a review within a week, especially if you use tele‑oncology. The real benefit is a fresh, independent confirmation of your RAS‑wild‑type status, a review of the latest evidence for anti‑EGFR versus bevacizumab, and an assessment of liver‑directed options or clinical trials that might fit your travel schedule. It can also surface side‑effect profiles that align better with your need to stay on the road (e.g., choosing a regimen with less neuropathy or fatigue). In short, a second opinion usually strengthens your plan by adding confidence, options, and a tailored approach without significant delay.",
          "order": 8,
          "qid": "S14-Q08"
        },
        {
          "q": "How do you know when to switch before the scan says so?",
          "gt": "**When to switch before the next scan?**  \n1. **Clinical decline** – new or worsening pain, weight loss, fatigue, or loss of appetite that isn’t explained by treatment side‑effects.  \n2. **Performance‑status drop** – if you can’t drive or meet clients because of worsening symptoms, it’s time to consider a change.  \n3. **Laboratory signals** – rising tumor markers (CEA) or worsening liver function tests that suggest tumor activity.  \n4. **Toxicity plateau** – if you’re experiencing cumulative neuropathy, mucositis, or other side‑effects that impair your daily life, a switch may be warranted.  \n5. **Radiologic hints** – even a small new lesion or growth on a prior scan can prompt a change, especially if it’s symptomatic.  \n\nUse a shared‑decision model: discuss these signs with your oncologist, weigh the risks of continuing versus switching, and choose a regimen that balances disease control with your ability to drive and work.",
          "order": 9,
          "qid": "S14-Q09"
        },
        {
          "q": "Is it okay to keep small goals, like hitting my sales summit, or is that denial?",
          "gt": "It’s not denial to set small, achievable goals—on the contrary, purposeful activity can improve mood, sense of normalcy, and even treatment tolerance. The key is to match the goal to your current energy and side‑effect profile. For example, if you’re on a regimen that can cause fatigue, neuropathy, or nausea, schedule the summit when you feel strongest, keep the drive short, and allow extra rest or a “buffer” day. If you notice worsening symptoms, pause the goal and focus on symptom control. In short, realistic, flexible goals are a healthy coping strategy, not avoidance. Keep your oncologist in the loop so treatment adjustments can be made if needed.",
          "order": 10,
          "qid": "S14-Q10"
        }
      ]
    },
    {
      "id": "S15",
      "title": "Sun runner (BRAF V600E metastatic melanoma)",
      "diagnosis": "BRAF V600E positive metastatic melanoma",
      "treatment_plan": "Immunotherapy and/or targeted BRAF/MEK inhibitors depending on goals and disease features",
      "narrative": "I'm 39, a trail runner with metastatic melanoma. I want to keep moving and not lose months to side effects if there’s a path that fits me.",
      "qa": [
        {
          "q": "How do we choose between immunotherapy and targeted pills without gambling my best shot?",
          "gt": "For a 39‑year‑old trail runner with BRAF V600E metastatic melanoma, the choice hinges on **speed of response vs. long‑term durability** and your tolerance for side effects.\n\n| Factor | Targeted BRAF/MEK (dabrafenib + trametinib, etc.) | Immunotherapy (nivolumab, pembrolizumab, ipilimumab) |\n|--------|----------------------------------------------|-----------------------------------------------------|\n| **Onset** | Rapid (1–2 weeks) – useful if you have high tumor burden or symptomatic disease | Slower (4–6 weeks) – may take months for a durable response |\n| **Durability** | Median progression‑free ~6–7 mo; overall survival ~2 yr | Durable in ~30–40 % of patients; can last years |\n| **Side‑effect profile** | Fatigue, rash, arthralgia, photosensitivity; manageable with dose‑adjustment | Immune‑related AEs (colitis, dermatitis, endocrinopathies); usually reversible with steroids |\n| **Impact on activity** | Can cause fatigue and joint pain; many patients maintain exercise with dose‑modification | AEs may limit activity, but many patients continue running once stable |\n| **Brain mets** | Good penetration; often first choice for symptomatic brain disease | Effective but slower; may need steroids if symptomatic |\n\n**Practical approach**\n\n1. **Assess disease burden** – If you have bulky or symptomatic disease (e.g., painful lesions, brain mets), start BRAF/MEK to shrink quickly.  \n2. **Consider performance status** – If you’re fit and can tolerate immune‑related AEs, immunotherapy offers a chance for long‑term control.  \n3. **Sequence or combine** – Many clinicians start with BRAF/MEK, then switch to immunotherapy after 3–6 mo if disease remains controlled, or vice‑versa.  \n4. **Discuss with your oncologist** – Bring your running goals and any prior side‑effect history; they can tailor dosing or add supportive measures (e.g., physical therapy, anti‑inflammatory meds).\n\nIn short, **rapid control → targeted therapy; durable control → immunotherapy**—but the best plan is individualized and often involves a short course of targeted pills followed by immunotherapy.",
          "order": 1,
          "qid": "S15-Q01"
        },
        {
          "q": "What side effects stop runs versus ones I can work around?",
          "gt": "**Side effects that usually make running unsafe or impossible**  \n- **Severe fatigue or malaise** (especially if it limits basic daily activity)  \n- **Intense arthralgia or myalgia** that makes joint motion painful  \n- **Peripheral neuropathy** that causes numbness, tingling, or loss of balance  \n- **Cardiotoxicity** (e.g., reduced ejection fraction, arrhythmias) or significant hypertension  \n- **Severe ocular toxicity** (e.g., retinal detachment, uveitis) that impairs vision  \n- **Severe colitis, pneumonitis, or other immune‑mediated organ inflammation** that requires steroids or hospitalization  \n\n**Side effects you can usually work around with adjustments**  \n- Mild to moderate fatigue → rest days, short, low‑intensity runs, adequate sleep, caffeine or low‑dose stimulants if tolerated.  \n- Mild arthralgia or skin rash → NSAIDs, topical steroids, reduce intensity, use supportive footwear, avoid extreme heat.  \n- Mild neuropathy → protective footwear, avoid high‑impact surfaces, use gait‑assessing shoes.  \n- Mild hypertension or mild cardiotoxicity → monitor BP, take antihypertensives, keep runs at moderate pace, avoid dehydration.  \n- Mild ocular changes → regular ophthalmology checks, use sunglasses, limit UV exposure, adjust running schedule if vision fluctuates.  \n\n**Practical tips**  \n1. **Track symptoms** in a diary and share with your oncology team.  \n2. **Use supportive meds** (NSAIDs, antihistamines, anti‑diarrheals) as prescribed.  \n3. **Hydrate and warm‑up** to reduce joint pain.  \n4. **Adjust terrain** (soft trails, avoid steep climbs) when fatigue or pain rises.  \n5. **Schedule rest days** strategically around treatment cycles.  \n\nIf any side effect worsens or you feel unsafe, stop running and consult your oncologist or a sports medicine specialist.",
          "order": 2,
          "qid": "S15-Q02"
        },
        {
          "q": "If I spike fevers on pills, am I done running for good?",
          "gt": "A low‑grade fever (≤ 38.5 °C) that comes on with a BRAF/MEK or checkpoint inhibitor is common and usually not a reason to quit running entirely. You can keep moving as long as you stay hydrated, avoid overexertion, and monitor how you feel. If the fever climbs above 38.5 °C, you develop chills, fatigue, or other systemic symptoms, or you feel dizzy or weak, pause the workout, rest, and contact your oncology team. They may adjust the dose or add supportive care (e.g., antipyretics). In short, mild fevers can be managed while you keep training, but high fevers or worsening symptoms warrant stopping and medical review.",
          "order": 3,
          "qid": "S15-Q03"
        },
        {
          "q": "Will immunotherapy make my body attack my thyroid or gut forever?",
          "gt": "Immunotherapy can trigger immune‑related adverse events (irAEs) such as thyroiditis or colitis, but they are **not always permanent**.  \n\n- **Thyroid**: About 10–20 % of patients develop transient or permanent hypothyroidism or hyperthyroidism. Most cases resolve or become manageable with levothyroxine or antithyroid medication after stopping therapy. A small fraction may need lifelong treatment, but this is uncommon.  \n- **Gut**: Colitis occurs in 5–10 % of patients. With prompt steroids (or infliximab if needed) the inflammation usually subsides, and bowel function often returns to baseline. Chronic inflammatory bowel disease is rare but possible.  \n\nKey points:  \n1. **Early detection** – regular thyroid function tests and prompt reporting of abdominal pain or diarrhea.  \n2. **Management** – steroids or biologics can control inflammation; most patients recover enough to continue activity.  \n3. **Monitoring** – if you’re a trail runner, keep your doctor informed; most irAEs are reversible and do not preclude continued movement.  \n\nSo, while immunotherapy can affect the thyroid or gut, it usually does **not** cause lifelong damage for everyone.",
          "order": 4,
          "qid": "S15-Q04"
        },
        {
          "q": "Can I still race this season if scans look better?",
          "gt": "**Short answer:** Yes—most people with metastatic melanoma can keep running, but you need a clear go‑ahead from your oncology team and a plan to manage therapy‑related fatigue, skin changes, and any new symptoms.\n\n**Practical steps**\n\n1. **Get clearance** – Ask your oncologist if your current treatment (immunotherapy or BRAF/MEK) and scan results allow you to race. They’ll consider any new lesions, organ function, and side‑effect profile.  \n2. **Monitor side effects** – Fatigue, rash, joint pain, or neuropathy can flare with exercise. If you notice worsening, pause or reduce intensity.  \n3. **Start low** – Begin with short, easy runs, then gradually increase distance and pace. Use supportive shoes, proper hydration, and sun protection (melanoma patients are more photosensitive).  \n4. **Watch for red flags** – New pain, swelling, unexplained weight loss, or fevers should prompt a medical check‑up.  \n5. **Stay flexible** – If a race feels too taxing, consider a shorter event or a “race‑in‑training” approach (running the course on a treadmill or track).\n\n**Bottom line:** With your scans improving, many patients race safely, but always coordinate with your oncology team and listen to your body.",
          "order": 5,
          "qid": "S15-Q05"
        },
        {
          "q": "Do I need to hide from the sun now?",
          "gt": "You don’t have to quit running, but you should treat the sun like a potential trigger for skin irritation and tumor flare‑ups.  \n- **Use a broad‑spectrum SPF 30+** (reapply every 2 h, especially after sweating).  \n- Wear a wide‑brim hat, UV‑blocking sunglasses, and long‑sleeved, breathable clothing.  \n- Avoid peak UV hours (10 a.m.–4 p.m.) and seek shade whenever possible.  \n- If you’re on BRAF/MEK inhibitors, photosensitivity is common—be extra vigilant.  \n- Immunotherapy alone usually doesn’t heighten sun sensitivity, but the same precautions still help prevent skin breakdown.  \n\nSo, keep running, but treat the sun with the same care you give your treatment plan—protect, shield, and monitor.",
          "order": 6,
          "qid": "S15-Q06"
        },
        {
          "q": "If brain spots show up later, does that end everything?",
          "gt": "Brain‑metastatic “spots” do **not** automatically mean the end of treatment or activity.  In melanoma, many patients with limited brain lesions can be treated with stereotactic radiosurgery (SRS), sometimes followed by whole‑brain radiation, and then continue systemic therapy.  BRAF‑targeted drugs (dabrafenib + trametinib) and immune checkpoint inhibitors (nivolumab, pembrolizumab, or a combination) penetrate the brain and can control or shrink lesions, especially when combined with local radiation.  Prognosis depends on the number and size of lesions, control of systemic disease, and your performance status.  If you’re fit and active, most oncologists will keep you on a tailored regimen that allows you to keep running while managing brain metastases.  Discuss early imaging and a multidisciplinary plan with your team.",
          "order": 7,
          "qid": "S15-Q07"
        },
        {
          "q": "Can I keep my job while doing this, or should I plan leave?",
          "gt": "Many patients with metastatic melanoma can continue working while on therapy, but it depends on the treatment chosen and how you tolerate side‑effects.  \n**Immunotherapy (nivolumab/ipilimumab, pembrolizumab, etc.)** often causes fatigue, flu‑like symptoms, and occasional rash or colitis that may require dose breaks or steroids.  \n**Targeted BRAF/MEK therapy** (dabrafenib + trametinib, encorafenib + binimetinib, etc.) can produce fatigue, skin rash, diarrhea, and, less commonly, cardiac or pulmonary issues that may need dose reductions or temporary discontinuation.  \n\nIf your job is physically demanding (trail running, outdoor work), you may need to adjust your schedule or shift to lighter duties until you feel stable. Many people successfully work part‑time, remotely, or with flexible hours while on treatment.  \n\n**Practical steps:**  \n1. Discuss your work demands with your oncologist and occupational health team.  \n2. Plan for short breaks or reduced intensity during flare‑ups.  \n3. Keep a symptom diary to anticipate when a dose pause might be needed.  \n\nIn short, you can often keep your job, but be prepared for occasional leave or schedule adjustments based on how your body responds to therapy.",
          "order": 8,
          "qid": "S15-Q08"
        },
        {
          "q": "What signals tell me to call you the same day?",
          "gt": "**Call your oncology team the same day if you notice any of the following:**\n\n- **Fever ≥ 38 °C (100.4 °F) or chills** – could signal infection or immune‑related fever.\n- **Severe or worsening pain, swelling, or redness** at a tumor site or new skin lesions.\n- **Unexplained shortness of breath, chest pain, or palpitations** – possible pneumonitis or cardiotoxicity.\n- **New neurological changes** (confusion, weakness, vision changes, seizures) – could indicate CNS involvement or neuro‑toxicity.\n- **Persistent vomiting, diarrhea, or abdominal pain** – signs of colitis or hepatitis.\n- **Uncontrolled bleeding** (from a lesion or mucosal sites) or new bruising.\n- **Elevated liver enzymes** (if you have recent labs) or jaundice.\n- **Sudden vision changes or eye pain** – possible uveitis or retinal toxicity.\n- **New rash with itching, swelling, or blistering** that spreads rapidly.\n- **Any sudden, severe fatigue, dizziness, or fainting**.\n\nIf you’re unsure, err on the side of caution and call immediately. Your team can triage and decide if you need urgent evaluation or a visit.",
          "order": 9,
          "qid": "S15-Q09"
        },
        {
          "q": "If I choose wrong first, did I ruin my chance at the other option?",
          "gt": "Choosing the first line of therapy doesn’t permanently lock you out of the other option. In metastatic BRAF‑V600E melanoma, many patients start with either immunotherapy (e.g., nivolumab + ipilimumab or pembrolizumab alone) or a BRAF/MEK inhibitor (dabrafenib + trametinib). If you begin with a BRAF/MEK combo and it works, you can still switch to immunotherapy later if the disease progresses or you develop resistance. Conversely, if you start with immunotherapy and it’s effective, you can add a BRAF/MEK inhibitor for a “bridge” or use it later if the tumor becomes refractory. The key is close monitoring, early assessment of response, and a flexible plan that allows switching when needed. Discuss with your oncologist the best sequencing for your goals and lifestyle.",
          "order": 10,
          "qid": "S15-Q10"
        }
      ]
    },
    {
      "id": "S16",
      "title": "Hospital or home (newly diagnosed AML at 67)",
      "diagnosis": "Acute myeloid leukemia in a 67-year-old",
      "treatment_plan": "Either intensive inpatient induction or lower-intensity therapy (hypomethylating agent + venetoclax) with transfusion support; infection prophylaxis; consider trial",
      "narrative": "I'm 67 and blindsided by leukemia. They’re talking about weeks in the hospital or a gentler plan mostly at home. I want time, but I also want myself.",
      "qa": [
        {
          "q": "If I choose the hospital route, how long am I really there and what does a day look like?",
          "gt": "If you opt for intensive inpatient induction, you’ll usually stay in the hospital for **7–10 days** of chemotherapy (often 7 days of cytarabine + daunorubicin or a similar regimen). After that, you’ll be monitored closely for 2–4 weeks—sometimes a few more days if you’re neutropenic or need transfusions—before being discharged.  \n\n**A typical day**:  \n- **Morning**: blood counts, vitals, and a brief check‑in with the oncology team.  \n- **Mid‑day**: chemo infusion (usually 1–2 hours), followed by a recovery period.  \n- **Afternoon**: labs, medication administration (antibiotics, antifungals, growth factors), and transfusion support if needed.  \n- **Evening**: routine nursing care, pain control, and a brief review of the next day’s plan.  \n\nThroughout, the team monitors for infections, organ toxicity, and blood‑count recovery, adjusting supportive care as needed.",
          "order": 1,
          "qid": "S16-Q01"
        },
        {
          "q": "If I choose the at-home regimen, am I less likely to be alive for my granddaughter’s birthday?",
          "gt": "Choosing the home‑based hypomethylating agent + ven",
          "order": 2,
          "qid": "S16-Q02"
        },
        {
          "q": "Will I be transfusion-dependent for months?",
          "gt": "In most AML patients, the first few weeks after starting therapy—whether intensive induction or a lower‑intensity regimen—are the period of greatest cytopenia. During this time you’ll likely need red‑cell and platelet transfusions to keep hemoglobin above ~8 g/dL and platelets above 20 × 10⁹/L. That support can last 4–8 weeks, sometimes longer if the marrow takes time to recover or if you have complications (infection, bleeding, or a suboptimal response). Once you achieve remission, the marrow usually regains enough function to stop transfusions, though some patients may need occasional transfusions for a few months. Discuss your transfusion plan with your team so you know what to expect and how to manage it at home.",
          "order": 3,
          "qid": "S16-Q03"
        },
        {
          "q": "How do we prevent infections when my immune system vanishes?",
          "gt": "When your white‑cell count drops, the body’s first line of defense is gone, so the plan is to keep you as “clean” as possible and to catch problems early.\n\n**Daily precautions**  \n- Wash hands with soap or alcohol gel before meals, after bathroom use, and after touching surfaces.  \n- Wear a mask and avoid crowds, especially in winter or during flu season.  \n- Keep your home clean; avoid dusty or moldy areas.  \n- Use a HEPA filter if possible and keep windows closed when pollen counts are high.\n\n**Diet & hydration**  \n- Eat cooked, well‑washed foods; avoid raw meats, unpasteurized dairy, and raw sprouts.  \n- Stay hydrated to help your kidneys clear toxins.\n\n**Medications**  \n- Your oncologist may give prophylactic antibiotics (e.g., fluoroquinolone), antifungals (posaconazole), and antivirals (acyclovir) while neutropenic.  \n- G‑CSF (filgrastim) can shorten neutropenia if your regimen allows.\n\n**Watch for fever**  \n- A temperature >38 °C (100.4 °F) is a red flag—call your team immediately.  \n- Blood cultures, chest X‑ray, and other labs are done promptly.\n\n**Vaccinations**  \n- Get updated flu and pneumococcal shots before treatment starts; keep boosters current.\n\n**Supportive care**  \n- Regular transfusions of platelets and red cells keep you stable.  \n- Keep your clinic or home nurse on standby for any signs of infection.\n\nBy combining strict hygiene, prophylactic drugs, careful diet, and rapid response to fever, you give your weakened immune system the best chance to stay protected.",
          "order": 4,
          "qid": "S16-Q04"
        },
        {
          "q": "What if the plan isn’t working—do we know early enough to pivot?",
          "gt": "If the chosen regimen isn’t working, we can usually tell within a few weeks.  \n\n**Intensive induction**: After 7–10 days we repeat a CBC and, if needed, a bone‑marrow aspirate. Failure to reach a ≥50 % blast reduction or to achieve a complete remission (CR) by day 14–21 prompts a switch to a salvage regimen (e.g., FLAG‑Ida, low‑dose cytarabine, or a clinical trial).  \n\n**Hypomethylating agent + venetoclax**: We assess response after 4–6 weeks. Persistent >20 % blasts or no cytopenia improvement signals that the combination isn’t effective, and we may add a second‑line agent (e.g., low‑dose cytarabine) or enroll in a trial.  \n\nEarly monitoring (weekly CBCs, scheduled marrow checks) and clear communication with your team let you pivot promptly while maintaining supportive care and infection prophylaxis.",
          "order": 5,
          "qid": "S16-Q05"
        },
        {
          "q": "Can I appoint my daughter to make decisions if I’m too sick?",
          "gt": "Yes—you can legally appoint your daughter to make medical decisions for you if you become unable to do so. In the U.S. this is called a **Durable Power of Attorney for Health Care** (sometimes called a health‑care proxy or surrogate decision‑maker).  \n\n**What to do next:**\n\n1. **Talk to your oncologist or a hospital social worker** about the paperwork.  \n2. **Fill out the state‑specific form** naming your daughter as your agent and describing any limits or preferences you have (e.g., treatment goals, comfort‑care only).  \n3. **Have the form signed, witnessed, and notarized** according to your state’s rules.  \n4. **Keep copies** for your daughter, your doctor, and the hospital; give one to each.  \n5. **Consider a living will** (advance directive) to record your wishes about life‑sustaining treatments.  \n\nWith these documents in place, your daughter can act on your behalf, ensuring your treatment choices are respected even if you’re too ill to speak. If you’re unsure of the exact form, a quick call to a local attorney or the hospital’s legal services can clarify the process.",
          "order": 6,
          "qid": "S16-Q06"
        },
        {
          "q": "Will chemo steal my mind or only my hair?",
          "gt": "Intensive induction (“7 + 3”) can be exhausting—fatigue, nausea, infections, and the classic hair‑loss are common. “Cognitive fog” (difficulty concentrating, memory lapses) is usually mild and transient, often related to the overall stress of treatment, fever, or medications rather than a direct “chemo‑brain” effect. Most patients recover normal cognition within weeks after therapy ends.\n\nThe lower‑intensity venetoclax + hypomethylating agent regimen is gentler: you’ll stay at home, get transfusions and antibiotics as needed, and the side‑effect profile is less intense. It still can cause fatigue and mild confusion, but these are usually manageable with supportive care.\n\nIn short, chemo can make you feel tired and a bit foggy, but it rarely “steals” your mind. With close monitoring, most people regain full mental clarity after treatment.",
          "order": 7,
          "qid": "S16-Q07"
        },
        {
          "q": "Do I have to stop my daily walk?",
          "gt": "It’s usually safe—and even helpful—to keep walking, but you’ll need to adjust how you do it.  \n- **During induction** (high‑dose chemo) you’ll likely be neutropenic for 2–3 weeks. Light, short walks (5–10 min) at home or in a quiet, well‑ventilated area are fine, but avoid crowded places, steep stairs, or anything that could cause a fall.  \n- **With hypomethylating + venetoclax** you’ll have less intense myelosuppression, so you can keep your usual routine, but still watch for fatigue, dizziness, or new bruising.  \n- **Listen to your body**: if you feel dizzy, short‑of‑breath, or unusually tired, cut back or rest.  \n- **Check with your oncologist** before changing intensity, especially if you develop fever or infection.  \n\nSo you don’t have to stop walking entirely—just tailor the pace, duration, and environment to your current health status.",
          "order": 8,
          "qid": "S16-Q08"
        },
        {
          "q": "How do costs and caregiver time differ between options?",
          "gt": "**Intensive inpatient induction (7‑10 days of high‑dose cytarabine/daunorubicin)**  \n- **Direct costs:** $30 k–$50 k per induction cycle (hospital stay, IV drugs, labs, transfusions, ICU if needed).  \n- **Caregiver time:** 1–2 hrs/day for visits, but most clinical work is done by nurses and physicians; you can rest and recover in the hospital.  \n\n**Lower‑intensity outpatient (hypomethylating agent + venetoclax)**  \n- **Direct costs:** $10 k–$20 k per 28‑day cycle (oral meds, outpatient labs, transfusions).  \n- **Caregiver time:** 4–6 hrs/day during the first 2–3 weeks for blood draws, transfusions, monitoring vitals, and infection precautions; then 1–2 hrs/week for routine visits.  \n\n**Bottom line:** Inpatient care is far more expensive but frees you from daily caregiving duties; outpatient therapy is cheaper overall but requires a significant caregiver commitment, especially early in treatment. Discuss your support network and financial resources with your oncology team to choose the best fit.",
          "order": 9,
          "qid": "S16-Q09"
        },
        {
          "q": "If I want to switch paths later, can I?",
          "gt": "It’s possible to change course, but the window is limited.  \nIf you start a hypomethylating agent + venetoclax and the disease remains stable, you can keep that plan for months or years. If the leukemia progresses, relapses, or you develop a high‑risk cytogenetic profile, your oncologist may recommend switching to intensive induction (cytarabine + anthracycline) or a clinical trial.  \n\nThe decision depends on your performance status, organ function, and how well you tolerate the first regimen. Early in treatment, the team can reassess every 2–3 months; if you become frailer, intensive therapy may be less feasible. Keep an open dialogue with your hematologist—most centers allow a switch if the biology and your health permit.",
          "order": 10,
          "qid": "S16-Q10"
        }
      ]
    },
    {
      "id": "S17",
      "title": "Waiting feels like doing nothing (CLL watch-and-wait)",
      "diagnosis": "Chronic lymphocytic leukemia, asymptomatic",
      "treatment_plan": "Active surveillance with regular labs and exams; start treatment when specific triggers are met",
      "narrative": "I'm 63 and told we aren't treating yet. It feels like ignoring a ticking clock.",
      "qa": [
        {
          "q": "How is 'watch and wait' not just 'wait and worry'?",
          "gt": "**Watch‑and‑wait is a structured, evidence‑based strategy, not passive neglect.**  \n- **Clear triggers**: You’ll start therapy only when blood counts, organ size, or symptoms cross defined thresholds.  \n- **Regular monitoring**: Blood tests every 3–6 months (or sooner if needed) catch changes early, so treatment can be initiated before complications arise.  \n- **Avoids overtreatment**: Many patients never need chemo or radiation, sparing them side‑effects and preserving quality of life.  \n- **Empowerment**: You control the plan—stay active, maintain healthy habits, and report new symptoms promptly.  \n- **Psychological support**: Discuss concerns with your oncologist or a counselor; you’re not alone, and the plan is designed to protect you, not leave you idle.",
          "order": 1,
          "qid": "S17-Q01"
        },
        {
          "q": "What exact signs mean it’s time to act so I’m not guessing?",
          "gt": "**When to start therapy in “watch‑and‑wait” CLL**\n\n| Trigger | Typical threshold | Why it matters |\n|---------|-------------------|----------------|\n| **Absolute lymphocyte count (ALC)** | > 30 × 10⁹/L (or > 50 % of total WBC) | Rapid rise suggests disease expansion. |\n| **Prolymphocytes or blasts** | > 10 % of circulating cells | Indicates a shift toward aggressive disease. |\n| **Bone‑marrow infiltration** | > 50 % of marrow cellularity | Predicts cytopenias and organ failure. |\n| **Cytopenias** | Hb < 10 g/dL, platelets < 100 × 10⁹/L, or neutropenia < 1.0 × 10⁹/L | Signals marrow failure. |\n| **Organomegaly** | New or enlarging lymph nodes, spleen, or liver | Can compress vessels or cause symptoms. |\n| **Constitutional symptoms** | New fatigue, night sweats, fevers, weight loss | Reflect systemic disease activity. |\n| **Genetic risk** | del(17p), TP53 mutation, unmutated IGHV | High‑risk biology often warrants earlier treatment. |\n\n**Practical steps**\n\n1. **Labs**: CBC with differential every 3–6 months (more often if ALC rises).  \n2. **Imaging**: CT or PET/CT if lymphadenopathy enlarges or new symptoms appear.  \n3. **Discuss**: Bring any new symptoms or lab changes to your hematologist promptly.  \n\nThese objective markers help you and your doctor decide when “watch‑and‑wait” ends and treatment begins.",
          "order": 2,
          "qid": "S17-Q02"
        },
        {
          "q": "Can I still travel without labs every month?",
          "gt": "Yes, you can travel, but you’ll need a plan to keep your monitoring on track.  \n- **Schedule labs before you leave** (or arrange for a local lab at your destination).  \n- Bring copies of your recent results and your doctor’s contact info.  \n- If you’ll be away for more than a week, consider a tele‑visit or a quick in‑person check‑up when you arrive.  \n\nTravel can expose you to infections, so keep vaccinations up‑to‑date, avoid large crowds, and stay hydrated. If you can’t get labs done within the usual 4‑week window, discuss postponing travel or adjusting the schedule with your oncologist. The key is to maintain regular monitoring so you can start treatment promptly if needed.",
          "order": 3,
          "qid": "S17-Q03"
        },
        {
          "q": "Will my immunity be weak even without treatment?",
          "gt": "In early, untreated CLL the immune system is usually only mildly impaired. The disease itself can reduce antibody production and neutrophil function, but many people remain healthy for years. Your “watch‑and‑wait” plan is designed to keep you out of the toxicities of chemo while still catching any decline early.  \n\nThat said, you should still be vigilant: keep up with routine labs, report fevers or infections promptly, and stay current on vaccines (influenza, pneumococcal, COVID‑19, shingles). Good nutrition, regular exercise, adequate sleep, and avoiding smoking or excessive alcohol help maintain immune resilience. If you notice any new symptoms or a drop in blood counts, your doctor will adjust the plan. So, while there is a small risk of immune weakness, it’s usually manageable and monitored closely.",
          "order": 4,
          "qid": "S17-Q04"
        },
        {
          "q": "Should I change my diet or supplements to slow this down?",
          "gt": "I understand how unsettling it can feel to “watch and wait.”  \nCurrent research shows no specific diet or supplement reliably slows CLL progression. The best evidence‑based approach is a balanced, nutrient‑dense diet that supports overall health and immune function:\n\n- **Eat plenty of fruits, vegetables, whole grains, and lean proteins** (fish, poultry, beans).  \n- **Maintain a healthy weight**; obesity is linked to worse outcomes in many cancers.  \n- **Limit processed foods, sugary drinks, and excess red meat**.  \n- **Avoid high‑dose antioxidant supplements (e.g., vitamin E, beta‑carotene)**, which may interfere with chemotherapy if treatment starts.  \n- **Stay hydrated** and consider a modest daily multivitamin only if your diet is lacking, after discussing with your oncologist.\n\nIf you’re considering any supplement, check with your hematologist first—some can interact with future therapies. Regular labs and exams remain the cornerstone of monitoring.",
          "order": 5,
          "qid": "S17-Q05"
        },
        {
          "q": "Will insurance balk when I’m not 'actively' treated?",
          "gt": "In most U.S. plans, a “watch‑and‑wait” strategy for asymptomatic CLL is covered as long as it follows accepted clinical guidelines (e.g., NCCN). Insurers typically require that you meet the documented trigger criteria (elevated lymphocyte count, cytopenias, organomegaly, or symptomatic disease) before approving therapy.  \n\nTo avoid coverage denials:  \n1. Keep a detailed log of labs, CBCs, and any symptoms.  \n2. Have your hematologist submit a formal treatment‑indication note each time you’re evaluated.  \n3. If a plan denies coverage for a specific drug, request a prior‑authorization appeal citing the guideline‑based trigger.  \n\nMost insurers will not penalize you for not being “actively” treated as long as you’re under regular surveillance and the plan’s criteria are met.",
          "order": 6,
          "qid": "S17-Q06"
        },
        {
          "q": "Is there a benefit to clinical trials now?",
          "gt": "For an asymptomatic 63‑year‑old under watch‑and‑wait, most clinical trials are designed for patients who already need therapy or who have relapsed disease. However, a few studies now target early‑stage CLL or minimal residual disease, offering access to novel agents (e.g., BTK or BCL‑2 inhibitors) that might delay progression or reduce future treatment intensity.  \n\n**Potential benefits**:  \n- **Early intervention** with a drug that could postpone the need for standard chemo‑immunotherapy.  \n- **Contribution to science** that may improve care for future patients.  \n- **Close monitoring** and supportive care that come with trial participation.  \n\n**Risks/considerations**:  \n- Possible side‑effects of investigational drugs.  \n- Trial protocols may require frequent visits or lab work.  \n- Many trials have strict eligibility (e.g., specific genetic markers or disease burden).  \n\nDiscuss with your hematologist to identify trials that fit your disease status and personal goals. If a suitable early‑stage trial exists, enrolling could provide a proactive option while still respecting the watch‑and‑wait approach.",
          "order": 7,
          "qid": "S17-Q07"
        },
        {
          "q": "How do I tell family I’m okay when the word leukemia scares them?",
          "gt": "**Keep it simple and reassuring.**  \nExplain that “leukemia” is a diagnosis, not a verdict. Tell your family, “I’m healthy right now. We’re doing regular blood tests and exams, and if anything changes we’ll start treatment immediately.”  \nUse a familiar analogy—“It’s like a car that’s on a routine check‑up; we’re watching the dashboard, and we’ll jump in if a warning light comes on.”  \nEmphasize that many people live years with a watch‑and‑wait plan and that early treatment is always available.  \nIf they’re still anxious, offer to share your monitoring schedule or bring them a pamphlet from your oncologist.  \nFinally, let them know you appreciate their concern but that you’re in good hands and that you’ll keep them updated.",
          "order": 8,
          "qid": "S17-Q08"
        },
        {
          "q": "Can stress make this speed up?",
          "gt": "In the current evidence, psychological stress does **not** appear to accelerate the natural course of chronic lymphocytic leukemia (CLL). Large studies and meta‑analyses have not shown a clear link between anxiety or depression and faster disease progression or earlier need for treatment. Stress can, however, affect immune function and overall well‑being, which may influence how you feel and how you manage appointments or lifestyle changes.\n\nPractical steps:  \n- Practice relaxation techniques (deep breathing, meditation, gentle yoga).  \n- Maintain a routine of regular exercise and balanced nutrition.  \n- Stay connected with supportive friends, family, or a counselor.  \n- Keep a symptom diary and report any new changes promptly.\n\nThese measures help you feel more in control and may improve quality of life while you remain under watch‑and‑wait.",
          "order": 9,
          "qid": "S17-Q09"
        },
        {
          "q": "How often do people never need treatment?",
          "gt": "In early‑stage, asymptomatic CLL, most patients do **not** need treatment for several years.  Roughly **60–70 %** of people under a watch‑and‑wait plan will avoid therapy for the first 5–10 years, and about **30–40 %** will never require treatment at all during their lifetime.  The decision to start therapy is based on specific blood‑count or symptom triggers, not on time alone.  So while it can feel like a ticking clock, many patients live years—often decades—without needing any drugs.",
          "order": 10,
          "qid": "S17-Q10"
        }
      ]
    },
    {
      "id": "S18",
      "title": "Finding my voice again (papillary thyroid cancer)",
      "diagnosis": "Papillary thyroid carcinoma after thyroidectomy",
      "treatment_plan": "Surgery followed by thyroid hormone replacement; consider radioactive iodine based on risk; lifelong surveillance",
      "narrative": "I'm 35, a teacher. Surgery took my thyroid. My voice is hoarse and the scar is new territory. I’m trying to feel normal again.",
      "qa": [
        {
          "q": "Will my voice return to my old classroom strength?",
          "gt": "After a thyroidectomy the recurrent laryngeal nerves are the most common culprit for hoarseness. In most cases the nerves are only stretched or mildly irritated, and vocal strength improves over weeks to a few months with rest, hydration, and voice‑therapy exercises. Full recovery to “old classroom” volume is common, but some people notice a subtle, permanent change in pitch or endurance. The scar itself does not affect the voice. If you’re still hoarse after 6–8 weeks, a speech‑language pathologist can tailor a program to strengthen your vocal folds and teach safe vocal habits. Early referral and consistent practice give the best chance of regaining your former classroom presence.",
          "order": 1,
          "qid": "S18-Q01"
        },
        {
          "q": "Do I need radioactive iodine, or can we skip it safely?",
          "gt": "I’m sorry you’re dealing with both a new scar and a hoarse voice—those are common after thyroid surgery, but they’re not related to radioactive iodine (RAI). Whether you need RAI depends on your tumor’s risk profile, not on the voice change.  \n\n**Low‑risk** (tumor ≤1 cm, no lymph node spread, no extrathyroidal extension) can safely skip RAI; you’ll just have regular thyroglobulin checks and neck ultrasounds.  \n\n**Intermediate‑risk** (larger tumor, microscopic nodal disease, or minimal extrathyroidal extension) usually gets a low‑dose RAI to reduce recurrence.  \n\n**High‑risk** (large tumor, gross extrathyroidal extension, distant metastases, or aggressive histology) gets a higher‑dose RAI.  \n\nAsk your surgeon or endocrinologist for your specific risk category and the evidence behind their recommendation. If you’re still unsure, a second opinion can help you feel more confident.",
          "order": 2,
          "qid": "S18-Q02"
        },
        {
          "q": "How do we set my hormone dose so I’m not anxious and sleepless?",
          "gt": "After thyroidectomy you’ll need levothyroxine to keep your TSH in the low‑normal range (≈0.5–2.5 mIU/L) for most patients with papillary cancer.  The usual approach is:\n\n1. **Start dose** – 1.6 µg/kg/day (≈75–100 µg for most adults).  \n2. **First check** – 6 weeks after starting or after a dose change.  \n3. **Adjust** – Increase by 12.5–25 µg if TSH > 2.5 mIU/L; decrease if TSH < 0.5 mIU/L or you feel overly energetic, anxious, or insomnia.  \n4. **Re‑check** – 6–8 weeks after any adjustment.  \n5. **Long‑term** – Every 6–12 months, or sooner if symptoms change.\n\nIf you still feel anxious or sleepless despite a normal TSH, discuss adding a low‑dose T3 (e.g., 5 µg daily) or a short course of a sleep aid/CBT.  Keep a symptom diary (energy, mood, sleep) to share with your endocrinologist.  Small, gradual dose tweaks usually restore normalcy without overtreatment.",
          "order": 3,
          "qid": "S18-Q03"
        },
        {
          "q": "Will this scar always shout 'cancer' at people?",
          "gt": "Your scar is a normal result of the thyroid surgery, not a sign of cancer. Over time it will fade and become less noticeable—most people’s scars darken, thin, and blend into the surrounding skin. If you’re concerned about its appearance, you can discuss options such as silicone sheets, laser therapy, or gentle massage to help it heal more smoothly.  \n\nThe hoarseness comes from temporary nerve irritation or injury during the operation; many patients notice improvement within weeks to months, and speech therapy can accelerate recovery.  \n\nSo, the scar won’t “shout” cancer to others; it’s simply a healed surgical mark, and your voice should gradually return to normal.",
          "order": 4,
          "qid": "S18-Q04"
        },
        {
          "q": "Can I get pregnant safely on these medicines?",
          "gt": "After thyroidectomy you’ll need lifelong levothyroxine replacement. Pregnancy is safe as long as your thyroid hormone is well‑controlled. Your doctor will adjust the dose so that your TSH stays in the pregnancy‑target range (≈0.5–2.5 mIU/L). If you received radioactive iodine, you must wait at least 6–12 months (often 12 months) before trying to conceive, because the radioiodine can affect the developing fetus. Once you’re off iodine and your TSH is stable, you can plan a pregnancy. Keep regular prenatal visits, and inform your obstetrician that you’re on levothyroxine; they’ll monitor your levels and adjust the dose as needed. Your voice hoarseness is usually due to nerve injury from surgery and does not affect fertility or pregnancy safety.",
          "order": 5,
          "qid": "S18-Q05"
        },
        {
          "q": "What follow-up keeps me safe without over-testing?",
          "gt": "**Follow‑up plan (typical for a low‑risk papillary thyroid cancer after total thyroidectomy)**  \n\n| What | Frequency | Why | How |\n|------|-----------|-----|-----|\n| **TSH‑suppression therapy** | Check TSH every 3–6 months for the first 2 years, then annually | Keeps TSH <0.1 mIU/L to reduce recurrence risk | Simple blood draw |\n| **Serum thyroglobulin (Tg) & anti‑Tg antibodies** | Every 6 months for 2 years, then annually | Tg is the tumor marker; rising levels flag recurrence | Blood test |\n| **Neck ultrasound** | Every 6–12 months for 2 years, then annually | Detects nodules or lymph node changes | 15‑minute scan |\n| **Voice & scar care** | As needed; see ENT or speech therapist if hoarseness persists | Voice changes can be nerve‑related; early rehab helps | Referral if symptoms worsen |\n| **Annual physical & labs** | Once a year | Routine check for thyroid hormone levels, general health | Routine visit |\n\n**Key points**\n\n- No routine whole‑body scans or CTs are needed unless Tg rises or ultrasound shows suspicious nodes.  \n- Keep TSH low (≤0.1 mIU/L) with levothyroxine; adjust dose based on labs.  \n- If Tg stays undetectable and ultrasound is clear, the schedule can be relaxed to yearly visits.  \n\nThis balanced approach protects against recurrence while avoiding unnecessary tests. If you notice new neck lumps, voice changes, or weight/energy shifts, contact your endocrinologist sooner.",
          "order": 6,
          "qid": "S18-Q06"
        },
        {
          "q": "Is my calcium low forever after surgery?",
          "gt": "After a total thyroidectomy the parathyroid glands can be injured or removed, which is why many people feel low‑calcium symptoms right after surgery. In most cases the hypocalcemia is **transient** – calcium levels usually return to normal within a few weeks to a few months as the remaining parathyroids recover. Permanent hypocalcemia occurs in only about 5–10 % of patients.  \n\n**What to do:**  \n1. **Check your calcium and PTH** 2–4 weeks post‑op.  \n2. If low, your doctor will give oral calcium (1–2 g/day) and vitamin D (800–1 000 IU/day) or a single‑dose IV calcium if severe.  \n3. Re‑check every 3–6 months until levels stabilize.  \n4. If calcium remains low after 6–12 months, you’ll need lifelong supplementation, but this is uncommon.  \n\nSo, most people do not have permanent low calcium after thyroidectomy, but keep the follow‑up appointments to be sure.",
          "order": 7,
          "qid": "S18-Q07"
        },
        {
          "q": "Can I sing in choir again?",
          "gt": "After a thyroidectomy, many people can return to singing, but it depends on how the surgery affected your vocal cords and voice quality.  \n**Key points to consider**\n\n1. **Vocal cord function** – If the recurrent laryngeal nerves were preserved and you have no hoarseness or breathiness, you’re more likely to sing safely.  \n2. **Voice quality** – A mild hoarseness or reduced range is common early on. Voice therapy can help you regain strength and control.  \n3. **Gradual return** – Start with gentle vocal exercises, avoid shouting or high‑loud singing, and gradually increase intensity while monitoring for fatigue or pain.  \n4. **Medical clearance** – Ask your ENT or speech‑language pathologist to assess your vocal cords and give a “ready to sing” sign.  \n\nIf you’re still experiencing significant hoarseness or voice fatigue, wait until your voice stabilizes and consider a short voice‑therapy course before rejoining the choir.",
          "order": 8,
          "qid": "S18-Q08"
        },
        {
          "q": "Do I need to avoid certain foods because of iodine?",
          "gt": "After a thyroidectomy your body no longer needs iodine for hormone production, so you don’t have to avoid iodine‑rich foods for everyday health.  \nHowever, if you’re scheduled for radioactive‑iodine (RAI) therapy, you’ll need a short iodine‑restricted diet (usually 2–4 weeks before treatment) to maximize uptake of the therapeutic iodine. During that period, limit high‑iodine foods such as seaweed, kelp, iodized salt, dairy, and certain breads.  \nOnce the RAI is done, you can return to a normal diet—no special iodine restriction is required. If you’re unsure about timing or specific foods, check with your endocrinologist or the RAI clinic for personalized instructions.",
          "order": 9,
          "qid": "S18-Q09"
        },
        {
          "q": "How do I keep from defining myself by this scar?",
          "gt": "I’m sorry you’re feeling weighed by the scar. It’s normal to notice it, but you can keep it from defining you by shifting focus and building a supportive routine.\n\n1. **Reframe the narrative** – view the scar as a symbol of survival, not a flaw. Write a short “victory statement” (e.g., “I am a survivor, not a scar”) and repeat it when you feel self‑critical.\n\n2. **Engage in self‑care that highlights your strengths** – practice voice‑therapy or singing if your voice allows, exercise, or hobbies that bring joy. These activities remind you that you’re more than a physical mark.\n\n3. **Seek peer support** – join a thyroid‑cancer support group or online community. Hearing others’ stories can normalize the scar and reduce isolation.\n\n4. **Professional counseling** – a therapist trained in body image or oncology can help you process feelings and develop coping strategies.\n\n5. **Celebrate milestones** – mark each follow‑up visit, each month of hormone stability, or each lesson you teach. Celebrate progress, not the scar.\n\nRemember, the scar is a reminder of resilience, but it does not dictate your identity. Focus on what you can control—your health, your voice, and your life.",
          "order": 10,
          "qid": "S18-Q10"
        }
      ]
    },
    {
      "id": "S19",
      "title": "Runner with a new scar (high-grade thigh sarcoma)",
      "diagnosis": "High-grade soft tissue sarcoma of the thigh",
      "treatment_plan": "Limb-sparing surgery with radiation (pre- or post-operative) and rehabilitation",
      "narrative": "I'm 46, a half-marathoner. A deep thigh mass turned out to be sarcoma. I want to keep my leg strong and my life moving.",
      "qa": [
        {
          "q": "Will surgery steal my stride, or can I run again?",
          "gt": "A limb‑sparing operation can preserve most of your thigh’s strength and range of motion, but the outcome depends on how much muscle, nerve, and bone were removed and whether you need radiation. In most cases, with a dedicated physiotherapy program, patients return to running within 6–12 months. Early rehab focuses on restoring quadriceps power, hip stability, and ankle‑foot coordination, while gradual mileage increases help rebuild endurance. Possible setbacks include temporary weakness, joint stiffness, or lymphedema, but these are usually manageable with targeted exercises and compression garments. Discuss your specific surgical plan with your surgeon and rehab team; they can tailor a timeline and set realistic milestones so you can keep your stride—and your half‑marathon goals—alive.",
          "order": 1,
          "qid": "S19-Q01"
        },
        {
          "q": "Pre-op or post-op radiation—what protects my leg best?",
          "gt": "**Pre‑op vs. post‑op radiation for a thigh sarcoma**\n\n- **Pre‑operative radiation** (usually 50 Gy in 25 fractions) is given before surgery.  \n  - **Pros**: Smaller total dose, less radiation‑induced fibrosis, better preservation of muscle and nerve function, and a lower risk of wound complications compared with post‑op radiation.  \n  - **Cons**: The tumor is still present, so the surgical field may be more inflamed, and there is a small risk of delayed wound healing if the tumor is large or close to critical structures.\n\n- **Post‑operative radiation** (typically 60–66 Gy in 30–33 fractions) is delivered after resection.  \n  - **Pros**: More precise targeting of the surgical bed, potentially better local control if margins are close or positive.  \n  - **Cons**: Higher total dose, greater risk of late fibrosis, joint stiffness, and neurovascular injury, which can impair leg strength and mobility.\n\n**Which protects the leg best?**  \nFor a high‑grade thigh sarcoma in a fit, active patient, most multidisciplinary teams favor **pre‑operative radiation** because it reduces the overall dose to surrounding tissues and preserves muscle and nerve function, supporting a stronger, more mobile leg after limb‑sparing surgery. However, the final decision depends on tumor size, proximity to neurovascular bundles, and surgical margins, so discuss with your radiation oncologist and surgeon to tailor the plan to your specific anatomy and goals.",
          "order": 2,
          "qid": "S19-Q02"
        },
        {
          "q": "How do I avoid lymphedema or swelling that ends training?",
          "gt": "**Preventing post‑surgery swelling for a high‑grade thigh sarcoma**\n\n1. **Early, supervised rehab** – Start gentle range‑of‑motion and strengthening 1–2 weeks after surgery, guided by a physio experienced in oncology.  \n2. **Compression** – Wear a well‑fitted compression sleeve or stocking (30–40 mm Hg) during activity and at night, as directed by your team.  \n3. **Manual lymph‑drainage** – If available, periodic sessions can reduce fluid accumulation.  \n4. **Avoid high‑impact** – Replace half‑marathon training with low‑impact cardio (elliptical, cycling) until you’re cleared for running.  \n5. **Skin care & hydration** – Keep the skin moisturized, avoid cuts, and stay well‑hydrated to support lymph flow.  \n6. **Weight control** – Maintain a healthy BMI; excess weight strains lymphatics.  \n7. **Monitor early signs** – Swelling, heaviness, or tightness should be reported immediately; early intervention prevents progression.  \n\nWork closely with your surgical, radiation, and rehab teams to tailor these measures to your specific treatment plan.",
          "order": 3,
          "qid": "S19-Q03"
        },
        {
          "q": "If margins are close, does that mean I’ll lose the leg?",
          "gt": "A “close” margin means the tumor is within a few millimeters of the edge of the tissue you removed. It does **not automatically mean you’ll lose the leg**. In most high‑grade thigh sarcomas, surgeons try to get clear margins first, then use additional treatments to control microscopic disease:\n\n1. **Re‑excision** – If the margin is close but the tumor is still resectable, a second surgery can widen the margin while preserving the limb.  \n2. **Radiation** – Pre‑ or post‑operative radiation (or both) can sterilize cells left behind, reducing the need for a more radical operation.  \n3. **Amputation** – Only considered if the tumor is too close to critical structures (nerves, vessels, bone) and cannot be removed safely with a limb‑sparing approach.\n\nYour surgical team will weigh these options, often using imaging and intra‑operative pathology, to keep the leg functional while ensuring oncologic safety.",
          "order": 4,
          "qid": "S19-Q04"
        },
        {
          "q": "Can I work remotely during recovery?",
          "gt": "Yes—remote work is usually feasible during the recovery from limb‑sparing surgery and radiation, but it depends on how you feel day‑to‑day. After surgery you’ll need rest, especially in the first 2–4 weeks, and radiation can add fatigue and skin irritation that may limit long hours.  \n\n**Practical tips**  \n1. **Set a realistic schedule** – start with 4–6 hour blocks, gradually increasing as pain and fatigue allow.  \n2. **Ergonomic workstation** – use a supportive chair, monitor at eye level, and keep your keyboard/ mouse at a comfortable height.  \n3. **Regular breaks** – stand, stretch, and walk 5–10 min every hour to keep circulation good.  \n4. **Communicate with your employer** – discuss a flexible timetable and the possibility of occasional in‑office visits if needed.  \n\nIf you experience significant pain, swelling, or radiation‑related fatigue, pause work and focus on rehabilitation. Always follow your surgeon’s and physiotherapist’s guidance.",
          "order": 5,
          "qid": "S19-Q05"
        },
        {
          "q": "What about nerve damage—will my foot drop?",
          "gt": "I’m sorry you’re facing this uncertainty. Foot drop occurs when the peroneal (fibular) nerve, which supplies ankle dorsiflexion, is injured. In thigh sarcoma surgery the nerve is usually at least 5–10 cm away from the tumor, so surgeons routinely spare it. However, if the tumor is close to the nerve or if the surgeon needs to remove a wide margin, the nerve may be cut or stretched, leading to foot drop.\n\n**What you can expect**\n\n| Scenario | Likelihood of foot drop | Typical outcome |\n|----------|------------------------|-----------------|\n| Nerve preserved | Low (≈5–10 %) | Normal gait, no drop |\n| Nerve cut but repaired | Moderate (≈20–30 %) | May recover over 6–12 months; physiotherapy helps |\n| Nerve permanently damaged | Rare (≈<5 %) | Persistent drop; orthosis or tendon transfer may be needed |\n\n**What you can do**\n\n1. **Ask the surgeon** to map the nerve intra‑operatively (nerve monitoring) and to spare it if possible.  \n2. **Post‑op rehab**: early ankle‑foot strengthening, gait training, and use of a foot‑drop orthosis if needed.  \n3. **Monitor**: any new weakness or numbness should be reported immediately; early intervention improves recovery.\n\nIn most limb‑sparing cases, foot drop is avoided or resolves with rehab. Keep the conversation open with your surgical and rehab teams—they’ll tailor the plan to protect your nerve and preserve your running goals.",
          "order": 6,
          "qid": "S19-Q06"
        },
        {
          "q": "Are scans forever, and how often?",
          "gt": "**Surveillance schedule for high‑grade thigh sarcoma**\n\n- **Years 1–3**: **Every 3–4 months** – chest CT (or low‑dose CT) + MRI/CT of the thigh (or PET‑CT if high risk).  \n- **Years 4–5**: **Every 6 months** – same imaging.  \n- **After 5 years**: **Annually** – chest CT and local MRI/CT, unless your doctor recommends otherwise.\n\nThese scans are not “forever” but are kept for at least 5–10 years because most recurrences happen in that window. If you’re doing well, your oncologist may adjust the interval, but the above is the standard plan. Keep your follow‑up appointments and discuss any new symptoms promptly.",
          "order": 7,
          "qid": "S19-Q07"
        },
        {
          "q": "Is chemo part of this?",
          "gt": "For most high‑grade soft‑tissue sarcomas of the thigh, the standard of care is wide, limb‑sparing resection followed by radiation (pre‑ or post‑operative) and a structured rehab program. Chemotherapy is **not routinely required** for localized disease. It is usually reserved for:\n\n- **Very large tumors** (>10 cm) or those with close/positive margins after surgery  \n- **High‑grade histologies** that are known to be chemosensitive (e.g., synovial sarcoma, leiomyosarcoma)  \n- **Metastatic or unresectable disease**  \n\nYour oncologist will review your pathology, tumor size, and surgical margins to decide if adjuvant chemo adds benefit. If it’s recommended, it’s typically given after radiation and surgery to spare the limb and preserve function. Discuss these options with your multidisciplinary team so you can keep training and stay strong.",
          "order": 8,
          "qid": "S19-Q08"
        },
        {
          "q": "How do I fuel healing without gaining weight when I can’t run?",
          "gt": "I’m glad you’re thinking ahead. Healing needs calories, but the goal is quality, not quantity.  \n**1. Prioritize protein** – 1.2–1.5 g/kg body‑weight per day (lean meats, fish, eggs, dairy, beans, tofu). Protein fuels tissue repair and helps preserve muscle while you’re less active.  \n**2. Choose complex carbs** – whole grains, sweet potatoes, legumes. They give steady energy and fiber, keeping you full without excess calories.  \n**3. Add healthy fats** – nuts, seeds, avocado, olive oil. A few tablespoons a day supply essential fatty acids and satiety.  \n**4. Keep portions in check** – use a small plate, eat slowly, and stop when you’re 80 % full.  \n**5. Stay hydrated** – water, herbal teas, and low‑calorie drinks.  \n**6. Strength‑train** – light resistance or body‑weight exercises (squats, lunges, resistance bands) maintain muscle mass and boost metabolism.  \n**7. Monitor weight** – track weekly; adjust portions if you’re creeping up.  \n**8. Work with a dietitian** – they can tailor a plan to your surgery, recovery, and activity level.  \n\nBalancing protein, complex carbs, healthy fats, and strength work will support healing while keeping weight stable.",
          "order": 9,
          "qid": "S19-Q09"
        },
        {
          "q": "What if I trip on fear every time I lace up?",
          "gt": "It’s normal to feel a knot of fear when you think about running again. The key is to treat that fear as a muscle that can be strengthened—just like the rest of your body.  \n\n1. **Rehabilitation first** – work with a physio to rebuild strength, balance, and proprioception. Start with low‑impact activities (cycling, swimming) and progress to short, supervised runs.  \n2. **Gradual exposure** – lace up for a 5‑minute jog, then a 10‑minute walk, and slowly increase distance. Celebrate each milestone.  \n3. **Mind‑body tools** – use breathing, visualization, or brief CBT‑based scripts (“I’ve healed; I’m safe”) before each session.  \n4. **Support network** – share your plan with a trusted friend, a running group, or a cancer survivorship community; accountability reduces anxiety.  \n5. **Professional help** – if fear feels overwhelming, a therapist experienced in oncology can provide targeted coping strategies.  \n\nRemember, the scar is a reminder of survival, not a barrier. With structured rehab and mental rehearsal, you can lace up confidently and keep moving forward.",
          "order": 10,
          "qid": "S19-Q10"
        }
      ]
    },
    {
      "id": "S20",
      "title": "Left the field mid-game (stage II testicular cancer)",
      "diagnosis": "Stage II testicular cancer (seminoma or nonseminoma)",
      "treatment_plan": "Orchiectomy followed by surveillance, chemotherapy, or radiation depending on type and spread; fertility preservation recommended",
      "narrative": "I'm 28, play in a weekend soccer league, and just lost a testicle to cancer. I’m scared about fertility, masculinity, and telling my team.",
      "qa": [
        {
          "q": "Is banking sperm urgent, or can I wait until after the next scan?",
          "gt": "It’s best to bank sperm as soon as possible, but it’s not an emergency if you’re on surveillance.  \n- **Why bank now?** If you need chemotherapy or radiation later, those treatments can damage the remaining testicle. Sperm banking before any such therapy guarantees you have viable material.  \n- **If you’re only under surveillance:** You can wait until after your next scan, provided you’re not scheduled for immediate treatment. The remaining testicle usually produces enough sperm for most men, but fertility can still be affected by future therapy.  \n- **Practical tip:** The banking process takes a few minutes and can be done at a local fertility clinic or hospital. If you can, schedule it now; if not, plan to do it after the next scan and before any planned treatment.",
          "order": 1,
          "qid": "S20-Q01"
        },
        {
          "q": "Will chemo wreck my lungs or stamina permanently?",
          "gt": "I’m really sorry you’re going through this. For most stage II testicular cancers the standard chemotherapy is a cisplatin‑based regimen (e.g., BEP: bleomycin, etoposide, cisplatin).  \n\n**Pulmonary effects** – Bleomycin can cause lung inflammation, but the incidence of permanent pulmonary fibrosis is < 5 % and usually occurs only with high cumulative doses or pre‑existing lung disease. Your oncologist will monitor lung function (spirometry, chest imaging) before, during, and after therapy, and the dose is carefully limited to keep risk low.  \n\n**Stamina & fatigue** – Chemotherapy can cause temporary fatigue and reduced exercise tolerance, but most patients recover fully within weeks to months. A structured return‑to‑sports plan, gradual conditioning, and adequate rest help restore your pre‑treatment fitness.  \n\nIn short, while there is a small risk of lung toxicity, it is rare and reversible, and most men return to normal activity levels after treatment. Discuss any specific concerns with your oncology team—they’ll tailor monitoring and supportive care to your situation.",
          "order": 2,
          "qid": "S20-Q02"
        },
        {
          "q": "Do I need a prosthesis to feel 'normal'?",
          "gt": "A testicular prosthesis is **optional**, not mandatory. It can help you feel more “whole” and may improve body‑image confidence, but many men live comfortably without one. If you choose a prosthesis, it’s usually inserted during the same surgery that removes the cancer or in a later procedure; it’s made of silicone and is designed to mimic the size and feel of a natural testicle. It does not affect fertility (sperm are produced in the remaining testicle) or hormone levels. Discuss the decision with your urologist and a mental‑health professional—consider how you feel about body image, your sports activity, and your personal comfort. Ultimately, the choice should reflect what makes you feel most at ease and confident.",
          "order": 3,
          "qid": "S20-Q03"
        },
        {
          "q": "Is radiation still used, and will it affect fertility?",
          "gt": "For stage II seminoma, external‑beam radiation to the retro‑peritoneal nodes is still an accepted option, but many clinicians now favor a single cycle of cisplatin‑based chemotherapy because it gives similar cure rates with fewer long‑term side effects. For non‑seminoma, radiation is rarely used; chemotherapy is the standard.\n\nRadiation can damage the remaining testis and reduce sperm counts, especially if the dose is high or the field includes the testis. Chemotherapy (cisplatin, etoposide, ifosfamide) also affects spermatogenesis, often temporarily but sometimes permanently.  \n\n**What you can do:**  \n1. **Sperm banking** before any treatment.  \n2. Discuss with your oncologist the exact radiation field and dose; modern techniques (IMRT) can spare the testis.  \n3. If chemotherapy is chosen, fertility preservation is still recommended.  \n\nIn short, radiation is still used for seminoma but is less common for non‑seminoma, and both radiation and chemotherapy can impair fertility—sperm banking is the safest preventive step.",
          "order": 4,
          "qid": "S20-Q04"
        },
        {
          "q": "What if tumor markers bounce—am I relapsing?",
          "gt": "A “bounce” is a transient rise in AFP, hCG, or LDH that then falls back to baseline without treatment. It can happen after surgery or during surveillance, especially in early‑stage disease. A true relapse usually shows a sustained, progressive increase in the same marker, often accompanied by a new mass on ultrasound, CT, or MRI.  \n\n**What to do:**  \n1. Repeat the same marker in 1–2 weeks.  \n2. If it remains elevated or rises again, get imaging (scrotal US, chest/abdomen CT).  \n3. If imaging is negative and the marker keeps falling, you can continue surveillance.  \n\nIf imaging shows a lesion or the marker keeps climbing, that’s evidence of relapse and treatment (chemo or radiation) is indicated. Keep close contact with your oncologist; they’ll decide the next step based on the pattern of markers and imaging.",
          "order": 5,
          "qid": "S20-Q05"
        },
        {
          "q": "Can I be intimate during treatment?",
          "gt": "Yes—sexual activity is generally safe while you’re undergoing treatment, but there are a few practical points to keep in mind.  \n\n**Chemotherapy** (e.g., BEP) can temporarily lower sperm counts and may cause fatigue, nausea, or mild erectile changes. If you’ve had sperm banking, you can use that or, if you’re not planning a pregnancy, condoms are a simple precaution.  \n\n**Radiation** to the pelvis can affect the remaining testicle’s function, so discuss fertility preservation with your oncologist before starting.  \n\n**Pain or fatigue** from surgery or treatment may make intercourse less comfortable; take breaks, use lubricants, and communicate with your partner.  \n\nOverall, you can be intimate, but coordinate with your care team about timing, contraception, and any side‑effect management.",
          "order": 6,
          "qid": "S20-Q06"
        },
        {
          "q": "How do I tell my teammates without jokes swallowing the room?",
          "gt": "**How to share with your team**\n\n1. **Pick a calm moment** – a break or after practice, not in the middle of a game.  \n2. **Be honest but brief** – “I had surgery for testicular cancer. I’m on treatment and will be back soon. I’d appreciate your support and understanding.”  \n3. **Set boundaries** – “I’m not looking for jokes or details. If you have questions, I’ll share what I’m comfortable with.”  \n4. **Offer a quick update** – “I’m on surveillance/chemotherapy and my fertility is being preserved. I’ll keep you posted on my recovery.”  \n5. **Invite support** – “If you want to talk or just be there, that means a lot.”  \n6. **Handle jokes calmly** – respond with a simple “Thanks for caring, but let’s keep it respectful.” or change the topic.  \n7. **Follow up** – share progress at the next practice or send a brief email if you’re nervous about speaking in person.  \n\nRemember, you’re not alone—most teammates will respect your courage and want to help.",
          "order": 7,
          "qid": "S20-Q07"
        },
        {
          "q": "Will insurance question a prosthesis?",
          "gt": "Most insurers treat a testicular prosthesis as a medical device rather than a purely cosmetic item, so it is often covered after an orchiectomy. However coverage varies by plan, and many carriers require a pre‑authorization or a letter from your urologist stating that the prosthesis is medically necessary to restore body image and improve quality of life.  \n\n**What to do:**  \n1. Ask your surgeon to provide a brief note explaining the need for the prosthesis.  \n2. Submit that note to your insurance for pre‑authorization.  \n3. If denied, appeal with the same documentation and, if needed, a second opinion.  \n\nIn most cases, once approved, the prosthesis is covered under the medical device portion of your policy.",
          "order": 8,
          "qid": "S20-Q08"
        },
        {
          "q": "Does losing a testicle change my hormones forever?",
          "gt": "A single healthy testicle usually produces enough testosterone to keep your hormone levels in the normal range. Most men who have an orchiectomy for testicular cancer have normal serum testosterone, LH, and FSH after the first few months, and the remaining testicle adapts to compensate. In rare cases a slight drop in testosterone can occur, but it is usually mild and can be managed with a short course of testosterone replacement if needed.  \n\nFertility is a different issue: sperm production comes from both testes, so losing one can reduce sperm count. Sperm banking before treatment is strongly advised if you wish to preserve fertility.  \n\nIn short, your hormonal balance is generally preserved, but keep regular follow‑up labs and discuss any symptoms with your oncologist.",
          "order": 9,
          "qid": "S20-Q09"
        },
        {
          "q": "If I relapse, is cure still on the table?",
          "gt": "If you relapse after initial orchiectomy and surveillance (or adjuvant therapy), the disease is still highly curable—especially for seminoma.  In seminoma, relapse is usually detected early by rising tumor markers or imaging, and a single course of cisplatin‑based chemotherapy (e.g., 4–6 cycles of BEP) cures >90 % of patients.  For non‑seminoma, salvage therapy is also effective: a second course of cisplatin‑based chemo (often 4–6 cycles of BEP or EP) cures about 70–80 % of relapsed patients; in the rare refractory cases, high‑dose chemotherapy with autologous stem‑cell rescue can still achieve long‑term remission.  Early detection and prompt treatment are key, so regular marker checks and imaging are essential.",
          "order": 10,
          "qid": "S20-Q10"
        }
      ]
    },
    {
      "id": "S21",
      "title": "Keys and the road (brain metastases, stereotactic radiosurgery)",
      "diagnosis": "Limited brain metastases from solid tumor",
      "treatment_plan": "Stereotactic radiosurgery (SRS) to brain lesions; systemic therapy continues or adjusts; seizure precautions and neuro follow-up",
      "narrative": "I'm 56, I drive for work and play piano at church. Small brain spots showed up on my scan. They recommend focused radiation.",
      "qa": [
        {
          "q": "Can I still legally drive after SRS?",
          "gt": "After stereotactic radiosurgery (SRS) most people can resume driving once they’re symptom‑free, but the exact timing is set by your local motor‑vehicle authority and your treating team.  \n\n**Key points**\n\n| What matters | Typical guidance |\n|--------------|------------------|\n| **Seizure risk** | If you’ve had a seizure or are on anti‑seizure meds, you’ll need a seizure‑free period (often 4–6 weeks) and a physician’s clearance. |\n| **Neurologic deficits** | Any new weakness, vision loss, or balance problems usually require a neurologic assessment before driving. |\n| **Cognitive function** | If you notice memory or concentration issues, a brief driving‑skills test may be requested. |\n| **Local regulations** | Many states allow driving after SRS if you’re symptom‑free and can demonstrate safe driving ability; some require a medical certificate. |\n\n**Practical steps**\n\n1. Discuss your driving plans with your oncologist or radiation oncologist.  \n2. If you’re seizure‑free, have no new deficits, and feel confident, ask for a written clearance.  \n3. Check your state’s DMV rules—some require a medical report or a driving assessment.  \n\nIn short, you can usually drive after SRS, but you’ll need to be symptom‑free, have a physician’s approval, and meet any local DMV requirements.",
          "order": 1,
          "qid": "S21-Q01"
        },
        {
          "q": "Will radiation change how I think or play music?",
          "gt": "Stereotactic radiosurgery (SRS) delivers a high dose of radiation to a very small area, sparing most of the surrounding brain. In most patients, the risk of noticeable changes in thinking or music‑playing ability is low—especially when the lesions are small and the total dose is carefully planned. Mild, transient effects such as fatigue, headaches, or a brief “brain fog” can occur, but these usually resolve within weeks. Rarely, if a lesion is near language or motor areas, subtle changes in speech or fine‑motor control might happen, but they are uncommon with modern SRS techniques.\n\nIf you notice any new difficulty with concentration, memory, or piano playing, let your radiation oncologist or neurologist know right away. They can assess whether the symptoms are related to the treatment and recommend supportive measures (e.g., cognitive exercises, medication adjustments, or a brief break from intense activities). Overall, SRS is designed to preserve cognitive function while treating the metastases.",
          "order": 2,
          "qid": "S21-Q02"
        },
        {
          "q": "Do I lose my hair in patches?",
          "gt": "Stereotactic radiosurgery (SRS) delivers a very precise, high‑dose beam to the tumor(s) while sparing surrounding brain and scalp tissue. Because the radiation field is tiny, you **will not experience the patchy hair loss that can occur with whole‑brain or conventional external‑beam radiotherapy**. Some patients report mild scalp redness or a temporary “sunburn” sensation, and a few may notice slight hair thinning in the exact spot that received the dose, but this is usually minimal and often resolves over weeks. If you’re concerned, discuss scalp‑protective measures (e.g., gentle shampoo, avoiding tight hats) with your radiation oncologist. Overall, SRS is designed to preserve hair and scalp integrity.",
          "order": 3,
          "qid": "S21-Q03"
        },
        {
          "q": "How do you decide which lesions to treat now versus watch?",
          "gt": "**Deciding what to treat now vs. watch‑and‑wait**\n\n| Factor | Why it matters | Practical tip |\n|--------|----------------|---------------|\n| **Number of lesions** | 1–3 lesions → treat all. 4–10 lesions → treat the largest 1–3; consider whole‑brain RT or systemic therapy for the rest. | Count and size on MRI. |\n| **Size & growth** | Lesions > 2–3 cm or rapidly enlarging are more likely to cause symptoms. | Use serial MRI to spot growth. |\n| **Location** | Lesions in eloquent cortex, brainstem, or deep structures risk deficits if untreated. | Prioritize those near critical functions. |\n| **Symptoms** | Any focal deficits, seizures, or increased intracranial pressure warrant immediate treatment. | Treat symptomatic lesions first. |\n| **Systemic disease status** | Controlled systemic disease → focus on brain control. Uncontrolled disease → treat only symptomatic or largest lesions; systemic therapy may dominate. | Coordinate with medical oncology. |\n| **Patient factors** | Age, performance status, comorbidities, and personal goals (e.g., driving, piano). | Discuss quality‑of‑life priorities. |\n| **Radiation tolerance** | Cumulative dose limits brain tissue; treat fewer lesions to stay below thresholds. | Use dose‑planning software. |\n\n**Bottom line:** Treat all symptomatic or large lesions, prioritize those in critical areas, and watch smaller, asymptomatic lesions that are stable on serial imaging. Regular MRI follow‑up (every 2–3 months for the first year) lets you catch any change early. Discuss the plan with your radiation oncologist and medical oncologist to align with your overall treatment goals.",
          "order": 4,
          "qid": "S21-Q04"
        },
        {
          "q": "Does this mean my systemic treatment failed?",
          "gt": "Brain metastases don’t automatically mean your systemic therapy has failed. Many cancers spread to the brain even while the primary disease is controlled elsewhere. The brain is a “sanctuary” site where drugs may not reach therapeutic levels, so a lesion can appear despite otherwise good systemic control. Stereotactic radiosurgery (SRS) is a local treatment that targets those spots while you can continue or adjust systemic therapy based on your overall disease status. Your oncologist will review your tumor biology, prior response, and current imaging to decide whether to change systemic agents, add targeted therapy, or keep the current regimen. So, the appearance of brain lesions is a local event, not automatically a sign of systemic failure.",
          "order": 5,
          "qid": "S21-Q05"
        },
        {
          "q": "If a new spot appears later, do we do SRS again?",
          "gt": "If a new lesion appears, we usually re‑evaluate it on a repeat MRI and consider a second SRS session.  SRS can be repeated safely for a limited number of new lesions, provided the cumulative dose to surrounding brain tissue stays within tolerance and the new site is amenable to precise targeting.  If the new metastasis is in a previously treated area, too close to critical structures, or if several new lesions appear, we may shift to a different strategy—often whole‑brain radiotherapy (WBRT) or a combination of SRS plus systemic therapy.  Your oncologist will weigh the size, location, prior dose, and your overall treatment goals before deciding.  Regular imaging (every 3–6 months) helps catch new spots early so we can act promptly.",
          "order": 6,
          "qid": "S21-Q06"
        },
        {
          "q": "What symptoms should make me call immediately?",
          "gt": "After stereotactic radiosurgery (SRS) for brain metastases, call your oncologist or the radiation oncology team **right away** if you notice any of the following:\n\n- **Sudden or worsening severe headache** that is new, worse than usual, or not relieved by over‑the‑counter pain meds.  \n- **New or worsening neurological deficits** – weakness or numbness in a limb, trouble walking, slurred speech, vision changes (blurred, double, loss of vision), or difficulty with coordination.  \n- **Seizure activity** – any tonic‑clonic or focal seizure, even a single episode.  \n- **Signs of increased intracranial pressure** – persistent vomiting, nausea, confusion, drowsiness, or a change in mental status.  \n- **New or worsening confusion, memory loss, or personality changes** that are rapid or progressive.  \n\nIf you experience any of these symptoms, especially if they are sudden or severe, call 911 or go to the nearest emergency department. For less urgent but concerning symptoms, contact your oncology team promptly. Early evaluation can prevent complications and keep your treatment on track.",
          "order": 7,
          "qid": "S21-Q07"
        },
        {
          "q": "Can I fly for work next week?",
          "gt": "After stereotactic radiosurgery (SRS) you can usually fly without a formal restriction, but it’s best to check with your radiation oncologist first. Most patients tolerate air travel 24–48 hours after SRS, provided they have no recent seizures, severe fatigue, or other acute side‑effects.  \n\n**Practical tips if you’re cleared to fly:**\n\n- **Medication:** Take your anti‑seizure or anti‑nausea meds as prescribed; bring a spare supply.  \n- **Hydration & rest:** Stay hydrated, avoid alcohol, and try to rest during the flight.  \n- **Seat choice:** A window seat gives you more space to stretch and easier access to the aisle.  \n- **Emergency plan:** Keep your oncologist’s contact info and a note about your recent SRS in case of sudden symptoms.  \n\nIf you feel unusually tired, dizzy, or have a seizure‑like episode, postpone travel and seek medical evaluation. Safe travels!",
          "order": 8,
          "qid": "S21-Q08"
        },
        {
          "q": "Will steroids make me jittery or hungry?",
          "gt": "Steroids such as dexamethasone are often used to reduce brain swelling before or after SRS.  Most people do notice some side‑effects, but they vary widely.  Commonly reported changes include:\n\n- **Increased appetite and weight gain** – steroids can stimulate hunger and alter metabolism.  \n- **Mood swings, irritability, or “jitterness”** – especially if taken in the morning or at higher doses.  \n- **Insomnia or difficulty sleeping** – can also make you feel restless.  \n\nNot everyone experiences all of these, and the dose you receive is usually the lowest effective amount.  If you notice jitteriness or a sudden rise in hunger, let your oncologist know.  They may adjust the dose, shift the timing to bedtime, or add a short‑acting antihistamine for sleep.  Keeping a food diary and staying hydrated can help you manage appetite changes.  Discuss any concerns with your care team so they can tailor the steroid plan to your needs.",
          "order": 9,
          "qid": "S21-Q09"
        },
        {
          "q": "How often are MRIs after this?",
          "gt": "After stereotactic radiosurgery (SRS) for limited brain metastases, most centers follow a routine MRI schedule to monitor for local control and new lesions:\n\n1. **Baseline** – MRI before SRS (already done).  \n2. **Early follow‑up** – 3–6 months post‑SRS to assess the treated sites for residual disease or radiation changes.  \n3. **Intermediate** – Every 6 months for the next 1–2 years, especially if you have active systemic disease or multiple lesions.  \n4. **Long‑term** – Annually thereafter, unless new symptoms arise.  \n\nIf you develop headaches, seizures, or neurological deficits, an MRI should be obtained sooner. Discuss your exact schedule with your radiation oncologist; they’ll tailor it to your overall cancer status and treatment plan.",
          "order": 10,
          "qid": "S21-Q10"
        }
      ]
    },
    {
      "id": "S22",
      "title": "Second chances (liver cancer with cirrhosis)",
      "diagnosis": "Hepatocellular carcinoma in the setting of cirrhosis",
      "treatment_plan": "Locoregional therapy (e.g., ablation or embolization) or systemic therapy; transplant evaluation when appropriate; manage liver function",
      "narrative": "I'm 64 with cirrhosis and now a liver tumor. I quit drinking last year. I want to live long enough to walk my daughter down the aisle.",
      "qa": [
        {
          "q": "Am I a transplant candidate, or did I miss that window?",
          "gt": "I’m sorry you’re facing this. Whether you’re a transplant candidate depends on a few key factors that your transplant team will review:\n\n| Factor | Typical threshold for transplant | What it means for you |\n|--------|----------------------------------|-----------------------|\n| **Tumor size & number** | ≤ 5 cm single tumor **or** ≤ 3 tumors each ≤ 3 cm (Milan criteria) | If your lesion fits, you’re in the “window.” |\n| **AFP level** | < 400 ng/mL (often < 200 ng/mL) | Lower AFP correlates with better outcomes. |\n| **Liver function** | Child‑Pugh A or well‑controlled B (bilirubin ≤ 2 mg/dL, INR ≤ 1.5, platelets ≥ 50 k/µL) | Good function means you can tolerate surgery. |\n| **Portal hypertension** | No clinically significant varices or ascites | Severe portal hypertension usually excludes transplant. |\n| **Other comorbidities** | No uncontrolled infection, active alcohol use, or other organ failure | You’ve quit drinking, which is a big plus. |\n\n**Next steps:**  \n1. **Get a formal transplant evaluation** (usually within a few weeks).  \n2. Your hepatologist will order imaging, AFP, liver function labs, and a portal pressure measurement.  \n3. If you meet the criteria, you’ll be placed on the waiting list; if not, we’ll discuss locoregional or systemic therapy to control the tumor while you keep your liver function as good as possible.\n\nEven if you’re outside the strict Milan window, some centers use expanded criteria (e.g., up to 6.5 cm or 3 tumors ≤ 4 cm) and can still offer transplant. The key is early evaluation—don’t wait.  \n\nI hope this helps you plan the next steps toward walking your daughter down the aisle.",
          "order": 1,
          "qid": "S22-Q01"
        },
        {
          "q": "Does treatment hurt my liver more than the cancer does?",
          "gt": "Treatments for hepatocellular carcinoma (HCC) are chosen to balance tumor control with preservation of the cirrhotic liver.  \n• **Locoregional therapies** (radiofrequency ablation, microwave ablation, transarterial chemo‑embolization) are usually well tolerated; they target the tumor while sparing most normal liver. Minor liver enzyme elevations are common but often reversible.  \n• **Systemic agents** (e.g., sorafenib, lenvatinib, immunotherapy) can cause fatigue, hand‑foot syndrome, and mild transaminitis, but dose adjustments and close monitoring keep liver injury uncommon.  \n• **Transplant** removes the diseased liver entirely, but only a few patients qualify.\n\nIn most cases, the cancer’s progressive destruction of liver tissue outweighs the modest, manageable damage from treatment. With careful selection, monitoring, and supportive care, you can often preserve enough liver function to live a meaningful, active life.",
          "order": 2,
          "qid": "S22-Q02"
        },
        {
          "q": "What if my legs swell and I can’t fit shoes—does that mean it’s all downhill?",
          "gt": "Leg swelling in cirrhosis is usually a sign of portal hypertension or fluid overload, not a direct “death sentence.” It can be managed and often improves with the right treatment.  \n\n**What to do next:**  \n1. **Check your weight and sodium** daily; keep salt < 2 g/day.  \n2. **Diuretics** (spironolactone + furosemide) are the mainstay—your hepatologist can titrate them.  \n3. **Compression stockings** and leg elevation help reduce edema.  \n4. **Rule out heart failure** or infection; a quick echo or blood work can clarify.  \n5. **Keep follow‑up imaging** for the tumor—early locoregional therapy can still be curative.  \n\nEdema is treatable and doesn’t automatically mean your cancer is progressing. With close monitoring and adjustments, you can keep walking—perhaps even down the aisle. Stay in touch with your liver team and let them tweak the plan as needed.",
          "order": 3,
          "qid": "S22-Q03"
        },
        {
          "q": "Do I have to swear off every celebration forever?",
          "gt": "You don’t have to give up every celebration, but you do need to keep the liver safe.  \n**Alcohol** is the single biggest risk factor for cirrhosis progression and HCC recurrence, so any celebration that involves drinking should be avoided or limited to a strict “no‑alcohol” policy.  If you choose to attend a party, bring a non‑alcoholic drink and let friends know you’re abstaining.  \n\nOther factors matter too:  \n* **Calorie‑dense foods** can worsen liver inflammation—opt for lean proteins, vegetables, and whole grains.  \n* **Stress** can affect liver health; plan for rest and relaxation.  \n* **Medications** (including over‑the‑counter pain relievers) should be reviewed with your hepatologist.  \n\nIn short, you can celebrate, but keep alcohol out of the equation and watch your diet and stress.  Discuss any specific plans with your liver specialist to tailor the safest approach for you.",
          "order": 4,
          "qid": "S22-Q04"
        },
        {
          "q": "How risky is bleeding during procedures with my platelets low?",
          "gt": "I’m really sorry you’re facing this uncertainty. Low platelets in cirrhosis do raise bleeding risk, but the exact danger depends on the platelet count, the type of procedure, and how well your liver is working.\n\n| Platelet count | Typical risk for percutaneous ablation/embolization | Typical risk for liver biopsy | Typical risk for transplant‑related surgery |\n|----------------|-----------------------------------------------------|------------------------------|-------------------------------------------|\n| > 80 × 10⁶/L | Low (≈ 5–10 %) | Low (≈ 5–10 %) | Low (≈ 10–15 %) |\n| 50–80 × 10⁶/L | Moderate (≈ 10–20 %) | Moderate (≈ 10–20 %) | Moderate (≈ 15–25 %) |\n| < 50 × 10⁶/L | Higher (≈ 20–30 %) | Higher (≈ 20–30 %) | Higher (≈ 25–35 %) |\n\n**What can be done**\n\n1. **Platelet transfusion** – raise counts to > 50 × 10⁶/L before most percutaneous procedures; > 80 × 10⁶/L for high‑risk or surgical interventions.  \n2. **Desmopressin (DDAVP)** – can improve platelet function even if counts are modest.  \n3. **Avoidance of anticoagulants/NSAIDs** and use of proton‑pump inhibitors to reduce GI bleeding risk.  \n4. **Close monitoring** – repeat counts 6–12 h after the procedure and watch for bruising, hematuria, or abdominal pain.\n\n**Bottom line**: With a platelet count around 50–80 × 10⁶/L and proper pre‑procedure support, the bleeding risk is manageable and many patients safely undergo ablation or embolization. Discuss your exact numbers with your hepatology and interventional radiology teams; they’ll tailor transfusion thresholds and monitoring to keep you as safe as possible while you pursue treatment.",
          "order": 5,
          "qid": "S22-Q05"
        },
        {
          "q": "If the tumor shrinks, can I get on a transplant list?",
          "gt": "I’m so glad you’re thinking ahead. In general, a liver transplant is reserved for patients whose cancer is still within the accepted criteria (Milan: one tumor ≤5 cm or up to three tumors each ≤3 cm, no macro‑vascular invasion or extra‑hepatic spread). If locoregional therapy shrinks the tumor so that it now meets those limits, you can be “down‑staged” and become eligible for transplant evaluation. The transplant team will also look at your overall liver function (MELD/Child‑Pugh), portal‑vein status, and psychosocial factors. If the tumor remains outside the criteria even after shrinkage, transplant is usually not an option, and we’ll focus on continued systemic or locoregional treatment. Let’s keep working together to keep those possibilities open.",
          "order": 6,
          "qid": "S22-Q06"
        },
        {
          "q": "What does a bad day look like so my family knows when to act?",
          "gt": "A “bad day” is when your liver suddenly stops working well enough to keep you stable. Watch for these red‑flag signs:\n\n- **Sudden confusion, drowsiness, or disorientation** (hepatic encephalopathy).  \n- **Severe abdominal pain or swelling** that feels like a new, sharp ache or a sudden increase in belly size.  \n- **Unexplained vomiting or bleeding** (from the mouth, nose, or stool).  \n- **Marked jaundice** (yellowing of skin or eyes) or dark urine.  \n- **Rapid weight gain** from fluid retention (ascites).  \n- **New or worsening shortness of breath** or swelling in legs.\n\nIf any of these occur, call your oncologist or go to the nearest emergency department immediately. Early intervention can prevent a full decompensation and give you the best chance to keep walking your daughter down the aisle.",
          "order": 7,
          "qid": "S22-Q07"
        },
        {
          "q": "Can I still walk the neighborhood safely?",
          "gt": "Walking is usually safe for most people with cirrhosis and early‑stage hepatocellular carcinoma, especially if your liver function tests are stable, you have no significant ascites, encephalopathy, or severe portal hypertension. Start with short, gentle strolls—5–10 minutes—and gradually increase the distance as you feel comfortable. Pay attention to fatigue, dizziness, abdominal pain, or worsening swelling; if any of these appear, stop and contact your hepatology team. Keep your medications up to date, stay hydrated, and avoid alcohol or heavy meals before walking. Regular follow‑up imaging and labs will help your team adjust treatment and ensure you remain fit for the walk down the aisle. If you’re unsure, a quick check‑in with your doctor can confirm that your current status allows safe ambulation.",
          "order": 8,
          "qid": "S22-Q08"
        },
        {
          "q": "Will I itch forever?",
          "gt": "Pruritus in cirrhosis is usually due to bile‑salt and other pruritogens that build up when the liver can’t clear them. It often improves when liver function is stabilized—after alcohol abstinence, effective locoregional therapy, or systemic treatment that slows tumor growth. If your liver continues to work well enough, the itch can diminish or disappear. However, if cirrhosis remains advanced or the tumor progresses, the itch may persist or recur. Practical steps—keep skin moisturized, use cool compresses, avoid hot showers, and discuss antihistamines, bile‑acid binders (cholestyramine), or rifampicin with your hepatologist. In many patients, treating the underlying liver disease and tumor gives significant relief, so there’s hope for a quieter skin and a longer walk to the aisle.",
          "order": 9,
          "qid": "S22-Q09"
        },
        {
          "q": "How do I keep hope without pretending this isn’t serious?",
          "gt": "It’s normal to want to keep hope alive while still facing a serious diagnosis.  \n1. **Know the facts** – Your tumor is treatable with ablation, embolization, systemic drugs, or transplant if you qualify.  \n2. **Stick to the plan** – Attend every imaging, lab, and follow‑up. Early detection of recurrence or progression lets you act quickly.  \n3. **Optimize liver health** – Eat a balanced, low‑salt diet, stay hydrated, avoid alcohol, and manage diabetes or hypertension.  \n4. **Stay active** – Light exercise (walking, gentle stretching) improves circulation and mood.  \n5. **Seek support** – Talk to a counselor, join a liver‑cancer support group, and involve family in your care.  \n6. **Balance hope with realism** – Celebrate each treatment milestone, but keep realistic expectations about outcomes.  \nWith a clear plan, healthy habits, and a supportive network, you can maintain hope while confronting the seriousness of the disease.",
          "order": 10,
          "qid": "S22-Q10"
        }
      ]
    },
    {
      "id": "S23",
      "title": "Stigma and steel (locally advanced cervical cancer)",
      "diagnosis": "Locally advanced cervical cancer",
      "treatment_plan": "Definitive pelvic radiation with weekly cisplatin and brachytherapy; survivorship sexual health support",
      "narrative": "I'm 37 and a mom of two. The word 'cervical' makes me feel judged. Treatment is radiation with weekly chemo and internal radiation later.",
      "qa": [
        {
          "q": "I feel ashamed telling people what kind of cancer I have. How do I carry this without hiding?",
          "gt": "It’s normal to feel judged, but you don’t have to hide who you are.  \n1. **Use neutral language** – say “I’m receiving treatment for cervical cancer” or “I’m in a cancer treatment program.” This keeps the focus on the disease, not the word “cervical.”  \n2. **Choose your audience** – share with people you trust (close friends, family, or a support‑group member). If someone asks, you can politely say, “I’m not comfortable discussing it in detail, but I’m doing well.”  \n3. **Set boundaries** – let people know what you’re comfortable sharing and what you’d rather keep private.  \n4. **Leverage support** – join a local or online cervical‑cancer support group; hearing others’ stories can reduce shame and give you coping tools.  \n5. **Professional help** – a counselor or therapist experienced in oncology can help you process stigma and build confidence.  \n\nRemember, you’re not alone, and your courage in facing treatment is what matters most.",
          "order": 1,
          "qid": "S23-Q01"
        },
        {
          "q": "Will sex ever feel normal again?",
          "gt": "It’s normal to feel anxious about how sex will change after pelvic radiation and weekly cisplatin. Radiation can cause vaginal dryness, shortening, and sometimes mild scarring, while chemotherapy may add fatigue and hormonal shifts. Most women notice improvement within a few months, especially with early intervention:  \n\n- **Vaginal dilators** (starting 2–4 weeks after treatment) keep the canal supple.  \n- **Lubricants and moisturizers** (water‑based, fragrance‑free) reduce dryness and pain.  \n- **Pelvic floor physical therapy** can strengthen muscles and improve sensation.  \n- **Counseling or sex‑therapy** helps address emotional concerns and intimacy issues.  \n\nIf you experience persistent pain or discomfort, discuss topical estrogen or other treatments with your oncologist. With these supportive measures, many patients regain a satisfying, “normal” sexual experience. Stay in touch with your care team—early help makes a big difference.",
          "order": 2,
          "qid": "S23-Q02"
        },
        {
          "q": "Do I need a port for the weekly chemo?",
          "gt": "For most patients receiving weekly cisplatin, a temporary peripheral IV is sufficient—no permanent port is required. A port is usually considered only if you have difficult or fragile veins, if you anticipate many future chemotherapy cycles, or if you prefer a single, long‑term access site.  \n\nIf a port is placed, it’s inserted under local anesthesia, typically in the chest or arm, and can be used for all subsequent chemo and any future treatments. It requires regular flushing and occasional imaging to ensure it’s functioning.  \n\nDiscuss with your radiation oncologist or medical‑oncology team: they’ll assess your vein status and overall treatment plan to decide whether a port is the best option for you.",
          "order": 3,
          "qid": "S23-Q03"
        },
        {
          "q": "What if childcare blows up on treatment days?",
          "gt": "I’m sorry you’re juggling so much. Most cancer centers have a **patient‑care coordination team** that can help you arrange reliable childcare. Ask your oncology nurse or social worker about:\n\n* **Hospital‑run “cancer‑care” babysitting** or a “family‑care” program that lets children stay in the oncology wing while you’re treated.  \n* **Community resources** – local churches, nonprofits, or the American Cancer Society often run volunteer‑based babysitting or “cancer‑care” groups.  \n* **Flexible scheduling** – if you’re on a 5‑day‑a‑week regimen, see if a day‑off or a later‑time appointment can be arranged for a critical childcare crisis.  \n* **Support from friends/family** – set up a rotating “child‑watch” schedule in advance; a simple text chain can keep everyone informed.  \n\nIf a childcare emergency arises, call your oncology team immediately; they can help you reschedule or provide emergency support. You’re not alone—most hospitals have a plan for parents in your situation.",
          "order": 4,
          "qid": "S23-Q04"
        },
        {
          "q": "Will I burn or peel from radiation?",
          "gt": "Radiation to the pelvis can cause skin changes, but most women experience only mild, temporary effects. During treatment you may see redness, dryness, or a “sunburn‑like” rash that can peel a little. These reactions usually peak a week or two into therapy and improve within a few weeks after you finish. Weekly cisplatin can make the skin a bit more sensitive, but it does not usually cause severe burns.\n\n**What to do:**\n- Keep the area clean with mild soap and lukewarm water.  \n- Apply a fragrance‑free moisturizer or a barrier ointment (e.g., petroleum jelly) after bathing.  \n- Avoid hot showers, tight clothing, and direct sun exposure.  \n- Report any blistering, severe pain, or signs of infection to your oncology team right away.\n\nMost skin reactions resolve fully, and the benefits of treatment outweigh these temporary side effects. If you’re concerned, bring it up at your next visit; your team can adjust supportive care as needed.",
          "order": 5,
          "qid": "S23-Q05"
        },
        {
          "q": "How do you make sure the internal radiation isn’t traumatic?",
          "gt": "I understand how the word “internal radiation” (brachytherapy) can feel intimidating. Here are a few ways to keep the experience as calm and respectful as possible:\n\n1. **Clear, step‑by‑step explanation** – Your radiation oncologist will walk you through the procedure, the purpose of each step, and what you’ll feel. Ask questions; no detail is too small.\n\n2. **Comfort‑focused positioning** – The applicator is placed in a way that minimizes pressure and pain. The team will use cushions, gentle restraints, and a relaxed environment to keep you comfortable.\n\n3. **Pain control** – Local anesthesia or mild sedation is often used. If you’re anxious, discuss anxiolytics or a relaxation technique (deep breathing, guided imagery) with your team.\n\n4. **Privacy and dignity** – The procedure is performed in a private room with a nurse or physician present. You can request a female provider if that feels more comfortable.\n\n5. **Post‑procedure support** – After the session, you’ll receive instructions on care and any side‑effects. A follow‑up call or visit can help you process the experience.\n\nOpen communication with your care team and expressing your concerns early will help keep the procedure as non‑traumatic as possible.",
          "order": 6,
          "qid": "S23-Q06"
        },
        {
          "q": "Can I keep working, or should I plan leave?",
          "gt": "It’s common to wonder whether you can keep working while you’re on chemoradiation. Most people with locally advanced cervical cancer can stay at work, especially if the schedule is flexible and you can take breaks. Weekly cisplatin and external‑beam radiation often cause fatigue, nausea, and mild mucositis—symptoms that can be managed with rest, hydration, and anti‑emetics. Start by discussing your job duties with your oncologist and occupational health team; they can help you plan a gradual return, part‑time shifts, or remote work if needed. If you experience severe fatigue, pain, or infection, a short leave of absence may be the safest option. Keep a symptom diary and check in regularly—your treatment team can adjust your plan to keep you as productive and healthy as possible.",
          "order": 7,
          "qid": "S23-Q07"
        },
        {
          "q": "Does this mean I can’t have more children?",
          "gt": "Radiation to the pelvis can damage the ovaries and fallopian tubes, so your fertility is at risk.  The exact impact depends on the dose, field size, and whether the ovaries are moved out of the radiation field (ovarian transposition) or protected with shielding.  Many women who receive pelvic radiation still conceive, but the chance is lower and may require assisted reproduction (IVF, donor eggs, or gestational surrogacy).  Discuss fertility preservation with your radiation oncologist and a reproductive endocrinologist before treatment starts.  If you’re not ready to preserve fertility now, you can still plan for future options, but it’s wise to explore them early.",
          "order": 8,
          "qid": "S23-Q08"
        },
        {
          "q": "How will you know it worked without surgery?",
          "gt": "After definitive chemoradiation you’ll be monitored with a combination of clinical exam, imaging, and symptom review—no surgery is needed to confirm response.\n\n1. **Clinical exam** – A pelvic exam (often with a speculum) is done every 4–6 weeks during treatment and then at 3, 6, 12 months, and yearly. The tumor should shrink, the cervix should feel firm, and any ulceration or bleeding should resolve.\n\n2. **Imaging** – MRI of the pelvis (or PET/CT if available) is performed 6–8 weeks after completing therapy. A significant drop in tumor size or metabolic activity indicates a good response. Follow‑up scans at 6–12 months help detect early recurrence.\n\n3. **Symptom and marker review** – Pain, bleeding, or discharge should improve. If you had a pre‑treatment HPV or CA‑125 level, a drop can support response, though it’s not definitive.\n\n4. **Long‑term surveillance** – Regular visits every 6–12 months for 5 years (or longer if high‑risk features) will catch any recurrence early.\n\nSo, a combination of exam, imaging, and symptom resolution gives us confidence that the treatment worked.",
          "order": 9,
          "qid": "S23-Q09"
        },
        {
          "q": "What if the cancer comes back—what’s next?",
          "gt": "If the cancer recurs, the next steps depend on where it’s found and how long it’s been since your initial treatment.\n\n**Local or regional relapse** (in the pelvis or nearby lymph nodes) can sometimes be treated with a second course of external‑beam radiation, high‑dose‑rate brachytherapy, or a **salvage radical hysterectomy** if you’re a surgical candidate.  \n**Distant recurrence** (lungs, bones, liver, etc.) is usually managed with systemic therapy—platinum‑based chemotherapy, a taxane, or newer agents such as bevacizumab, pembrolizumab, or clinical‑trial drugs.  \nYou’ll also be offered **palliative care** to control symptoms and maintain quality of life.  \n\nDiscuss each option with your oncology team, including potential benefits, side‑effects, and whether you qualify for a clinical trial. Your goals and preferences will guide the best plan.",
          "order": 10,
          "qid": "S23-Q10"
        }
      ]
    },
    {
      "id": "S24",
      "title": "Fixing the fence (diffuse large B-cell lymphoma)",
      "diagnosis": "Diffuse large B-cell lymphoma, curative intent",
      "treatment_plan": "R-CHOP every 3 weeks for 6 cycles (or tailored regimen); interim PET after a few cycles",
      "narrative": "I'm 66 and run a small farm. A fast-growing node appeared in my neck. They’re aiming to cure this with chemo.",
      "qa": [
        {
          "q": "Does 'curative intent' really mean cure for someone my age?",
          "gt": "**Curative intent means the treatment plan is designed to eradicate the lymphoma, not that a cure is guaranteed.**  \nFor a 66‑year‑old with diffuse large B‑cell lymphoma (DLBCL) treated with R‑CHOP, the 5‑year overall survival is roughly 60–70 % for early‑stage disease and 50–60 % for more advanced stages, assuming good performance status and no major comorbidities. Age alone is not a definitive barrier; many patients in their 60s and 70s achieve long‑term remission.  \n\nHowever, older patients may have reduced tolerance to chemotherapy, and comorbidities can affect both treatment intensity and outcomes. “Curative intent” reflects the physicians’ belief that cure is achievable with the chosen regimen, but it does not guarantee it. Discuss your overall health, goals, and any concerns with your oncologist to tailor the plan to your situation.",
          "order": 1,
          "qid": "S24-Q01"
        },
        {
          "q": "How sick will I be after each cycle—will the animals still get fed?",
          "gt": "**What to expect after each R‑CHOP cycle (every 3 weeks)**  \n\n| Day | Common side‑effects | Practical tips for farm duties |\n|-----|---------------------|--------------------------------|\n| 0 – 1 | Mild nausea, fatigue, low appetite | Take a short break; keep a light snack (nuts, fruit) handy. |\n| 2 – 5 | Low white‑cell count → higher infection risk, mild fever | Wear a mask if you’re around animals; avoid crowded barns. |\n| 6 – 10 | Hair loss, mouth sores, mild anemia | Keep the mouth moist with sugar‑free lozenges; wear a hat to protect scalp. |\n| 11 – 14 | Fatigue peaks, possible mild dizziness | Plan lighter chores; let a partner or family member handle heavy tasks. |\n| 15 – 21 | Recovery begins; blood counts improving | Gradually resume feeding animals; monitor for any new symptoms. |\n\n**Key points**\n\n- Most people feel “okay” after the first 2–3 days; fatigue usually subsides by day 10–14.  \n- If you’re the sole caretaker, arrange a short‑term helper (family, friend, or farmhand) for the first week of each cycle.  \n- Keep a symptom diary and report any fever, severe pain, or prolonged weakness to your oncologist.  \n\nWith proper planning and support, you can keep feeding your animals while undergoing treatment.",
          "order": 2,
          "qid": "S24-Q02"
        },
        {
          "q": "Will I lose my hair and beard?",
          "gt": "**Hair and beard loss with R‑CHOP**\n\n- **Scalp hair** – About 70–80 % of patients experience noticeable thinning or temporary baldness, usually starting after the 2nd–3rd cycle. The hair usually regrows within 3–6 months after the last dose.  \n- **Beard and other body hair** – These areas are less frequently affected, but some men do lose beard hair or notice thinning. If it does happen, it also tends to regrow after therapy ends.  \n- **What you can do** – Use a gentle shampoo, avoid heat styling, and consider a wig or beard cover if you’re concerned. Discuss scalp cooling (a “cold cap”) with your oncologist; it can reduce hair loss in some patients.\n\nIn short, scalp hair loss is common with R‑CHOP, but beard loss is less predictable—many men keep their beard, while others may experience some thinning that usually resolves after treatment.",
          "order": 3,
          "qid": "S24-Q03"
        },
        {
          "q": "I’m worried about infection from hay dust and barns. Is that a real risk?",
          "gt": "I’m sorry you’re facing this extra worry. While on R‑CHOP, your white‑cell count drops, especially neutrophils, so any environment that can harbor bacteria or fungi becomes a potential source of infection. Hay dust can contain mold spores (e.g., *Aspergillus*) and bacteria, and barns can have higher levels of airborne pathogens.  \n\n**Practical steps:**  \n- Keep barns and hay storage closed during treatment.  \n- If you must be around hay, wear a well‑fitted mask (N95 or equivalent).  \n- Maintain good hand hygiene and avoid touching your face.  \n- Keep your home and work areas clean and well‑ventilated.  \n\nYour oncology team will monitor your neutrophil counts and may give prophylactic antibiotics or antifungals if your ANC falls below 500 /µL. Discuss any specific exposure concerns with them; they can tailor precautions to your schedule.",
          "order": 4,
          "qid": "S24-Q04"
        },
        {
          "q": "What does the interim PET actually change?",
          "gt": "Interim PET (usually after 2–3 R‑CHOP cycles) is a “road‑map” test.  \n* **Good response (negative or low uptake)** – you continue the planned 6‑cycle course; the PET gives you a reassuring prognosis.  \n* **Poor or equivocal response (high uptake)** – the treating team may consider:  \n  – adding or switching to a more intensive regimen (e.g., R‑CHOP + rituximab‑based boost, or R‑CHOP + radiotherapy for bulky disease),  \n  – shortening the course if the disease is already responding well, or  \n  – enrolling in a clinical trial.  \n\nThus, the PET can change the treatment plan only when it shows inadequate response; otherwise it mainly confirms that the current plan is on track. False positives can occur, so results are interpreted with clinical context.",
          "order": 5,
          "qid": "S24-Q05"
        },
        {
          "q": "Can heart issues happen with this regimen?",
          "gt": "Yes. The R‑CHOP regimen contains doxorubicin, an anthracycline that can damage heart muscle. The risk rises with higher cumulative doses, older age, pre‑existing heart disease, hypertension, or diabetes. Symptoms may include shortness of breath, fatigue, palpitations, or swelling. Your oncologist will usually perform a baseline echocardiogram or MUGA scan and monitor left‑ventricular ejection fraction during treatment. If the cumulative dose approaches 400 mg/m² or if you develop cardiac symptoms, the team may switch to a liposomal doxorubicin formulation, reduce the dose, or add cardioprotective agents (e.g., dexrazoxane). Keep your doctor informed of any new heart‑related symptoms and maintain regular follow‑up to catch any issues early.",
          "order": 6,
          "qid": "S24-Q06"
        },
        {
          "q": "Will steroids make me edgy and sleepless?",
          "gt": "**Short answer:**  \nYes—dexamethasone (the steroid in R‑CHOP) can cause mood swings, anxiety, and trouble sleeping. These effects are usually short‑lived, peaking a few days after each dose and fading within a week.\n\n**What to do:**  \n- **Timing:** Take the steroid in the morning (or early afternoon) to give your body time to wind down before bed.  \n- **Sleep hygiene:** Keep a regular bedtime routine, avoid screens an hour before sleep, and create a cool, dark sleeping environment.  \n- **Stress‑relief:** Gentle stretching, deep‑breathing, or a short walk can calm the nervous system.  \n- **Talk to your team:** If agitation or insomnia become severe, let your oncologist know—dose adjustments or a short‑acting sleep aid may help.\n\nThese measures usually keep steroid‑related restlessness manageable while you pursue curative therapy.",
          "order": 7,
          "qid": "S24-Q07"
        },
        {
          "q": "If a cycle is delayed, does that ruin my chance of cure?",
          "gt": "A brief delay (a few days to a week) usually doesn’t wipe out the chance of cure, but the longer the gap, the higher the risk that the lymphoma can grow or become harder to treat. R‑CHOP is most effective when the cycles are spaced about 3 weeks",
          "order": 8,
          "qid": "S24-Q08"
        },
        {
          "q": "Should I get extra vaccines now?",
          "gt": "**Vaccines you should consider before or during R‑CHOP**\n\n| Vaccine | Why it matters | Timing |\n|---------|----------------|--------|\n| **Influenza (inactivated)** | Chemo‑induced neutropenia increases flu risk. | Give as soon as possible, ideally before the next cycle. |\n| **COVID‑19 mRNA booster** | Immunosuppression can blunt protection; boosters keep you safer. | If you haven’t had a recent booster, get one now. |\n| **Shingrix (recombinant zoster)** | 66 yrs old, high risk of shingles; vaccine is safe in chemo. | Can be given before or during treatment; 2‑dose series 2 months apart. |\n| **Pneumococcal (PCV15 + PPSV23)** | Reduces invasive pneumococcal disease; safe with chemo. | If not previously vaccinated, give PCV15 first, then PPSV23 6–12 months later. |\n\n**Live‑attenuated vaccines (e.g., MMR, varicella, yellow fever) are contraindicated during R‑CHOP.**  \n\nIf you’re already up‑to‑date, you’re in good shape. If not, talk to your oncologist or pharmacist about scheduling these shots before the first cycle or as soon as your blood counts allow. This helps keep infections at bay while you fight lymphoma.",
          "order": 9,
          "qid": "S24-Q09"
        },
        {
          "q": "What happens if it doesn’t respond?",
          "gt": "If the interim PET shows that the lymphoma is still active after 2–3 R‑CHOP cycles, the oncologist will usually **extend the course to 6–8 cycles** or add a dose‑intensifying agent (e.g., high‑dose methotrexate or a second rituximab).  \nIf the disease remains refractory after the full course, the next step is **salvage chemotherapy** (e.g., R‑ICE, R‑ESHAP, or a polatuzumab‑based regimen) followed by **high‑dose chemotherapy with autologous stem‑cell transplant** if you’re fit for it.  \nFor patients who can’t tolerate transplant, newer options include **CAR‑T cell therapy** (axi‑mab or tisa‑mab) or participation in a clinical trial.  \nIn all cases, the treatment plan is tailored to your age, organ function, and overall health, so a close discussion with your oncologist is essential.",
          "order": 10,
          "qid": "S24-Q10"
        }
      ]
    },
    {
      "id": "S25",
      "title": "Trailhead ahead (metastatic kidney cancer)",
      "diagnosis": "Metastatic renal cell carcinoma",
      "treatment_plan": "Combination immunotherapy or immunotherapy plus targeted therapy; monitor for immune-related side effects",
      "narrative": "I'm 61 and love national parks. I want a plan that lets me keep hiking without ignoring warning signs.",
      "qa": [
        {
          "q": "How do we choose between combinations without wrecking my stamina?",
          "gt": "**Choosing a regimen that preserves your stamina**\n\n1. **Start with your overall health** – Your ECOG performance status, kidney function, and any other chronic conditions (e.g., heart disease, diabetes) guide the choice.  \n2. **Side‑effect profiles** –  \n   * **ICI alone (nivolumab + ipilimumab)**: common fatigue, thyroiditis, colitis; usually manageable with steroids and early symptom reporting.  \n   * **ICI + VEGF inhibitor (e.g., pembrolizumab + lenvatinib or cabozantinib)**: adds hypertension, hand‑foot syndrome, diarrhea, and can increase fatigue.  \n3. **Biomarkers & prior therapy** – PD‑L1 status, VEGF‑targeted therapy exposure, and previous toxicities help refine the choice.  \n4. **Shared decision‑making** – Discuss your hiking goals, willingness to tolerate potential side effects, and the need for frequent monitoring (blood pressure, labs, symptom diary).  \n5. **Early intervention** – Promptly report fatigue, shortness of breath, or new pain; use supportive measures (hydration, rest, low‑dose steroids if needed).  \n\nIn short, weigh the likelihood of fatigue and other side effects against your activity goals, and choose the regimen that offers the best balance of efficacy and tolerability for you.",
          "order": 1,
          "qid": "S25-Q01"
        },
        {
          "q": "What immune side effects should make me stop the trail and call?",
          "gt": "**When to pause therapy and call your oncologist**\n\nIf you develop any of the following *severe* immune‑related symptoms, stop the drug and seek care immediately:\n\n| System | Red‑flag signs |\n|--------|----------------|\n| **Pulmonary** | New or worsening shortness of breath, cough, chest pain, or oxygen desaturation (pneumonitis). |\n| **Gastrointestinal** | Severe diarrhea (≥3 stools/day), bloody stools, abdominal pain, vomiting, or fever (colitis). |\n| **Hepatic** | Yellowing of skin/eyes, dark urine, severe abdominal pain, or markedly elevated liver enzymes (hepatitis). |\n| **Renal** | Oliguria, swelling, or rising creatinine (nephritis). |\n| **Endocrine** | Sudden fatigue, dizziness, low blood pressure, confusion, or severe headache (hypothyroidism, adrenal insufficiency, hypophysitis). |\n| **Dermatologic** | Large, blistering rash, bullae, or skin necrosis. |\n| **Neurologic** | New weakness, numbness, vision changes, seizures, or severe headache. |\n\n**Action**  \n- Stop the medication.  \n- Call your oncology team or go to urgent care/emergency.  \n- Mild, manageable symptoms (e.g., low‑grade rash or mild fatigue) can often be treated while continuing therapy, but any of the above warrants immediate evaluation.",
          "order": 2,
          "qid": "S25-Q02"
        },
        {
          "q": "Can I camp far from hospitals?",
          "gt": "**Short answer:** It’s safest to stay within a reasonable distance of a hospital—ideally a 30‑minute drive—while you’re on immunotherapy or targeted therapy.  \n\n**Why?**  \n- Immune‑related adverse events (colitis, pneumonitis, thyroiditis, etc.) can develop suddenly and may need urgent steroids, antibiotics, or hospitalization.  \n- Targeted‑therapy side effects (hypertension, hand‑foot syndrome, liver toxicity) can also worsen quickly.  \n- If you’re far from care, you risk delayed treatment of a serious reaction, which can worsen outcomes.  \n\n**Practical plan:**  \n1. **Map out nearby medical centers** and keep a list of emergency contacts.  \n2. **Carry a “medical kit”** with your current medications a steroid‑dose kit (if prescribed), and a list of your treatment schedule.  \n3. **Arrange a support person** who can monitor you and call for help if you feel unwell.  \n4. **Use telehealth** for routine check‑ins; schedule a visit if you notice new symptoms (fever, shortness of breath, severe pain).  \n\nEnjoy the parks, but keep a safety net close by.",
          "order": 3,
          "qid": "S25-Q03"
        },
        {
          "q": "Will high altitude be a problem?",
          "gt": "High altitude can be a concern while on immunotherapy or targeted therapy for metastatic kidney cancer.  \n- **Hypoxia and cardiovascular strain**: Even mild altitude (2,000–3,000 m) can lower oxygen saturation, which may worsen fatigue, shortness of breath, or hypertension—side effects common with TKIs and immune‑related pneumonitis.  \n- **Pulmonary complications**: Immune‑related lung inflammation or drug‑induced pulmonary edema can be aggravated by the lower barometric pressure and cold air.  \n- **Acclimatization**: Gradual ascent, staying well‑hydrated, and monitoring SpO₂ (≥94 %) are essential.  \n- **Practical tips**: Plan hikes for lower elevations, avoid strenuous climbs, carry a portable pulse oximeter, and have a clear plan for medical care if symptoms worsen.  \nDiscuss your hiking goals with your oncologist; they can tailor your treatment schedule and provide specific altitude‑related precautions.",
          "order": 4,
          "qid": "S25-Q04"
        },
        {
          "q": "Does diet matter for these meds?",
          "gt": "**Short answer:**  \nYes—what you eat can influence how well your immunotherapy and targeted drugs work and how you tolerate them.  \n\n**Why it matters**  \n- **Immune support:** A diet rich in fruits, vegetables, whole grains, and lean protein helps keep your immune system functioning, which is essential for immunotherapy.  \n- **Metabolism & side‑effects:** Some targeted agents (e.g., VEGF inhibitors) are processed by the liver and can be affected by high‑fat meals or alcohol.  \n- **Blood pressure & edema:** Low‑sodium foods help control hypertension and fluid retention that can accompany these drugs.  \n- **General well‑being:** Adequate calories, protein, and hydration keep you strong for hiking and reduce fatigue.  \n\n**Practical tips**  \n- Aim for a balanced plate: half veggies/fruits, a quarter protein, a quarter whole grains.  \n- Limit processed, high‑salt, and high‑fat foods.  \n- Stay hydrated; avoid excessive alcohol.  \n- If you’re on a VEGF inhibitor, keep sodium <2 g/day.  \n- Consider a registered dietitian familiar with oncology nutrition for a personalized plan.  \n\nStaying nourished supports both your treatment and your love of the trails.",
          "order": 5,
          "qid": "S25-Q05"
        },
        {
          "q": "What about blood pressure spikes I’ve heard about?",
          "gt": "**Blood‑pressure spikes with kidney‑cancer therapy**\n\nMany of the drugs we’ll use—especially VEGF‑targeted agents (sunitinib, pazopanib, axitinib) and, less often, immune‑checkpoint inhibitors—can raise blood pressure. The rise is usually modest at first but can become significant if left unchecked.\n\n**What to do**\n\n1. **Check BP regularly** – at home twice a day (morning and evening) and bring the readings to every visit.  \n2. **Keep a log** – note the time, value, and any symptoms (headache, vision changes, dizziness).  \n3. **Treat promptly** – most patients need a low‑dose antihypertensive (e.g., an ACE‑inhibitor, ARB, or calcium‑channel blocker).  \n4. **Adjust therapy** – if BP stays >140/90 mm Hg despite medication, the oncologist may lower the cancer drug dose or switch agents.  \n5. **Lifestyle** – limit sodium, stay hydrated, avoid excessive caffeine, and maintain a moderate exercise routine that fits your hiking schedule.\n\nWith routine monitoring and early treatment, you can keep hiking safely while staying on track with your cancer therapy.",
          "order": 6,
          "qid": "S25-Q06"
        },
        {
          "q": "Can I still donate blood to the park drives?",
          "gt": "**Short answer:** While you’re on active immunotherapy or targeted therapy for metastatic kidney cancer, you’re generally **not eligible to donate blood**. Most blood‑bank guidelines (e.g., the American Red Cross) defer cancer patients for at least 3 months after the last dose of systemic therapy.  \n\n**What to do next:**\n\n1. **Check with your oncologist** – they can confirm when you’ll be cleared to donate.  \n2. **Contact the local blood‑donation center** – ask about the specific deferral period for your treatment regimen.  \n3. **Plan a future donation** – once you’ve completed therapy and the deferral window has passed, you can usually donate again.  \n\nIn the meantime, you can still support the park drives by volunteering, fundraising, or spreading awareness. Keep monitoring for side effects and stay in touch with your care team.",
          "order": 7,
          "qid": "S25-Q07"
        },
        {
          "q": "If scans show stable disease, is that a win or just holding pattern?",
          "gt": "Stable disease means the cancer isn’t growing or shrinking on the scans—so it’s a **positive sign** that your treatment is working, but it isn’t a cure. Think of it as a “holding pattern” that keeps the disease in check while you maintain your life goals, like hiking.  \n\n**What it means for you:**  \n- You can usually keep the current therapy and continue monitoring every 8–12 weeks.  \n- If you’re feeling well and side‑effects are manageable, you can keep hiking, just stay alert for new symptoms (pain, swelling, fatigue).  \n- If the disease starts to progress or side‑effects worsen, we’ll discuss switching or adding therapy.  \n\nSo, stable disease is a win in that it keeps the cancer from advancing, but it also signals we need to stay vigilant and keep the treatment plan on track.",
          "order": 8,
          "qid": "S25-Q08"
        },
        {
          "q": "What if my joints ache too much to hike?",
          "gt": "I’m sorry you’re dealing with joint pain. Joint aches can be an immune‑related side effect of the therapy you’re receiving. Here are practical steps that let you stay active while protecting your joints:\n\n1. **Medical check‑in** – Tell your oncologist about the pain. Mild arthralgia is often managed with NSAIDs (e.g., ibuprofen) or acetaminophen, but if it’s persistent or worsening, steroids or a dose adjustment may be needed.  \n2. **Physical therapy** – A PT can teach low‑impact strengthening and stretching that keeps joints mobile without overloading them.  \n3. **Modify hiking** – Shorter, flatter trails, use a walking stick or trekking poles, and take frequent rests. Warm‑up before you go and cool‑down afterward.  \n4. **Supportive gear** – Well‑fitting shoes, compression sleeves, or a brace can reduce strain.  \n5. **Listen to your body** – If pain spikes, pause the hike and rest; resume when it eases.  \n\nBalancing treatment and hiking is doable—just keep the lines of communication open with your care team.",
          "order": 9,
          "qid": "S25-Q09"
        },
        {
          "q": "If this stops working, what’s next?",
          "gt": "If the current combination (e.g., nivolumab + ipilimumab or a TKI + PD‑1 inhibitor) no longer controls disease, the next step is a systematic reassessment: imaging, performance status, and any new symptoms.  \n1. **Confirm progression** (CT/MRI, RECIST).  \n2. **Re‑biopsy or liquid biopsy** to look for actionable mutations or resistance mechanisms.  \n3. **Switch to a second‑line targeted agent**—commonly a VEGF‑TKI such as axitinib, cabozantinib, or lenvatinib + everolimus.  \n4. **Consider a different immunotherapy combo** (e.g., pembrolizumab + axitinib) if not already used.  \n5. **Enroll in a clinical trial** whenever possible; trials often offer novel agents or combinations.  \n6. **Palliative/supportive care** should be integrated early to maintain quality of life and keep you hiking safely.  \n\nDiscuss these options with your oncologist to tailor the plan to your health status and preferences.",
          "order": 10,
          "qid": "S25-Q10"
        }
      ]
    },
    {
      "id": "S26",
      "title": "Hope in a cooler (CAR-T for relapsed lymphoma)",
      "diagnosis": "Relapsed/refractory large B-cell lymphoma, candidate for CAR-T",
      "treatment_plan": "Leukapheresis, bridging therapy as needed, lymphodepleting chemo, CAR-T infusion; monitor for CRS/ICANS; caregiver required",
      "narrative": "I'm 59 and my lymphoma came back. They say my own cells can be turned into medicine. I’m hopeful and scared of the side effects I’ve read about.",
      "qa": [
        {
          "q": "How long am I away from home from collection to infusion?",
          "gt": "**Typical timeline (from apheresis to CAR‑T infusion)**  \n\n| Step | Approx. time after apheresis | Notes |\n|------|-----------------------------|-------|\n| **Leukapheresis** | Day 0 | Blood is drawn, cells are collected. |\n| **Manufacturing** | 1–2 weeks | Your T‑cells are engineered into CAR‑T cells. |\n| **Bridging therapy** | 0–2 weeks (if needed) | Chemotherapy or steroids may be given to keep the lymphoma under control while the product is made. |\n| **Lymphodepleting chemo** | 2 days before infusion | Usually fludarabine + cyclophosphamide. |\n| **CAR‑T infusion** | Day 0 of infusion | You receive the final product. |\n\nSo, from the day you give your blood to the day you receive the CAR‑T cells, you’re typically away from home for **about 3–4 weeks**. In some cases—if the product takes longer to manufacture or if additional bridging therapy is required—it can extend up to 5–6 weeks. Your care team will keep you updated on the exact schedule and any adjustments.",
          "order": 1,
          "qid": "S26-Q01"
        },
        {
          "q": "What does a caregiver actually do, and for how long?",
          "gt": "A caregiver’s job is to be the patient’s “eyes and ears” during the CAR‑T journey.  \n**Before the infusion** they help with appointments, transportation, and paperwork, and they prepare the home for a possible short hospital stay.  \n**During the infusion** they sit with the patient, monitor for early signs of cytokine release syndrome (fever, chills, shortness of breath) and neurologic changes (confusion, seizures), and report any symptoms to the team.  \n**Afterward** most patients stay in the hospital 7–10 days for close monitoring; the caregiver may stay overnight or be on call for the first 48–72 hours. Once discharged, the patient is observed for 30 days in clinic or via telehealth for late CRS or ICANS, and then routine follow‑up visits continue every 3–6 months.  \n\nSo, the caregiver is present from the day of leukapheresis through the first month after CAR‑T, with the most intense support during the first week post‑infusion.",
          "order": 2,
          "qid": "S26-Q02"
        },
        {
          "q": "What does cytokine release syndrome feel like?",
          "gt": "Cytokine release syndrome (CRS) is the body’s immune‑system “flare‑up” after CAR‑T cells start attacking lymphoma cells. It usually begins 1–3 days after infusion and can last a few days to a week. Common sensations include:\n\n- **Flu‑like symptoms**: fever (often >38 °C), chills, sweats, fatigue, and muscle aches.  \n- **Cardiovascular changes**: rapid heartbeat, low blood pressure, shortness of breath, or feeling light‑headed.  \n- **Gastrointestinal upset**: nausea, vomiting, diarrhea, or abdominal pain.  \n- **Neurologic signs** (if CRS is severe): confusion, agitation, or headaches.\n\nMost cases are mild (grade 1–2) and respond to antipyretics and supportive care. Severe CRS (grade 3–4) may require intravenous steroids, tocilizumab (an IL‑6 blocker), or ICU monitoring. Your team will watch vital signs, labs, and symptoms closely, and will intervene early if you feel dizzy, short of breath, or unusually weak. If you notice any of these signs, let your nurse or doctor know right away.",
          "order": 3,
          "qid": "S26-Q03"
        },
        {
          "q": "What about the brain side effects—will I know if my words tangle?",
          "gt": "**ICANS (neurotoxicity) is the main brain‑related risk with CAR‑T.**  \nIt usually appears 1–10 days after infusion, often while you’re still in the hospital. The most common signs are:\n\n| Symptom | What to watch for | When to call the team |\n|---------|-------------------|-----------------------|\n| **Language changes** (words tangled, trouble naming, “word salad”) | Notice if you can’t find the right word or sentences feel jumbled | If it starts or worsens |\n| **Confusion or disorientation** | Feeling “foggy,” not knowing where you are | If you can’t follow simple directions |\n| **Seizures** | Sudden convulsions, loss of consciousness | Immediate emergency call |\n| **Motor weakness or tremor** | Trouble walking, shaking hands | If it becomes noticeable |\n| **Headache or vision changes** | Severe headache, blurred vision | If it’s persistent or severe |\n\n**What to do:**  \n- **Report any new or worsening symptoms** to your nurse or oncologist right away.  \n- **Daily neurologic checks** (orientation, speech, motor strength) are routine while you’re in the hospital.  \n- **If you’re at home** and notice any of the above, call your oncology team or go to the nearest emergency department.\n\nEarly detection and prompt treatment (often steroids or supportive care) usually prevent serious long‑term effects. Stay alert to changes in speech and cognition, and don’t hesitate to reach out—your team is ready to help.",
          "order": 4,
          "qid": "S26-Q04"
        },
        {
          "q": "Can I work remotely during all this?",
          "gt": "**Short answer:**  \nYes—remote work is usually possible, but it depends on how you feel during each phase of CAR‑T therapy.  \n\n**What to consider**\n\n| Phase | Typical side‑effects | Work‑feasibility |\n|-------|---------------------|------------------|\n| **Leukapheresis & bridging** | Mild fatigue, bruising | Often fine; you can work from home if you’re comfortable. |\n| **Lymphodepleting chemo** | Nausea, low blood counts, fatigue | You may need a few days off or a lighter schedule. |\n| **CAR‑T infusion** | Hospital stay (1–3 days), possible fever, chills | You’ll be in the hospital; remote work isn’t needed. |\n| **Post‑infusion (CRS/ICANS risk)** | Fever, low blood pressure, confusion, headaches | If you develop CRS or ICANS, you’ll need to stay in the hospital or rest at home. Once stable, many patients resume remote work within a week or two. |\n\n**Practical tips**\n\n1. **Talk to your oncology team** about your job’s demands and any required accommodations.  \n2. **Plan for flexibility**: schedule remote work around hospital visits and recovery days.  \n3. **Prioritize rest**—fatigue is common; allow yourself breaks and avoid over‑exertion.  \n4. **Have a backup plan**: if you feel dizzy, confused, or severely fatigued, stay home and let your employer know.  \n\nIn short, remote work is usually feasible, but stay in close contact with your medical team and adjust your schedule as your body recovers.",
          "order": 5,
          "qid": "S26-Q05"
        },
        {
          "q": "If the cells don’t grow in the lab, then what?",
          "gt": "If the harvested T‑cells fail to expand in the lab, the CAR‑T product is considered “non‑viable” and the infusion cannot be performed.  In that case the treatment team will usually:\n\n1. **Re‑evaluate the sample** – sometimes a second apheresis is possible, especially if the first was done early in the disease course or if the patient’s immune system is still functional.  \n2. **Consider alternative therapies** – this may include other salvage regimens, targeted agents, or enrollment in a clinical trial (e.g., allogeneic CAR‑T, bispecific antibodies, or novel immunotherapies).  \n3. **Discuss supportive care** – if no other options are feasible, focus shifts to palliative measures and symptom control.\n\nYour team will keep you informed at each step and help you decide the best next move.",
          "order": 6,
          "qid": "S26-Q06"
        },
        {
          "q": "Is infection risk higher after CAR-T?",
          "gt": "Yes—people who receive CAR‑T therapy are at a higher risk of infection than after many other treatments. The lymphodepleting chemotherapy (fludarabine/cyclophosphamide) and the CAR‑T cells themselves can cause prolonged neutropenia, B‑cell aplasia, and hypogammaglobulinemia. These changes reduce your body’s ability to fight bacteria, viruses, and fungi.  \n\n**What it means for you**\n\n* **Early monitoring** – Your team will check blood counts and watch for fever or other signs of infection right after infusion.  \n* **Prophylaxis** – Many centers give antibiotics, antivirals, and antifungals during the first weeks.  \n* **Immunoglobulin replacement** – If IgG levels fall below 400 mg/dL, IVIG may be started.  \n* **Vaccinations** – Live vaccines are avoided; inactivated vaccines can be given after recovery.  \n\nStay alert for fevers, chills, or new symptoms, and report them promptly. With careful monitoring and preventive measures, most infections are manageable.",
          "order": 7,
          "qid": "S26-Q07"
        },
        {
          "q": "Will I lose my hair again?",
          "gt": "**Short answer:**  \nCAR‑T cell infusion itself does **not** cause hair loss. Hair loss usually comes from the chemotherapy you receive before the CAR‑T product is given (the “lymphodepleting” regimen, usually fludarabine + cyclophosphamide, and any bridging therapy you might need). If you had a full‑body chemo course before, you may have already lost hair; if you’re only getting the lymphodepleting combo, the hair loss is usually mild to moderate and usually starts a week or two after the infusion and then regrows over a few months.\n\n**What to expect:**  \n- **Lymphodepletion:** 2–3 days of fludarabine/cyclophosphamide can cause temporary thinning or shedding.  \n- **CAR‑T infusion:** No direct effect on hair.  \n- **Bridging therapy:** If you need additional chemo while waiting for the CAR‑T product, that could add to hair loss.\n\nIf you’re concerned, bring up the specific chemo drugs you’ll receive with your oncologist; they can give you a clearer timeline and discuss scalp‑protective measures (e.g., wearing a loose hat, using gentle hair care). Hair usually returns to its normal state within 3–6 months after the lymphodepleting regimen.",
          "order": 8,
          "qid": "S26-Q08"
        },
        {
          "q": "How soon will I know if it worked?",
          "gt": "After the CAR‑T infusion you’ll be monitored closely for the first 2–3 weeks for cytokine‑release syndrome (CRS) and neurologic toxicity (ICANS). Those early reactions are not a measure of tumor response, but they let the team know the cells are active.  \n\nThe first formal assessment of whether the lymphoma has responded is usually done with imaging (CT, PET‑CT, or MRI) about **4–6 weeks after the infusion**. In many patients a reduction in tumor size or disappearance of metabolic activity can already be seen at that time.  \n\nIf the disease is still active, the next evaluation is typically at 3 months, and then every 3–6 months for the first year. So you’ll get a clear answer on response within a month, with follow‑up imaging every few months thereafter.",
          "order": 9,
          "qid": "S26-Q09"
        },
        {
          "q": "If it works, how long can it last?",
          "gt": "If the CAR‑T cells successfully eradicate the lymphoma, the duration of benefit varies but is often measured in years rather than months. In large‑B‑cell lymphoma trials, median progression‑free survival (PFS) is about 12–18 months, but roughly 30–40 % of patients remain disease‑free at 3 years and a smaller group (10–15 %) achieve durable remissions beyond 5 years. Factors that influence this include the specific CAR‑T product, the patient’s prior therapies, the lymphoma’s biology (e.g., double‑hit disease), and how well the cells persist in the body. Even after a long remission, regular follow‑up is essential because late relapses can occur. If relapse happens, additional treatments—such as a second CAR‑T, stem‑cell transplant, or targeted therapy—may still be options.",
          "order": 10,
          "qid": "S26-Q10"
        }
      ]
    },
    {
      "id": "S27",
      "title": "Semester on hold (acute lymphoblastic leukemia, young adult)",
      "diagnosis": "Ph-negative acute lymphoblastic leukemia in a 24-year-old",
      "treatment_plan": "Multi-phase chemotherapy (induction, consolidation, maintenance); CNS prophylaxis; central line; fertility counseling",
      "narrative": "I'm 24 and in grad school. The schedule looks like a second full-time job. I want to live—and still graduate.",
      "qa": [
        {
          "q": "How much of my semester is realistically salvageable?",
          "gt": "You’ll likely be in the hospital for the first 6–8 weeks of the semester (induction + CNS prophylaxis). During that time most students can only attend a handful of in‑person classes or rely on recorded lectures. After induction, consolidation is a bit less intense—weekly visits, but you can usually manage a reduced course load or remote participation. Maintenance is spread over years and is the least disruptive. In practice, about 30–50 % of a typical 15‑week semester can be salvaged with accommodations (online work, recorded lectures, a leave of absence or reduced credit load). Talk early with your advisor and faculty; most programs allow flexible schedules for patients in treatment.",
          "order": 1,
          "qid": "S27-Q01"
        },
        {
          "q": "Will a central line change how I sleep or shower?",
          "gt": "A central line (usually a PICC or tunneled catheter) will change a few daily habits, but most people adapt quickly.\n\n**Sleeping** – You can sleep on either side, but avoid sleeping on the side with the line for the first 24–48 h to reduce pressure on the insertion site. After that, most patients sleep comfortably in a normal position. If you feel a “tight” sensation, a small pillow under the arm can help.\n\n**Showering** – You can shower normally. Keep the line and dressing dry: use a waterproof cover or a plastic bag over the site, and avoid soaking the dressing for 24 h after placement. If you’re using a tunneled line, the exit site is usually below the collarbone and can be showered with a gentle rinse. If you’re on a PICC, keep the dressing moist but not saturated.\n\n**Other tips**  \n- Keep the dressing clean and dry; change it per your nurse’s instructions.  \n- Avoid heavy lifting or activities that strain the arm.  \n- Report any redness, swelling, or drainage promptly.\n\nWith a little routine, the line shouldn’t interfere much with your sleep or showering, and you can keep up with grad school and self‑care.",
          "order": 2,
          "qid": "S27-Q02"
        },
        {
          "q": "How do I handle friends who say 'you don’t look sick' when I’m exhausted?",
          "gt": "When friends say “you don’t look sick,” it’s usually a mix of concern and a lack of understanding about how leukemia and its treatment feel. Here’s a quick, practical approach:\n\n1. **Set a gentle boundary** – Acknowledge their care, then say, “I appreciate that, but I’m still dealing with fatigue and side‑effects. It’s not always visible.”  \n2. **Educate briefly** – Share a one‑sentence fact: “Chemotherapy can cause profound tiredness, brain fog, and pain that aren’t obvious on the outside.”  \n3. **Invite empathy, not judgment** – Ask, “Can you help me by checking in or offering a short break?”  \n4. **Use visual cues** – Wear a discreet band or carry a note that says “I’m on chemo” so people see a reminder.  \n5. **Seek supportive circles** – Connect with fellow patients or online groups where the experience is shared and understood.\n\nRemember, you’re allowed to set limits and ask for the support you need.",
          "order": 3,
          "qid": "S27-Q03"
        },
        {
          "q": "What does 'maintenance' actually feel like?",
          "gt": "**Maintenance** is the longest phase—often 18–24 months—after induction and consolidation. It’s usually a “low‑dose” daily or weekly chemotherapy (e.g., 6‑mercaptopurine, methotrexate, vincristine) plus oral steroids, given at home or in a clinic.  \n\n*What it feels like:*  \n- **Routine**: Most days you’ll take pills or receive a short infusion; the schedule is predictable, so you can plan classes or work around it.  \n- **Side‑effects**: Mild fatigue, mouth sores, nausea, and occasional low blood counts. Most people tolerate it well, but you’ll need regular blood tests (every 1–2 weeks).  \n- **Impact on life**: You can usually keep up with grad‑school work, but you’ll need to monitor for infections and manage fatigue.  \n- **Support**: A close team (oncologist, nurse, pharmacist) will adjust doses if you feel overwhelmed.  \n\nIn short, maintenance is a steady, manageable routine that lets you focus on recovery while still pursuing your studies.",
          "order": 4,
          "qid": "S27-Q04"
        },
        {
          "q": "Can we preserve fertility without delaying induction?",
          "gt": "**Short answer:**  \nYes—especially for men, you can bank sperm right before induction without delaying treatment. For women, the most effective options (oocyte or embryo cryopreservation) require ovarian stimulation, which usually takes 2–3 weeks and can postpone induction. A GnRH‑agonist (e.g., leuprolide) can be started during induction to protect ovarian reserve, but evidence is limited and it does not guarantee future fertility.  \n\n**Practical steps:**  \n1. **Male:** Arrange sperm banking immediately; it takes a few hours and can be done before the first chemo dose.  \n2. **Female:** Consult a reproductive endocrinologist ASAP. If time allows, schedule ovarian stimulation and retrieval; otherwise, discuss GnRH‑agonist use and the possibility of post‑treatment fertility testing.  \n\n**Key point:** Your oncologist can coordinate fertility services so that induction proceeds on schedule while you still have a realistic chance of future fertility.",
          "order": 5,
          "qid": "S27-Q05"
        },
        {
          "q": "Do I have to give up my apartment with roommates?",
          "gt": "You don’t have to give up your apartment, but you’ll need to plan for the practicalities of intensive chemo.  \n**Key points to discuss with your roommates and your oncologist:**\n\n| Issue | Practical tip |\n|-------|---------------|\n| **Infection risk** | Keep the apartment clean, use a HEPA filter if possible, and avoid crowds. Your roommates can help with chores and grocery runs. |\n| **Medication timing** | Schedule chemo and oral meds around your study hours. A shared calendar can keep everyone on the same page. |\n| **Side‑effects** | Nausea, fatigue, and mouth sores may limit your ability to cook or clean. Ask a roommate to help with meals or set up a meal‑delivery service. |\n| **Isolation periods** | During neutropenic phases you’ll need a “clean” environment. A roommate can keep the house tidy and monitor for fevers. |\n| **Mental health** | Living with friends can reduce loneliness; just set clear boundaries for quiet study time. |\n\n**Bottom line:** With open communication, a shared schedule, and a willingness to adapt, you can keep your apartment and still focus on your treatment and grad work. If you ever feel overwhelmed, consider a short-term housing option (e.g., a nearby student dorm or a supportive friend’s place) while you recover.",
          "order": 6,
          "qid": "S27-Q06"
        },
        {
          "q": "What if chemo brain wrecks my studying?",
          "gt": "Chemo‑brain is common, but it usually improves after treatment. Talk to your oncologist about ways to minimize it—sometimes a lower dose of steroids or adding a short‑acting stimulant (e.g., methylphenidate) can help focus. In the meantime, use practical strategies:  \n\n1. **Structure your study** – block time, use a planner, and break tasks into 25‑minute focused sessions with 5‑minute breaks (Pomodoro).  \n2. **Active learning** – teach the material to a friend, use flashcards, or explain concepts aloud; this reinforces memory.  \n3. **Limit multitasking** – one task at a time, no background noise or notifications.  \n4. **Support tools** – note‑taking apps, mind‑mapping, and spaced‑repetition software.  \n5. **Ask for accommodations** – most grad programs allow flexible deadlines or reduced course loads during treatment.  \n\nIf symptoms persist, a neuropsychology referral can offer targeted cognitive rehabilitation. Remember, many patients return to their academic goals with these supports.",
          "order": 7,
          "qid": "S27-Q07"
        },
        {
          "q": "How strict is infection prevention during exams on campus?",
          "gt": "During induction and consolidation you’ll likely be neutropenic (ANC < 500 cells/µL). In that period, any crowded setting—classroom, library, cafeteria—poses a real infection risk. Most universities now require masks and hand‑sanitizer use for all students, and many offer remote or “hybrid” exams.  \n\n**Practical steps:**  \n1. **Ask for accommodations**—request a virtual exam or a quiet, low‑traffic room.  \n2. **If you must attend in person**: wear a high‑filtration mask, wash hands before and after, avoid touching your face, and keep at least 6 ft from others.  \n3. **Limit exposure**—skip non‑essential campus events and use online resources for study.  \n\nSpeak with your school’s disability services; they can arrange the safest exam environment for you.",
          "order": 8,
          "qid": "S27-Q08"
        },
        {
          "q": "If a phase is delayed, does it ruin the whole plan?",
          "gt": "Delaying a phase can be managed, but it matters how long the pause is and why it happens. Short, planned gaps (e.g., a week‑long recovery from neutropenia or a brief holiday) are usually built into the schedule and don’t compromise the overall cure rate. However, repeated or prolonged delays—especially if they push a phase past the “window” recommended by the protocol—can allow the leukemia to grow back and may reduce long‑term survival.  \n\nTalk with your medical‑oncology team before any break: they can adjust doses, add growth factors, or shift the next cycle to keep the plan on track. Keep a log of symptoms, infections, and any side‑effects so you can anticipate and prevent future delays. In short, a single brief delay is often fine, but sustained postponements should be avoided and managed proactively.",
          "order": 9,
          "qid": "S27-Q09"
        },
        {
          "q": "What’s plan B if remission isn’t complete?",
          "gt": "If induction fails to achieve a complete remission (CR), the next step is usually a **salvage or “second‑induction”** regimen—often a different combination of drugs (e.g., hyper‑CVAD, L-asparaginase‑based protocols, or high‑dose methotrexate).  \n\nIf CR is still not reached, the treatment plan shifts to **high‑dose chemotherapy followed by an allogeneic stem‑cell transplant (allo‑SCT)**, which is the only curative option for many adults who relapse after first‑line therapy.  \n\nIn parallel, we’ll assess minimal residual disease (MRD) and molecular markers to guide the transplant choice and post‑transplant maintenance.  \n\nIf transplant isn’t feasible or the disease remains refractory, enrollment in a **clinical trial** (targeted agents, CAR‑T, bispecific antibodies) is pursued, and palliative care is introduced early to maintain quality of life.  \n\nYour oncologist will tailor these options to your specific risk profile and overall health.",
          "order": 10,
          "qid": "S27-Q10"
        }
      ]
    },
    {
      "id": "S28",
      "title": "Which way do I pee (muscle-invasive bladder cancer)",
      "diagnosis": "Muscle-invasive urothelial carcinoma",
      "treatment_plan": "Neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy with urinary diversion (ileal conduit or neobladder)",
      "narrative": "I'm 65. They’re removing my bladder after chemo, and I have to choose how I’ll pee for the rest of my life. I want dignity and practicality.",
      "qa": [
        {
          "q": "Is there a way to avoid removing the bladder if chemo works well?",
          "gt": "I’m sorry you’re facing this tough decision. For muscle‑invasive bladder cancer, the standard of care is radical cystectomy after neoadjuvant cisplatin‑based chemotherapy. However, if your tumor responds completely to chemo, a “bladder‑preservation” strategy can be considered. This usually involves a combination of chemotherapy and external‑beam radiation (or sometimes intravesical therapy) with close surveillance—often called a trim‑and‑watch or chemoradiation protocol. It’s only offered to patients who meet strict criteria (e.g., no lymph node involvement, good performance status, and a clear response on imaging/biopsy). Even then, the risk of recurrence is higher, and you’d need frequent cystoscopies and imaging. Discuss these options with your oncologist and urologist; they can evaluate whether a bladder‑sparing approach is safe and appropriate for you.",
          "order": 1,
          "qid": "S28-Q01"
        },
        {
          "q": "Which diversion lets me travel without constant bathroom scouting?",
          "gt": "I understand how important it is to feel comfortable and independent while traveling.  \n**Ileal conduit** is usually the best choice for long‑distance travel. It creates a small stoma on the abdomen that drains urine into a pouch that you can empty at convenient times—no need to locate a restroom to void. The pouch can be emptied every 4–6 hours, and you can carry a spare bag or use a discreet “bag‑in‑bag” system for longer trips.  \n\nA **neobladder** (bladder‑like pouch) lets you urinate normally, but you’ll need to find a restroom to empty it, which can be challenging on flights, trains, or in unfamiliar places. If you’re comfortable with catheterization or have a reliable bathroom schedule, a neobladder can work, but for most travelers the ileal conduit offers greater freedom and peace of mind.  \n\nDiscuss with your surgeon and stoma nurse to tailor the plan to your lifestyle and preferences.",
          "order": 2,
          "qid": "S28-Q02"
        },
        {
          "q": "Will intimacy be possible after surgery?",
          "gt": "After a radical cystectomy, sexual activity is often still possible, but it depends on a few factors. If the surgeon performs a **nerve‑sparing cystectomy** (possible in selected men), erections can usually be preserved, and many men regain sexual function with or without phosphodiesterase‑5 inhibitors (e.g., sildenafil). In women, the removal of the bladder does not usually affect vaginal function, though the pelvic floor may feel different.  \n\nWith an **ileal conduit**, the external stoma can be managed with a pouch, and sexual activity is generally unaffected. A **neobladder** may require some adjustment to timing and comfort, but most patients report normal sexual function.  \n\nIn short, intimacy is usually possible after surgery, though you may need to discuss medications, timing, and any pelvic floor support with your urologist to optimize comfort and function.",
          "order": 3,
          "qid": "S28-Q03"
        },
        {
          "q": "How visible is an external bag under clothes?",
          "gt": "An ileal‑conduit bag is a small, round pouch (≈10–15 cm in diameter) that sits on the lower abdomen. With a well‑fitted, loose‑cut shirt or a slightly longer top, the bag can be largely hidden; the bulk is usually only noticeable if you’re wearing very tight or sheer clothing. The bag’s shape is fairly discreet, but it will still be visible if you’re in a tight‑fitting dress or a very short skirt. If you’re concerned about visibility, choose a bag with a low profile, use a snug‑fit belt or pouch to keep it in place, and pair it with a longer top or a cardigan. A neobladder, on the other hand, requires no external bag at all.",
          "order": 4,
          "qid": "S28-Q04"
        },
        {
          "q": "Will chemo damage my hearing or nerves permanently?",
          "gt": "Cisplatin can cause both hearing loss (ototoxicity) and peripheral neuropathy, but the extent varies. About 20‑30 % of patients develop some degree of hearing loss, usually in the high‑frequency range, and it can be permanent if it occurs. Peripheral neuropathy is less common (≈10 %) and often improves after stopping the drug, but in some cases it can persist. Your oncologist will monitor hearing with audiograms and nerve function with symptom checks. Dose adjustments, slower infusion, and protective agents (e.g., sodium thiosulfate) can reduce risk. If you have pre‑existing hearing problems or neuropathy, the team may choose a different regimen. Discuss your concerns with the medical team; they can tailor the plan to minimize long‑term damage while still treating the cancer effectively.",
          "order": 5,
          "qid": "S28-Q05"
        },
        {
          "q": "Can I swim with a stoma?",
          "gt": "Yes—you can swim after a cystectomy, but a few practical steps help keep the stoma healthy and you comfortable.\n\n1. **Use a waterproof pouch** – A snug, waterproof pouch (or a “stoma‑friendly” swim cover) protects the stoma and the drainage bag from water pressure and keeps the skin dry.  \n2. **Check the bag seal** – Before swimming, ensure the bag’s valve is secure and the pouch is tight; a loose seal can cause leaks or irritation.  \n3. **Avoid hot tubs and chlorinated pools** – High‑temperature or heavily chlorinated water can irritate the stoma skin and increase infection risk.  \n4. **Clean and dry afterward** – Rinse the stoma area with cool water, pat dry, and re‑apply a fresh pouch or dressing.  \n5. **Consult your stoma nurse** – They can give you a personalized pouch recommendation and show you how to manage the stoma in water.\n\nWith these precautions, swimming can remain a safe, dignified part of your routine.",
          "order": 6,
          "qid": "S28-Q06"
        },
        {
          "q": "What if I can’t pee with a neobladder at first?",
          "gt": "It’s normal to worry that a neobladder might not work right away. In the first 6–12 weeks most people experience some difficulty—low capacity, urgency, or incomplete emptying. The surgeon will give you a “rehab” plan: a timed voiding schedule, pelvic‑floor exercises, and a small‑volume catheter (or a “clean intermittent catheter” if you can’t empty fully). Most patients improve as the bowel‑bladder pouch remodels and the nerves recover. If, after 3–6 months, you still can’t empty comfortably, the team can adjust the pouch size, add a catheter, or, if needed, switch to an ileal conduit. The goal is to give you dignity and function, and most people find a workable solution with time and support.",
          "order": 7,
          "qid": "S28-Q07"
        },
        {
          "q": "How often are follow-ups after surgery?",
          "gt": "After a radical cystectomy and urinary diversion, your follow‑up schedule is usually:\n\n| Time after surgery | Typical visits | What’s done |\n|--------------------|----------------|-------------|\n| **2–4 weeks** | First post‑op visit | Wound check, catheter removal (if still in place), labs, review of recovery. |\n| **Every 3 months** (first 2 years) | Clinic visits | Physical exam, blood tests (CBC, electrolytes, renal function), imaging (CT chest/abdomen/pelvis or MRI), cystoscopy if you have a neobladder, and discussion of any symptoms. |\n| **Every 6 months** (years 3–5) | Same as above, but imaging may be less frequent if no concerns. |\n| **Annually** (after 5 years) | Routine check‑ups | Basic labs, physical exam, and imaging only if indicated. |\n\nIf you have a neobladder, cystoscopy is usually performed at 3, 6, 12, 18, 24, 36, 48, and 60 months, then annually. Your surgeon may adjust the schedule based on your individual risk factors, recovery, and any complications.",
          "order": 8,
          "qid": "S28-Q08"
        },
        {
          "q": "Will I smell or leak?",
          "gt": "**Ileal conduit (stoma bag)**  \n- **Odor:** Urine in the bag can produce a noticeable smell, but regular cleaning, bag changes, and odor‑neutralizing wipes or sprays usually keep it manageable.  \n- **Leakage:** The conduit is a fixed tube; leakage is rare once the stoma is healed. You’ll simply empty the bag when it’s full.\n\n**Neobladder (internal pouch)**  \n- **Odor:** Because the urine stays inside a pouch that’s lined with bowel tissue, the smell is usually minimal and comparable to a normal bladder.  \n- **Leakage:** Early on you may need to use a catheter or have occasional dribbling, but most people learn to control it with timed voiding, pelvic‑floor exercises, and sometimes a small “safety” catheter. Over time, leakage usually improves significantly.\n\n**Bottom line:**  \n- An ileal conduit offers no leakage but may have a stronger odor that can be controlled.  \n- A neobladder offers a more natural feel with less odor, but you may experience some initial leakage that usually improves with practice. Discuss your lifestyle, work, and personal preferences with your surgeon to choose the best option for dignity and practicality.",
          "order": 9,
          "qid": "S28-Q09"
        },
        {
          "q": "If pathology shows worse disease than expected, do we have backup options?",
          "gt": "If the final pathology shows more extensive disease (e.g., higher stage, positive nodes, or positive margins) you still have several practical options:\n\n1. **Adjuvant chemotherapy** – most guidelines recommend cisplatin‑based therapy after cystectomy for node‑positive or high‑grade disease.  \n2. **Extended pelvic lymph node dissection** – if not already done, a surgeon can add more nodes intra‑operatively, which may improve staging and local control.  \n3. **Choice of diversion** – if you had planned a neobladder but pathology shows high‑risk features, an ileal conduit is a reliable, low‑maintenance alternative that still preserves dignity.  \n4. **Clinical trials** – many trials evaluate novel agents (immunotherapy, targeted drugs) in the adjuvant setting.  \n5. **Palliative measures** – if surgery alone is insufficient, options such as radiation or systemic therapy can be added.\n\nDiscuss these with your surgeon and medical oncologist to tailor the plan to your goals and overall health.",
          "order": 10,
          "qid": "S28-Q10"
        }
      ]
    },
    {
      "id": "S29",
      "title": "Swallowing my fear (esophageal cancer)",
      "diagnosis": "Locally advanced esophageal or gastroesophageal junction cancer",
      "treatment_plan": "Neoadjuvant chemoradiation followed by surgery when appropriate; nutrition support",
      "narrative": "I'm 60 and losing weight because food gets stuck. Treatment is chemoradiation and possibly surgery. I want to eat with my family again.",
      "qa": [
        {
          "q": "How do I keep weight on when every bite scares me?",
          "gt": "I’m sorry you’re facing this. Here are practical steps that many patients find helpful:\n\n1. **Small, frequent meals** – 5–6 mini‑meals or snacks a day keep calories in without overwhelming the throat.  \n2. **High‑calorie, high‑protein liquids** – smoothies, protein shakes, or meal‑replacement drinks (e.g., Ensure, Boost) can add 200–300 kcal per serving.  \n3. **Texture‑modified foods** – pureed soups, mashed potatoes, or finely shredded meats reduce the need to swallow large pieces.  \n4. **Swallow‑therapy guidance** – a speech‑language pathologist can teach safe swallowing techniques and safe food choices.  \n5. **Pain and reflux control** – keep your oncologist updated; effective pain control and anti‑acid meds can improve swallowing comfort.  \n6. **Consider a feeding tube** – if oral intake falls below 60 % of needs for >2 weeks, a PEG tube can maintain weight while you recover.  \n7. **Support network** – involve family in meal prep; eating together can boost appetite and morale.  \n\nWork closely with your oncology dietitian and speech therapist to tailor these strategies to your specific symptoms.",
          "order": 1,
          "qid": "S29-Q01"
        },
        {
          "q": "Will chemoradiation make swallowing worse before it gets better?",
          "gt": "Chemoradiation can indeed make swallowing feel worse at first. The radiation and chemotherapy irritate the lining of the esophagus, causing mucositis, swelling, and sometimes temporary narrowing. Most patients notice the worst of this around 2–4 weeks into treatment, after which the inflammation usually subsides and swallowing improves.  \n\nTo help you cope:  \n* Work with a dietitian to plan soft, high‑calorie meals and small, frequent bites.  \n* Use a speech‑language pathologist for swallowing exercises if needed.  \n* If pain or difficulty becomes severe, a temporary feeding tube (PEG) can keep you nourished while the tissues heal.  \n\nWith supportive care, the initial dip is usually brief, and many people regain normal swallowing after the treatment course.",
          "order": 2,
          "qid": "S29-Q02"
        },
        {
          "q": "If surgery is needed, will I ever eat normally?",
          "gt": "If you need an esophagectomy, the goal is to restore a safe, functional swallow, but the “normal” you had before cancer may change. Most patients learn to eat again, often with a modified diet (soft, pureed, or small, frequent meals) for several months. A feeding tube (PEG) is usually placed during surgery and removed once you can tolerate oral intake. Swallow‑therapy and a dietitian help retrain the muscles and adjust textures. Some people experience long‑term issues—dry mouth, reflux, or occasional dysphagia—but many return to eating with family, sometimes with a few dietary tweaks. The recovery is gradual, but normal eating is achievable for most.",
          "order": 3,
          "qid": "S29-Q03"
        },
        {
          "q": "Am I going to choke or aspirate at home?",
          "gt": "I’m sorry you’re facing this worry. The risk of choking or aspiration depends on how your esophagus is affected and how you’re eating. If the tumor or radiation causes a significant narrowing, food can get stuck and you may cough or choke. After chemoradiation, swelling often improves, and many patients resume normal meals with simple adjustments—soft, pureed, or finely chopped foods, small bites, and slow chewing. If you notice coughing, choking, or a wet, gurgly sound after swallowing, or if you feel food is lingering in your throat, contact your oncology team or a speech‑language pathologist right away. They can assess swallowing safety and recommend a diet plan or swallowing therapy. With close monitoring and the right diet modifications, most patients eat safely at home.",
          "order": 4,
          "qid": "S29-Q04"
        },
        {
          "q": "Can I still drink coffee or wine?",
          "gt": "During neoadjuvant chemoradiation and after surgery the esophagus is very sensitive.  \n**Coffee** – the caffeine and acidity can irritate the lining, worsen reflux, and make swallowing painful. If you want to keep it, switch to a low‑acid, decaffeinated brew, let it cool, and sip slowly.  \n**Wine** – alcohol is a mucosal irritant and can delay healing, increase the risk of anastomotic leaks, and interfere with chemotherapy. It’s safest to avoid alcohol during treatment and for at least 6 weeks after surgery.  \n\nIf you’re craving a drink, try a warm, non‑acidic herbal tea or a small glass of water with a splash of fruit juice. Always check with your dietitian or oncologist before changing your beverage habits.",
          "order": 5,
          "qid": "S29-Q05"
        },
        {
          "q": "How long before I know if surgery is on the table?",
          "gt": "After you finish the neoadjuvant chemoradiation (usually 4–6 weeks of treatment), your oncologist will schedule a post‑therapy evaluation.  \n• **2–4 weeks after the last radiation dose** you’ll have a CT scan (sometimes PET‑CT) and a repeat endoscopy to see how the tumor has responded.  \n• The results are reviewed at a multidisciplinary tumor‑board meeting (oncology, surgery, radiology, nutrition).  \n• If the tumor has shrunk or is stable, the board will usually recommend surgery and schedule it within **4–6 weeks** of that evaluation.  \n\nSo, you can expect a definitive answer about surgery roughly **6–8 weeks after starting chemoradiation**—give or take a week or two depending on imaging timing and board scheduling. If the response is poor, the plan may shift to alternative therapies. Stay in close contact with your team; they’ll keep you updated every step of the way.",
          "order": 6,
          "qid": "S29-Q06"
        },
        {
          "q": "Do I need to sleep upright forever?",
          "gt": "You don’t have to stay upright forever, but for the first few weeks after chemoradiation (and often after surgery) many people find it helpful to keep the head of the bed elevated 30–45 ° or to sleep in a recliner. This position reduces reflux, aspiration risk, and can make swallowing easier while the esophagus heals. Once you’re tolerating meals without choking or significant pain, you can gradually return to a normal sleeping posture. If you still feel food getting stuck or have trouble breathing at night, keep the elevation or use a wedge until your surgeon or gastroenterologist says it’s safe to stop. The goal is to balance comfort, safety, and the ability to enjoy meals with family.",
          "order": 7,
          "qid": "S29-Q07"
        },
        {
          "q": "How do you keep me safe from dehydration?",
          "gt": "I’m sorry you’re going through this. Dehydration can sneak in quickly when swallowing is hard, so keep a few simple habits in place:\n\n1. **Small, frequent sips** – aim for 1–2 oz (30–60 ml) every 10–15 min. Use a straw or a small cup to make it easier.  \n2. **Oral rehydration solutions** (e.g., Pedialyte, Gatorade) give electrolytes and are more palatable than plain water.  \n3. **Monitor weight** daily; a 2 lb (≈1 kg) drop in 24 h signals dehydration.  \n4. **Watch for red flags**: dizziness, dark urine, dry mouth, rapid heartbeat, or confusion.  \n5. **Ask your team** about a **nasogastric or percutaneous feeding tube** if oral intake can’t meet needs.  \n6. **IV fluids** may be started if oral hydration fails or if you’re on chemotherapy that increases fluid loss.\n\nKeep a hydration log and bring it to appointments so your oncologist can adjust the plan promptly.",
          "order": 8,
          "qid": "S29-Q08"
        },
        {
          "q": "What does a 'good day' look like during treatment so I can plan moments with my spouse?",
          "gt": "A “good day” is one that balances treatment, nutrition, and family moments while keeping fatigue and swallowing at bay.  \n\n**Morning** – take your morning meds and a small, protein‑rich snack (e.g., a smoothie or yogurt with fruit). If you’re on chemo that day, eat a light breakfast 1–2 hrs before the infusion.  \n\n**Mid‑day** – after the infusion or radiation, rest for 30–60 min, then have a small, easy‑to‑swallow lunch (e.g., pureed soup or a soft sandwich). Use this time to call or video‑chat with your spouse if you’re too tired for in‑person visits.  \n\n**Afternoon** – gentle swallowing exercises, hydration, and a short walk if you feel up to it.  \n\n**Evening** – a light dinner (e.g., mashed potatoes, well‑cooked veggies, or a protein shake). Finish with a calm activity—reading, music, or a short walk with your spouse—when you have the energy.  \n\nPlan family time for the late afternoon or early evening, when you’re usually less fatigued, and keep meals small, frequent, and nutrient‑dense to support healing.",
          "order": 9,
          "qid": "S29-Q09"
        },
        {
          "q": "If I can’t face surgery, is there still a path?",
          "gt": "I’m sorry you’re facing this. In many locally advanced esophageal or GE‑junction cancers, surgery is the standard part of a curative plan, but it isn’t the only option. If you’re not ready for or able to undergo surgery, you can still pursue **definitive chemoradiation** alone—many patients achieve long‑term control with this approach, especially if the tumor responds well. Other strategies include:\n\n* **Endoscopic therapies** (e.g., photodynamic therapy, radiofrequency ablation) for small, superficial lesions.  \n* **Stenting** or dilation to relieve obstruction and improve swallowing.  \n* **Palliative care** focused on nutrition, pain control, and quality of life.  \n* **Clinical trials** that test new drugs or targeted regimens.\n\nDiscuss these alternatives with your oncology team; they’ll tailor the plan to your tumor’s stage, response, and overall health. Your goal of eating with family can still be achieved through a combination of these treatments and supportive nutrition care.",
          "order": 10,
          "qid": "S29-Q10"
        }
      ]
    },
    {
      "id": "S30",
      "title": "Fast and furious (extensive-stage small cell lung cancer)",
      "diagnosis": "Extensive-stage small cell lung cancer",
      "treatment_plan": "Platinum/etoposide chemotherapy with immunotherapy; symptom control; imaging to assess response",
      "narrative": "I'm 63 and this cancer showed up fast. They want to start chemo-immunotherapy now. I need relief and a plan that keeps my days meaningful.",
      "qa": [
        {
          "q": "How quickly might my cough and breathlessness improve?",
          "gt": "In most patients with extensive‑stage small cell lung cancer, the first cycle of platinum‑etoposide plus immunotherapy is given every 3–4 weeks. You can often notice a modest reduction in cough and shortness of breath within the first 1–2 weeks after starting treatment, especially if the tumor burden is high. A more pronounced improvement usually becomes evident after the second cycle (around 4–6 weeks), when the chemotherapy has had time to shrink the tumor and the immunotherapy begins to modulate the immune response. However, the exact timing varies: some people feel relief sooner, while others may need several cycles or additional supportive measures (e.g., bronchodilators, steroids, oxygen). Keep close contact with your oncology team; they’ll monitor your symptoms and adjust therapy or add supportive care as needed to keep your days meaningful.",
          "order": 1,
          "qid": "S30-Q01"
        },
        {
          "q": "What makes this cancer different from the others I read about?",
          "gt": "Small‑cell lung cancer (SCLC) is distinct in several key ways:\n\n1. **Rapid growth and early spread** – It doubles in size in just a few weeks and almost always has already metastasized by the time it’s diagnosed, so it’s called “extensive‑stage” when it’s beyond the chest.\n2. **High chemosensitivity** – Unlike many solid tumours, SCLC responds quickly to platinum‑based chemo (cisplatin or carboplatin) plus etoposide, and adding a checkpoint inhibitor (e.g., atezolizumab or durvalumab) improves survival.\n3. **Neuro‑endocrine biology** – It originates from neuro‑endocrine cells, producing hormones that can cause paraneoplastic syndromes (e.g., SIADH, Cushing’s).\n4. **Limited targeted options** – There are few driver mutations to exploit, so treatment relies on systemic therapy and symptom control rather than targeted drugs.\n\nThese features mean you’ll need aggressive, early systemic therapy and close monitoring, but the disease’s chemosensitivity offers a chance for meaningful control and quality‑of‑life improvement.",
          "order": 2,
          "qid": "S30-Q02"
        },
        {
          "q": "Will I be stuck in bed after each cycle?",
          "gt": "It’s normal to feel a bit wiped after each cycle, but you won’t be “stuck in bed” for long. Most people with extensive‑stage small‑cell lung cancer on platinum/etoposide plus immunotherapy recover enough to get up and move within 24–48 hours. Fatigue, nausea, and low blood counts are the main culprits; they usually peak 3–5 days after infusion and ease as the next cycle starts.  \n\nPlan to:\n\n1. **Rest when you need it** – a short nap or sitting up is fine, but try gentle walking or light stretching 1–2 hours after the infusion if you feel up to it.  \n2. **Nutrition & hydration** – keep protein, iron, and fluids high to support recovery.  \n3. **Pain & symptom control** – use prescribed meds (e.g., low‑dose opioids, anti‑emetics) before they become bothersome.  \n4. **Ask your team** – if fatigue or other symptoms persist beyond a few days, let them know; they can adjust doses or add supportive care.  \n\nWith this approach, most patients maintain a meaningful daily routine and avoid prolonged bed rest.",
          "order": 3,
          "qid": "S30-Q03"
        },
        {
          "q": "Can immunotherapy cause dangerous side effects?",
          "gt": "Yes, immunotherapy can produce serious side effects, although they are relatively uncommon. The most frequent problems are immune‑related adverse events (irAEs) that occur when the immune system attacks normal tissues. These can involve the skin (rash, itching), gut (diarrhea, colitis), lungs (pneumonitis), liver (hepatitis), endocrine glands (thyroiditis, adrenal insufficiency), and, rarely, the heart or nervous system. Severe irAEs may require high‑dose steroids or other immunosuppressants and can be life‑threatening if not recognized early. Other risks include infusion reactions, fatigue, and, rarely, an increased chance of infections. Your oncologist will monitor you closely with regular labs and imaging, and will intervene promptly if any symptoms arise. Discuss any new or worsening symptoms right away to keep your treatment safe and effective.",
          "order": 4,
          "qid": "S30-Q04"
        },
        {
          "q": "Should I quit smoking now, or is it too late to matter?",
          "gt": "Quitting now is still a powerful step—yes, it’s “too late” to reverse the cancer, but it can improve your treatment and quality of life. Stopping smoking reduces the risk of infections, heart and lung complications, and can enhance how well your chemotherapy and immunotherapy work. It also lowers the chance of a second cancer and can help you feel stronger during treatment. Even a short break can make a difference: aim for a quit date, use nicotine replacement or prescription meds, and lean on support from your care team, family, or a cessation program. Every day you stay smoke‑free is a day that gives you more energy, better tolerance for therapy, and a clearer path to meaningful living.",
          "order": 5,
          "qid": "S30-Q05"
        },
        {
          "q": "If my brain scan later shows spots, what then?",
          "gt": "If a later brain MRI shows “spots,” the first step is to determine whether they are metastases, benign lesions, or treatment‑related changes. A neuro‑oncology consult will usually order a high‑resolution MRI with contrast and, if needed, a PET scan or a stereotactic biopsy.  \n\nFor confirmed small‑cell lung cancer brain metastases, the standard options are:\n\n1. **Whole‑brain radiotherapy (WBRT)** – 30 Gy in 10 fractions, often combined with dexamethasone to reduce swelling.  \n2. **Stereotactic radiosurgery (SRS)** – a single, high‑dose treatment for 1–4 small lesions.  \n3. **Systemic therapy** – continue or adjust your platinum/etoposide‑immunotherapy regimen; some agents cross the blood‑brain barrier.  \n\nIf the spots are benign or inflammatory, steroids and close imaging follow‑up may suffice. Your care team will tailor the plan to keep you comfortable and active.",
          "order": 6,
          "qid": "S30-Q06"
        },
        {
          "q": "Can I keep my morning walks with my dog?",
          "gt": "It’s absolutely possible—and even helpful—to keep your morning walks with your dog while you’re on platinum‑etoposide plus immunotherapy. Light to moderate activity can improve mood, maintain muscle tone, and help you feel more in control. Here are a few practical tips:\n\n1. **Start small** – begin with 10–15 min walks, gradually increasing as you feel comfortable.  \n2. **Timing** – walk after your chemo infusion when you’re least likely to feel the peak of fatigue or nausea.  \n3. **Safety** – avoid crowded places or areas with many people to reduce infection risk, especially early in treatment.  \n4. **Hydration & rest** – bring water, take breaks, and stop if you feel dizzy, short‑of‑breath, or unusually tired.  \n5. **Listen to your body** – if you’re feeling weak or have a fever, postpone the walk until you recover.\n\nIf you notice any new symptoms or increased fatigue, let your oncology team know right away. Enjoy those walks—they’re a valuable part of your overall care plan.",
          "order": 7,
          "qid": "S30-Q07"
        },
        {
          "q": "How long does this treatment last?",
          "gt": "For extensive‑stage small‑cell lung cancer the standard first‑line regimen is 4–6 cycles of platinum/etoposide + an immune‑checkpoint inhibitor (e.g., atezolizumab or durvalumab).  \n- **Chemotherapy cycles:** 4–6, given every 3 weeks → about 3–4 months total.  \n- **Immunotherapy:** Usually continues after the last cycle as maintenance for up to 1 year or until the cancer progresses or side‑effects become intolerable.  \n\nSo you’ll have roughly 3–4 months of combined chemo‑immunotherapy, followed by up to a year of maintenance immunotherapy, with imaging checks every 2–3 months to gauge response.",
          "order": 8,
          "qid": "S30-Q08"
        },
        {
          "q": "What happens if it grows back fast?",
          "gt": "If the tumor recurs or progresses quickly after the initial platinum‑etoposide plus immunotherapy, it usually means the cancer has become resistant to that regimen. In that situation:\n\n1. **Re‑imaging** (CT/PET) is done within 6–8 weeks to confirm progression and to look for new sites.  \n2. **Second‑line therapy** is considered. Common options include topotecan, irinotecan, or a platinum‑based doublet with a different agent (e.g., carboplatin + paclitaxel).  \n3. **Clinical trials** are often available and can offer newer agents or combinations that may work when standard drugs fail.  \n4. **Palliative care** is integrated early to manage symptoms (pain, shortness of breath, fatigue) and maintain quality of life.  \n5. **Supportive measures**—oxygen, steroids, pain control, and psychosocial support—help keep daily activities meaningful.\n\nRapid regrowth typically shortens overall survival, but timely reassessment and switching to an alternative regimen can still provide disease control and symptom relief. Discuss these steps with your oncologist to tailor the next phase of care.",
          "order": 9,
          "qid": "S30-Q09"
        },
        {
          "q": "How do we protect good days for time with my family?",
          "gt": "**Protecting “good days” while you’re on chemo‑immunotherapy**\n\n1. **Plan ahead** – Ask your oncology team to schedule treatment on days that leave you with a “rest” day afterward. If possible, use a home‑infusion or a shorter clinic visit so you’re not exhausted all week.  \n2. **Manage side‑effects early** – Use anti‑emetics, anti‑nausea meds, and a low‑dose steroid if recommended. Keep a symptom diary and share it with your team so adjustments can be made before fatigue or pain spikes.  \n3. **Prioritize hydration and nutrition** – Small, frequent meals and a hydration plan help keep energy up. A dietitian can tailor a menu that’s easy to prepare and enjoyable.  \n4. **Set boundaries** – Let family know when you need quiet or rest. Use a simple “chemo‑day” sign or calendar reminder so everyone respects your recovery time.  \n5. **Leverage support services** – Home‑health aides, respite care, or a local hospice volunteer can give you and your loved ones a break, ensuring quality moments together.  \n6. **Early palliative care** – Integrating palliative specialists early helps balance aggressive treatment with comfort, preserving meaningful family time.  \n\nBy coordinating care, managing symptoms proactively, and setting clear boundaries, you can keep your days with family as joyful and restful as possible.",
          "order": 10,
          "qid": "S30-Q10"
        }
      ]
    }
  ]
}